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Abstract 
White matter integrity is crucial to healthy executive function, the cognitive domain that 
enables functional independence. However, in the ageing brain, white matter is highly 
vulnerable. White matter inflammation increases with age and Alzheimer disease (AD), 
which disrupts the normal function of white matter. This may contribute to executive 
dysfunction, but the relationship between white matter inflammation and executive 
function has not been directly evaluated in ageing nor AD. White matter is also particularly 
vulnerable to cerebrovascular disease, corresponding with the common presentation of 
executive dysfunction in vascular cognitive impairment (VCI). Thus, white matter may be 
an important substrate by which vascular injury exacerbates the cognitive impact of 
comorbid AD pathology and cerebrovascular pathology. To study the relationship 
between age, pathogenic amyloid precursor protein (APP), white matter inflammation, 
cerebrovascular disease, and executive dysfunction, the transgenic rat model of AD 
(TgAPP21) was evaluated for astrocytosis, microgliosis and cognitive impairment. The 
TgAPP21 rat was found to demonstrate spontaneously increased white matter microglia 
activation, impaired reversal learning, and a regressive impairment of behavioural 
flexibility, a key subdomain of executive function. The TgAPP21 rat also developed a 
precocious increase in white matter microglia activation. However, this was not matched 
by a continued increase in behavioural inflexibility, suggesting a dynamic and age-
dependent relationship between white matter inflammation and behavioural flexibility. 
Hypertension induced by chronic angiotensin-II infusion impaired both wildtype (Wt) and 
TgAPP21 rats’ working memory and behavioural flexibility. However, while Wt rats 
demonstrated a linear increase in white matter astrocytosis in response to blood pressure 
elevation, normotensive TgAPP21 rats already had an increased baseline level of white 
matter astrocytosis and further increase in response to hypertension was not observed. 
TgAPP21 rats also demonstrated a greater vulnerability to cerebrovascular disease, as 
focal striatal ischemic injury resulted in reduced set shifting efficiency. Thus, the TgAPP21 
rat is an important model for studying the complex relationship between age, pathogenic 
APP, and cerebrovascular disease and their impact on executive dysfunction. These 
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findings support the emerging significance of white matter inflammation and executive 
dysfunction in the pathophysiology of ageing, AD, and VCI.  
        
Keywords 
White Matter, Inflammation, Microglia, Cognitive Impairment, Executive Function, 
Behavioural Flexibility, Alzheimer Disease, Amyloid, Vascular Dementia, Ischemic 
Stroke, Hypertension, Animal/Rat Model.  
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Chapter 1: Introduction 
This chapter outlines the current literature pertaining to white matter integrity, 
neuroinflammation, and cognitive impairment in the context of Alzheimer disease (AD) 
and vascular cognitive impairment (VCI). AD and vascular pathology frequently occur 
together and important intersections of these two conditions are observed in white matter 
tissue. Investigating this link between AD and vascular pathology will develop our 
understanding of the early pathophysiology of the two leading causes of dementia.  
 
1.1 White Matter and Cognitive Function   
Neuroscience and behavioural neurology has traditionally focused on grey matter even 
though white matter occupies 40-50% of the adult human brain1. Although Jean-Martin 
Charcot described the white matter lesions observed in multiple sclerosis and 
amyotrophic lateral sclerosis in the 19th century2, it would not be until 1965 that the notion 
of “cerebral disconnection” as a more general mechanism for cognitive impairment would 
be introduced by Norman Geschwind1. Today, white matter continues to be understood 
generally as tissue that mediates the transfer of information, in contrast to the processing 
of information which is attributed to grey matter. This applies to all levels of cognition, but 
the striking abundance of white matter in the frontal lobes, the seat of integration and 
coordination, underscores the importance of white matter for higher-level domains of 
cognition,1 including inhibition, cognitive flexibility, planning, problem solving, reasoning, 
abstract thinking, complex social processing, and creativity. Comparative neuroanatomy 
identifies our species’ unique proportion of white matter volume, featuring an exceptional 
quantity of thick myelinated fibres, as crucial to our ability to excel in higher-level 
cognition3.  
Conversely, impairments of higher level cognition can be attributed to white matter 
disruptions, including lesions that are far subtler than what Jean-Martin Charcot could 
detect1. Aided by developments in neuroimaging, the term white matter dementia was 
introduced in 1988 to expand the scope of dementia research3. Similarly, recent decades 
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saw an increased interest in the role of glial cells in normal and disordered neurological 
function4,5. White matter is defined by a preponderance of axons, myelin, and 
oligodendrocytes but also includes an abundance of astrocytes, microglia, and blood 
vessels3, so the roles of glial cells in disorders of the central nervous system (CNS) would 
naturally direct more research to white matter4-7. The following sections will review current 
literature on the cognitive correlates of white matter and the general impairments 
observed with white matter dysfunction. Thereafter, white matter dysfunction will be 
described in the context of AD and VaD.  
 
1.1.1 White Matter Integrity 
Healthy white matter function depends on thick and well-organized myelination of axons8. 
White matter structure is also experience dependent, with ongoing white matter 
reorganization playing an important role in supporting cognitive plasticity9. White matter 
degeneration can present clearly in the form of volume loss, measured with neuroimaging 
or as gross atrophy on post-mortem studies. More subtle forms of white matter 
degeneration include microstructural changes that alter molecular diffusion 
characteristics as measured by diffusion-weighted magnetic resonance imaging (DW-
MRI), including an early form of this technique, diffusion tensor imaging (DTI)10. In short, 
DTI relies on differences in the displacements of water molecules depending on tissue 
type11. One of the most commonly metrics used in DTI is fractional anisotropy (FA), which 
quantifies how restricted water molecule diffusion is in a given voxel. FA measures range 
from 0 to 1, with low values seen in the CSF-filled ventricles where water diffusion is 
unrestricted in all directions, and high values in myelinated white matter tracts such as 
the corpus callosum, where water movement is greatly restricted to move primarily along 
the direction of the axons11,12.  
A loss of FA in white matter tissue, where FA is expected to be high, indicates 
microstructural changes that are presumed to be predominantly the result of 
demyelination or alterations in myelin structure11-13. However, FA also reflects axonal 
caliber, injury, and density, as well as uniformity of fibre direction and gliosis; research 
continues to identify the histopathological correlates of DTI metrics, including FA, and 
3 
 
 
how these radiological-histopathological correlates change in different disease 
contexts12. Despite this, and with some controversy10, DTI measures such as FA are 
widely inferred as a measure of white matter integrity. The limitations of this interpretation 
are well detailed by Jones et al10, but the appeal to inferring deleterious microstructural 
changes based on DTI measurements is supported by cognitive correlates12. In normal 
aging9,14-21 and many different neurodegenerative conditions22-28, loss of FA in white 
matter has been correlated with cognitive impairments, most often with processing speed 
and executive function.  
The clinical utility of measuring microstructural white matter changes is further 
demonstrated by the potentially diagnostic and prognostic value of leukoaraiosis. Also 
known as white matter hyperintensities, leukoaraiosis is a radiological phenomenon of 
diffuse hypodense (on CT) or hyperintense (on T2 MRI) white matter29-34. Leukoaraiotic 
white matter has reduced white matter integrity, as measured by DW-MRI35,36 and 
leukoaraiosis is an important risk factor for stroke, dementia, and death37-39. The term 
leukoaraiosis, derived from the Greek leuko (white) and araiosis (rarefaction) was coined 
intentionally so as not to assume any particular disease etiology;40 still to this day, the 
exact processes that causes leukoaraiosis has not been determined. Vascular pathology 
is commonly proposed as the underlying mechanism of leukoaraiosis41-44, although 
dysregulation of glial cells and inflammation have also been implicated45,46.  
 
1.1.1.1 White Matter Vascular Insufficiency 
White matter is particularly sensitive to vascular disruption44,47-52. When mild hypercapnia 
was induced in healthy subjects to produce systemic vasodilation, a significant steal 
phenomenon was observed that resulted in reduced blood flow to white matter50. The 
very regions that had reduced blood flow matched the common neuroanatomical 
locations of leukoaraiosis matter, namely periventricular44,50. This was also supported by 
a previous study of subjects with leukoaraiosis that had normal blood flow to grey matter 
but reduced white matter blood flow52. Reduced blood flow indicates a poorer 
cerebrovascular reserve in white matter, and the white matter regions that are relatively 
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more prone to leukoaraiotic changes indeed fall in the “watershed” regions in between 
the major arterial zones of the brain50,51,53,54. Moreover, white matter has been shown to 
be highly vulnerable to ischemic injury, with increased susceptibility seen with age51. The 
greater white matter vulnerability to ischemia is attributed to a relative paucity of 
collaterals in deep white matter53 and the high sensitivity of oligodendrocyte precursor 
cells to ischemia-induced oxidative stress51. In a rat model maintained on a high saturated 
fat, salt, and refined sugar diet, hypertension and cerebral small vessel blockage was 
associated with white matter atrophy 55.   
Hypertension also correlates with disruptions of white matter structure49,56 and is a key 
risk factor for leukoaraiosis47,57. At the same time, the presence of leukoaraiosis is more 
common in subjects with orthostatic hypotension58 and increased pulse pressure59,60. 
Cerebral small vessel disease (SVD) is an umbrella term for pathologies of perforating 
cerebral arterioles, capillaries, and venules42, and is associated with systemic vascular 
risk factors such as hypertension, atherosclerosis, diabetes mellitus, and atrial 
fibrillation61; cerebral SVD also often manifests as leukoaraiosis41-44. Thus, due to the 
organization of the cerebrovasculature50,53, white matter is extremely susceptible to 
common systemic cardiovascular conditions. A lot of histopathological heterogeneity has 
been observed in leukoaraiosis, so that in general, any vascular conditions that cause 
cerebral hypoperfusion, blood brain barrier (BBB) disruption, chronic ischemia, 
microinfarcts, venous collagenosis, vessel tortuosity, or vessel wall thickening is also 
thought to cause leukoaraiosis43,54,62.       
 
1.1.1.2 White Matter Gliosis and Inflammation 
In addition to the large variety of vascular abnormalities observed in leukoaraiotic white 
matter, many active and dystrophic glial cells are also observed43. This includes 
dysfunctional oligodendrocytes, clasmatodendritic astrocytes (abnormal astrocytes with 
swollen soma and short blunt processes), and activated microglia44,62,63. As glial cells 
actively maintain white matter integrity and homeostasis, they may be important targets 
for therapeutic intervention64,65. Neuroinflammation in neurodegenerative diseases is 
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thought to be driven primarily by microglia, which are involved in both cytokine secretion 
and phagocytosis4,66,67; microglia-mediated inflammation affects white matter in 
particular, both in normal aging and in neurodegenerative disease68. Indeed, 
experimental studies have shown that the inhibition of white matter microgliosis improves 
white matter integrity after cerebral hypoperfusion69-76, thus microglia play an important 
role in the vascular vulnerability of white matter. Although microglia activation does 
not capture the entire scope of neuroinflammation, microglial activation is a strong 
indicator of a proinflammatory environment67 and will be used as the key measure 
of neuroinflammation in this thesis. Astrocytes also interact with microglia in 
inflammatory conditions and are an important factor in both white matter maintenance 
inflammation5-7,66,77. Despite the importance of both microglia and astrocytes in 
maintaining white matter in neurodegenerative disease and in health, there is a paucity 
of literature on how dysregulation of these white matter glial cells affect cognition. In two 
recent rodent studies, white matter microglial activation was associated with executive 
dysfunction78,79, and two recent post-mortem studies of dementia pugilistica and alcohol-
related neuropathology also demonstrated an association between executive dysfunction 
with white matter astrocytosis80,81. The prevalence and burden of diseases that can 
induce dysregulation of white matter microglia and astrocytes, and consequentially, 
impair white matter integrity and executive function, warrants more research.   
 
1.1.2 Executive Function 
Executive function refers to a group of inter-dependent cognitive functions that enable 
planning, mental manipulation, and control over goal-directed behaviour. The core 
subdomains of executive function are inhibitory control, working memory, and cognitive 
flexibility82, which all rely on information processing in the prefrontal cortex (PFC) and its 
extensive connections with other cortical and subcortical brain regions. Although specific 
locations of leukoaraiosis do associate with impairments of specific subdomains28, 
leukoaraiosis in any region is also correlated with hypometabolism in the PFC and global 
impairments of executive function21,28,83. The substantial convergence of fibre pathways 
that connect the PFC1 may explain how pathology in even a small focal white matter 
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lesion could affect metabolism in the entire frontal cortex and cause broad impairments 
of executive function31.  
Of all cognitive domains, executive function is often the most sensitive to both 
environmental and physiological stressors82. Accordingly, executive function declines in 
late adulthood82,84, which has been linked to disruptions of white matter integrity14-21. Even 
in normal aging, white matter volume shows a greater decline than grey matter 
volume12,85. For patients diagnosed with dementia or at risk of dementia, one of the most 
difficult challenges is the loss of functional independence, which is strongly dependent on 
executive function86-88. In a clinical setting, functional independence is most often 
evaluated according to an individual’s capacity for activities of daily living (ADLs), 
including personal hygiene, mobility, and eating88. More complex ADLs such as the 
management of finances and medications, cooking, housekeeping, often referred to as 
instrumental ADLs (IADLs), are also evaluated to offer a more sensitive measure of 
cognitive impairment in earlier stages of neurodegenerative diseases88. Indeed, the 
cognitive domain that best predicts current and future functional independence, as 
measured by ADLs and IADLS, is executive function86-88. This emphasizes the 
importance of supporting general white matter health for maintaining executive function 
as well as functional independence. 
 
1.1.2.1 Inhibitory Control 
Inhibitory control of attention, thought, behaviour, and emotions constitutes one of the 
core subdomains of executive function82. Inhibitory control of attention can occur 
involuntarily, as with the filtering of stimuli at the level of perception such as background 
noise at a cocktail party. Inhibitory control of attention can also occur voluntarily, as when 
effort is made to ignore stimuli that distract from goal-directed behaviour82. The inhibition 
of both mental representations and behaviour can be best appreciated in conditions 
where such inhibition is impaired; intrusive memories and thoughts are a core component 
of post-traumatic stress disorder89,90, substance addiction91, and the obsessive 
component of obsessive-compulsive disorder92, while impairments of behavioural 
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inhibition are also seen in substance addiction91 and the compulsions seen in obsessive-
compulsive disorder92. Lastly, inhibitory control of emotions is regularly required in social 
interaction and maintaining motivation while delaying gratification through arduous tasks, 
such as writing a dissertation82.   
The PFC is responsible for regulating and inhibitory control over attention, thought, 
behaviour, and emotions. The inferior frontal gyrus in the ventrolateral PFC (VLPFC) 
plays an important role in inhibition via direct connections to other cerebral cortices, basal 
ganglia, the subthalamic nucleus, and cerebellar cortices93,94. In particular, the right 
VLPFC has been associated with behavioural inhibition, whereas the bilateral actions of 
the VLPFC contribute more to inhibition of attention and thoughts93-95. Inhibition of 
emotions appears to be more directly regulated by both the ventromedial PFC (VMPFC), 
which have extensive connections with the amygdala, hypothalamus, nucleus 
accumbens, and brainstem nuclei93,94. Both the VMPFC and VLPFC are considered to 
initiate top-down control of inhibition but other structures downstream are also crucial to 
inhibitory control, namely the basal ganglia and supplementary motor areas94. While focal 
lesions in any of these structures may cause specific impairments of inhibition, white 
matter lesions in any of the circuits that connect these structures will also impair inhibitory 
control93.  
 
1.1.2.2 Working Memory 
Another core domain of executive function is working memory, defined as the function of 
holding and manipulating information that is not perceptually present (mental 
representations)82. Working memory is often further distinguished by verbal and non-
verbal (visual-spatial) content, and is utilized in all instances of mental math, mental 
reorganization or revision of information, and relating different pieces of information such 
as verbal translation; working memory is essential for reasoning. Working memory may 
often be miscategorized as a type of short-term memory rather than a subdomain of 
executive function, but working memory is more closely linked to executive function in 
terms of neuroanatomy, childhood development, and function82.  
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There is considerable controversy over whether working memory is a dissociable 
cognitive domain. Of course, working memory and short-term memory are highly inter-
related. This is demonstrated by short-term memory tasks that require a longer 
(suprathreshold) number of information items, wherein working memory is automatically 
engaged to organize the information. The key distinction between working memory and 
short-term memory is that the former involves manipulations of information in addition to 
the mental holding of that information. Holding information activates the VLPFC during 
tasks that require either working memory or short-term memory, while working memory 
dependent tasks involving the manipulation of information are also associated with 
activation of the dorsolateral PFC (DLPFC)82. Similarly, working memory and inhibitory 
control are often functionally inter-dependent and show high neural co-activation82. 
Working memory directs inhibitory control, while inhibitory control regulates the 
information that can occupy working memory. This has lead many to view inhibitory 
control as derivative, with working memory enhancement of specific goals or thoughts 
considered to be sufficient to automatically repress unwanted goals or thoughts, that is, 
inhibitory control. Others still maintain that working memory and inhibitory control are 
dissociable domains, and that mental suppression requires more than just a relative lack 
of mental enhancement. While this debate continues82, most will agree that all 
subdomains of executive function are highly interdependent, including the subdomain of 
cognitive or behavioural flexibility.  
 
1.1.2.3 Cognitive/Behavioural Flexibility 
Cognitive flexibility, often referred to as behavioural flexibility in the context of rodent 
studies, builds on both inhibitory control and working memory. Cognitive flexibility 
describes the ability to change perspectives or goals, which involves the inhibition of 
current thoughts or goal-directed behaviours and the engagement of new ones82. 
Representative tasks that require cognitive flexibility include design fluency, verbal 
fluency, and category fluency, wherein a subject is asked to, respectively, think of different 
uses of a table, different words that begin with a certain letter, or alternate sequentially 
between letters and numbers82. Accordingly, cognitive flexibility is considered to be crucial 
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for creativity. Lesions of the dorsomedial PFC (DMPFC) produce the most consistent 
impairments of different types of fluency96,97.  
Another common task that requires cognitive flexibility is task switching. A relatively 
simple form of task switching is known as reversal, such as when a rewarding option is 
changed from a left switch to a right switch. Lesions of the orbitofrontal cortex (OFC), 
located between the VMPFC and VLPFC98, result in reversal impairments99,100. A more 
complex form of task switching is known as set shifting, which requires a subject to 
redirect their attention between different sets of cues; this is exemplified by the Wisconsin 
Card Sorting Task, wherein subjects need to shift between sorting rules that depend on 
shape, colour, or number101. In contrast to reversal, set shifting is impaired by lesions of 
the DLPFC99,100.  
Both reversal and set-shifting tests have also been adapted for rodent studies, wherein 
maze-based or operant-based challenges require rodents to reverse behaviour or shift 
behaviour according to attentional sets100. Although the functional divisions of the PFC 
do not arrange in the same neuroanatomical topography in rodents, reversal and set 
shifting impairments are similarly doubly dissociated in rats102. Additional pathways 
between the PFC, thalamus, and striatum that also contribute to set shifting behaviour 
are also conserved across species102, further supporting the interpretation that 
behavioural flexibility in rats is still very informative for the study of cognitive flexibility in 
humans98,100. Though there certainly are limitations to the human-rodent homology of 
cognitive-behavioural flexibility, other executive functions, and underlying neural 
correlates, the experimental possibilities of rodent studies are still crucial to identifying the 
neural substrates and disease mechanisms of neurodegenerative cognitive 
impairments100,103. 
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1.2  Alzheimer Disease  
Alzheimer disease (AD) is a devastating condition of progressive neurodegeneration and 
the most common cause of dementia104. AD is a terminal illness and no current therapies 
can stop or reverse disease progression. As with many diseases of advanced age, there 
is heterogeneity in disease presentation and progression, and there are many 
environmental and lifestyle factors that are considered to modify the risk of incidence104. 
Neuropathologically, AD presents with protein-rich plaques, neurofibrillary tangles 
(NFTs), and gliosis, but disease etiology remains undetermined. The following sections 
will outline the clinical and neuropathological features that currently define AD and explore 
emerging research on the role of glia and white matter pathology.  
 
1.2.1 Clinical Profile of Alzheimer Disease 
Patients with symptoms of dementia can be evaluated in a clinical setting and if the 
pattern of cognitive impairment and biomarkers are characteristic of AD, a diagnosis of 
“probable AD” can be made105. As current clinical diagnoses are not sufficiently sensitive 
nor specific for AD, diagnosis of AD is not confirmed until post-mortem evaluation106; 
currently, there are no cognitive impairments or biomarkers that can provide definitive 
clinical diagnosis. However, the most recent criteria put forward by National Institute of 
Aging-Alzheimer’s Association (NIA-AA) and the International Working Group for New 
Research Criteria for the Diagnosis of AD (IWG2) have endorsed the use of some 
biomarkers in aiding clinical diagnosis105,107. Though biomarkers are an active area of 
development107-109, recommendations from NIA-AA and the 4th Canadian Consensus 
Conference on the Diagnosis and Treatment of Dementia (CCCDTD4) do not recommend 
regular use of biomarkers in the diagnosis of AD until more definitive evidence of safety 
and benefit is available110. Current treatments offer only modest delays of symptom 
progression111,112, but early and accurate diagnosis does improve care planning and 
symptom management112.  
Memory impairment is considered to be a cardinal symptom of AD and different types of 
memory are affected in a typical sequence as the disease progresses113. As 
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neurodegeneration typically begins in the structures of the medial temporal lobe including 
the hippocampus, episodic memory is often the earliest to be impaired114. Episodic 
memory describes memory of autobiographical events. Episodic memory of recent events 
tends to be affected prior to impairments of remote memory recall and immediate recall, 
which rely more on extra-hippocampal structures114. For example, a patient with mild-
moderate AD may have difficulty recalling a family visit from a day prior but could recall 
childhood memories or the meal that they just completed. As the disease progresses, 
semantic memory becomes impaired as well, which are memories of non-
autobiographical facts such as the capital of a country. Procedural memory, which 
describes non-declarative memories including motor skills such as playing the piano, is 
spared until late in disease progression. More recently, several other cognitive domains 
have been recognized as important features of early AD: visuospatial, language, and 
executive. Since 2011, the NIA-AA has recommended that symptoms of amnesia are not 
required for a diagnosis of probable AD105. This also applies to recent versions of two 
other widely used diagnostic criteria: the 5th edition of the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-V)115 and the IWG2107. Executive dysfunction is 
observed in the majority of early AD patients, with complex attentional functions as the 
most commonly affected: working memory, dual processing, attentional control, and 
response selection116.   
The global prevalence of AD was estimated to be 35.6 million in 2010; this figure is 
projected to nearly double every 20 years, due to the expected growth of the elderly 
population117. Early onset AD (EOAD), defined as the onset of dementia before 65 years 
of age, is rare but follows strong inheritance patterns118,119. Late onset AD (LOAD; 
diagnosed after the age of 65) is also considered to be a genetic disorder but with complex 
interactions with environmental factors120. After the age of 65, 17% of women and 9% of 
men are predicted to be diagnosed with AD in their lifetime, with risk increasing with 
age121. Overall, AD contributes to 60-80% of all dementia cases104. Common genetic 
variation of Apolipoprotein E (ApoE), which is involved in cholesterol and lipid transport 
throughout the body, is the strongest known genetic risk factor specific to LOAD122. In 
particular, an estimated 27% of the general population carries at least one allele for the 
ApoE ε4 isoform; carriers of a single ε4 variant have a 2-3 fold increased risk of LOAD, 
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while the rare 2% of the public that are ε4/ε4 carriers have a 12-fold increased 
risk104,123,124. Though ApoE has been implicated in AD by direct CNS dysregulation, it may 
also affect AD pathophysiology indirectly by cerebrovascular dysregulation, as ApoE is 
also a major risk factor for cardiovascular morbidity125. However, variations in ApoE only 
account for 1/4 of the genetic variance that contributes to LOAD diagnosis, and genetics 
overall can only account for 1/2 of the variance in LOAD diagnosis126. Thus, potentially 
modifiable environmental factors may play an important role for the majority of the 
population.  
Mild cognitive impairment (MCI) is a clinical diagnosis that identifies patients with 
relatively minor functional challenges due to cognitive impairments. MCI is primarily 
distinguished from dementia in that ADLs are not severely impaired, despite impairments 
in one or more cognitive domains127. Though MCI is not attributed to any particular 
neuropathology and can progress to different forms of dementia128, of which AD is only 
one form of dementia, the NIA-AA identifies MCI due to AD as the symptomatic 
predementia phase of AD127. As with the use of emerging diagnostic biomarkers, the 
CCCDTD4 recommends that MCI due to AD is only diagnosed in specialized clinical 
practice and for research purposes. Patients with MCI are at increased risk of developing 
dementia129, but this is controversial as the annual conversion rate is highly variable (3-
20%) and the majority of MCI diagnosed patients might not progress to a diagnosis of 
dementia even after 10 years of follow up130-134. Ongoing research on MCI is focused on 
identifying factors that distinguish MCI from cognitively unimpaired older adults and 
factors that predict conversion to the different forms of dementia. A large range of clinical 
factors and biomarkers have been found to predict conversion to AD, offering insight into 
the early pathophysiology and trajectory of AD:127,128,134 multidomain impairment135-139, 
vascular risk factors140, ApoE isoforms139, plasma and CSF biomarkers141, and 
neuroimaging biomarkers142,143 including white matter hyperintensities144,145. 
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1.2.2 Neuropathology of Alzheimer Disease 
The pathophysiology of AD remains undetermined and the disease has considerable 
pathological heterogeneity. However, all presentations of AD feature aggregates of 
amyloid protein and NFTs, attributed to increased production and/or impaired protein 
clearance.  
Amyloid precursor protein (APP) is expressed widely throughout the brain and in many 
other organs146,147, but its physiological functions have not been fully identified148. 
Mutations of APP and key enzymes involved in the amyloidogenic cleavage pathway of 
APP (PSEN1/2) have been linked to autosomal dominant forms of EOAD, though not all 
mutations are fully penetrant118. Two post-translational cleavage pathways have been 
identified for APP, with the amyloidogenic pathway producing an extracellular amyloid-β 
(Aβ) fragment. Aβ aggregates into several forms, ranging in size from soluble oligomers 
to insoluble fibrils that can form plaques. More recently, soluble Aβ oligomers, also known 
as also known as Aβ-derived diffusible ligands (ADDLs), have been considered to be a 
key player in the neurotoxic mechanism of AD as Aβ oligomers can bind a range of 
synaptic receptors and induce synaptic loss149. Interestingly, Aβ oligomers also elicit pro-
inflammatory responses and impairment of essential glial functions149. Moreover, neurons 
are no longer considered to be the sole source of Aβ; reactive astrocytes can also 
contribute significantly to Aβ production150.  
Tau protein is another important molecular factor in the pathophysiology of AD. Under 
physiological conditions, tau protein stabilizes neuronal microtubules. Pathological 
stressors induce hyperphosphorylation of tau, which then aggregates to form neurotoxic 
NFTs151. In AD, NFTs present after the accumulation of Aβ plaques but are a stronger 
neuropathological correlate of cognitive impairment152. NFTs accumulate first in the 
entorhinal cortex, and as the disease progresses, NFTs propagate into hippocampal 
regions, the lateral temporal cortex, association cortices, and lastly to primary unimodal 
cortices153-155. This contrasts the propagation of Aβ plaques which follow a more inward 
direction, first accumulating in the neocortical association regions before spreading to 
allocortical structures, the limbic regions, diencephalon, and lastly, the brainstem and 
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cerebellum155-157. Despite this difference in neuropathological propagation, direct 
interactions of Aβ and tau protein are thought to be synergistically deleterious and central 
to the development of dementia158-160, with glial cells playing an important role in 
mediating the interaction of Aβ and tau dysregulation161,162.     
 
1.2.2.1  Current Diagnostic Criteria  
Although post-mortem evaluation continues to be considered the gold-standard for 
verifying a clinical diagnosis of AD, many cases of autopsy-identified AD do not have a 
clinical history of dementia106. While such cases may indicate pre-symptomatic AD, which 
was intended by design163, neuropathological criteria continue to be refined to improve 
correlation with clinical history164. Currently, the most widely recognized guidelines were 
put forward by the NIA-AA165, which determines the neuropathological stage of AD 
according to:  
• Extracellular Aβ deposits, also known as senile plaques, scored according to the 
Thal phases156.  
• Intracellular NFTs that feature aggregates of hyperphosphorylated tau protein, 
scored by Braak stages154 
• Dense aggregates of Aβ and dystrophic neurites known as neuritic plaques, scored 
according to the Consortium to Establish a Registry for Alzheimer Disease 
(CERAD) criteria166. These represent a subset of senile plaques and are more 
closely associated with neuronal injury.  
The scores of these 3 neuropathological features are combined to determine whether 
brain tissue has low, intermediate, or high levels of AD neuropathological changes. Senile 
plaques in the Thal phases include diffuse Aβ plaques, which are usually not associated 
with glial responses or synaptic loss167. Though diffuse Aβ plaques are a sensitive 
indicator of AD dementia, they are also common in elderly individuals without dementia. 
However, characterizing the distribution and density of all forms of senile plaques 
continues to play a role in the NIA-AA guidelines by improving sensitivity for cognitive 
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impairment168 and detection of early disease156,164. The Thal phases are also 
recommended for correlation with neuroimaging studies165. To offer improved diagnostic 
specificity for cognitive impairment, the CERAD criteria excludes diffuse plaques and 
emphasizes neuritic plaques, which are more closely associated with cognitive 
impairment167. The Braak distribution of NFTs provides even stronger clinicopathological 
correlation, as neocortical NFT burden provides the strongest neuropathological correlate 
for cognitive impairment152,167. However, NIA-AA guidelines clearly state that Aβ deposits, 
NFTs, and neuritic plaques should not be considered the comprehensive molecular profile 
of AD neuropathology165. Rather, the guidelines prompt further research into elucidating 
the unknown mechanisms by which amyloid and tau proteins are dysregulated and 
identifying the specific molecular processes that lead to neurodegeneration. Experimental 
animal models continue to be recommended for this line of research165.  
 
1.2.2.2  Role of Glia in Alzheimer Disease 
Both neuritic plaques and NFTs are associated with astrocytosis and microgliosis169. 
Whereas Aβ load plateaus early after symptom onset169,170, astrocytosis and microgliosis 
continue to increase linearly as the disease progresses169. Moreover, astrocytosis and 
microgliosis are correlated with NFT burden and loss of cortical thickness169, raising the 
question of whether these glial responses are merely reacting to the AD pathology or 
playing a central role in the disease mechanism66. As glial cells are fundamental to the 
maintenance of CNS homeostasis, including inflammatory processes, glial cells present 
a favorable therapeutic target for modifying the course of AD64,65. 
Neuroinflammation in AD is thought be driven primarily by microglia, the brain’s resident 
myeloid cells, which are involved in both cytokine secretion and phagocytosis66. This is 
distinct from the conditions that are traditionally defined as neuroinflammatory diseases, 
namely multiple sclerosis and the different forms of encephalitis, which are driven by 
peripheral leukocytes that migrate into the CNS from systemic circulation66. The adaptive 
immune response, mediated primarily by T- and B-lymphocytes, has not been implicated 
in AD neuroinflammation, so mechanisms seen in most autoimmune conditions are 
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unlikely to be observed in AD. Furthermore, astrocytes are also directly involved with AD 
neuroinflammation66,77. Unlike in MS, traumatic injury, or ischemic stroke, astrocytes in 
AD do not typically form glial scars even though they upregulate expression of glial 
fibrillary acidic protein (GFAP)66. Instead, reactive astrocytes appear to modulate 
microglial function and play an important role in Aβ degradation66,77,171. This is further 
complicated by the observation of senescent or dystrophic microglia and astrocytes 
associated with prolonged exposures of high Aβ concentrations, which may indicate a 
crucial decompensation in the course of AD66,172,173. It remains to be determined which 
specific processes in AD neuroinflammation are protective and which are detrimental66.  
Both preclinical and clinical studies suggest a critical role of glial-mediated inflammation 
in AD. Cognitive and neuropathological profiles of transgenic mouse models of AD have 
been improved by a breadth of molecules with anti-inflammatory properties: rapamycin, 
minocycline, pioglitazone, thalidomide, etanercept, and celastrol, all of which modulate 
tumour necrosis factor-α (TNF-α) signalling and the activation of pro-inflammatory 
microglia and astrocytes174-176. TNF-α is a pro-inflammatory cytokine that plays a pivotal 
role in inflammation throughout the body, and its expression is increased by both neurons 
and glial cells during both acute and chronic brain injury.176 Aβ activates several TNF-α 
dependent pathways, including cyclooxygenase (COX)-mediated inflammatory 
processes177. Non-steroidal anti-inflammatory drugs (NSAIDs) reduce these inflammatory 
processes by inhibiting COX in neurons, microglia, and astrocytes178,179, and NSAIDs may 
also offer neuroprotection by COX-independent pathways such as the direct promotion 
of non-amyloidogenic processing of APP179-181. Cohort studies of have shown promise in 
reducing the risk of AD, with the most recent meta-analysis of 236 000 participants from 
16 cohort studies citing a 19% relative risk reduction of AD diagnosis179. This supports 
the potential of anti-inflammatory drugs as a disease modifying therapy but the optimal 
NSAID type, dose, and the duration and timing of treatment have yet to be identified. 
Skepticism over this direction of research is raised by several studies that showed an 
increased incidence of AD among NSAID cohorts179. The only randomized-controlled trial 
of NSAID intervention did find reduced AD incidence if treatment was initiated in 
asymptomatic individuals, but increased incidence if treatment was initiated in patients 
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with cognitive impairment or dementia182, suggesting that the timing of NSAID intervention 
with regard to disease stage is a crucial factor. This consideration is likely to extend to 
other anti-inflammatory drug trials, such as the phase-II trial of the anti-TNF-α biologic, 
etanercept, which showed favourable but non-significant trends in patients with mild to 
moderate AD183. 
In AD, glial cell density increases throughout grey matter tissue, but also in white 
matter184. Oligodendrocytes provide important tropic supports to neurons, but Aβ is toxic 
to oligodendrocytes in vitro185,186. Histological changes of white matter are commonly 
observed in AD; while oligodendrocyte density is decreased, post-mortem evaluation has 
found astrocyte and microglia numbers to be increased in the white matter of patients 
with AD dementia187,188. PET studies have also identified increased white matter 
inflammation in AD patients68,189. 
 
1.2.2.3 White Matter Changes in Alzheimer Disease 
Much of AD continues to be defined by pathological changes in grey matter but white 
matter degeneration is also observed in AD, both on imaging and in histological 
samples23,190-193. In AD, white matter degeneration can range from demyelination to 
atrophy32,190,194. The specific patterns of white matter atrophy may also be crucial to 
differentiating potentially distinct forms of AD191. Whereas LOAD more typically featured 
white matter atrophy in the medial temporal regions, EOAD features greater cingulate 
atrophy191. Atypical variants of AD include the logopenic variant of primary progressive 
aphasia (lv-PPA), which features more left parietal white matter atrophy, and posterior 
cortical atrophy (PCA), which features more occipital white matter atrophy. Compared to 
LOAD, more white matter atrophy in the lateral temporal cortex, parietal cortex, cingulum, 
and corpus callosum were observed in EOAD, lv-PPA, and PCA191. Thus, specific 
patterns of white matter atrophy may aid in characterizing specific forms of AD.   
This has prompted the possibility that white matter disease may be a core feature of 
AD186. However, whether white matter atrophy is due to local degenerative changes or 
secondary to remote neuronal injury, i.e., due to Wallerian or anterograde degeneration 
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has not been determined190. Currently, there is more evidence in favour of white matter 
atrophy as a secondary process, as grey matter and white matter volume loss are usually 
correlated190. However, primary local damage and retrograde damage due to AD cannot 
be ruled out190. Oligodendrocytes may be sensitive to the increased concentrations of Aβ 
seen in the brains of patients with AD, and loss of oligodendrocytes due to increased 
concentrations of Aβ could contribute to white matter demyelination and consequent 
degeneration185,186. Moreover, the specific patterns of diffusion tensor changes seen in 
AD are not indicative of primarily Wallerian degeneration190,195,196. While grey matter and 
white matter volume loss may be correlated in AD, white matter damage seen in MCI 
showed no relationship with grey matter atrophy190,194. This suggests that especially in 
the early stages of disease, white matter may undergo atrophy due to local injury and 
retrograde degeneration as well as secondary degeneration due to grey matter injury and 
anterograde degeneration190. The growing evidence of glial dysregulation as a common 
feature of AD also suggests potential inflammatory mechanisms by which white matter 
could be damaged directly68,186,197, independent of grey matter senile plaques and 
NFTs167.  
Any observed primary local damage could also be attributed to vascular injury, as white 
matter is particularly sensitive to vascular disruption49-51 and cerebrovascular disease is 
highly comorbid with AD198,199. However, there is considerable overlap in the findings that 
are conventionally attributed to purely AD and purely vascular neuropathologies200-204, 
with many proposing that vascular disruption may be central to AD as well31,33,34,202,205,206. 
The intersection of AD and VaD may be most apparent in leukoaraiosis, the radiological 
phenomenon of diffuse hypodense (on CT) or hyperintense (on T2 MRI) white matter29-
34. Leukoaraiosis is associated with disruptions of white matter integrity35,36 and vascular 
pathology41,45,50,207-211, but leukoaraiosis is also an important risk factor for AD37-39 and 
leukoaraiosis volume has also been correlated directly with the severity of cognitive and 
functional impairment in AD212-214. Recently, CSF concentrations of Aβ were found to 
correlate with leukoaraiosis volume215,216. In the Dominantly Inherited Alzheimer Network 
(DIAN) study, which follows a cohort of carriers of genetic mutations known to cause 
EOAD (PSEN1/2, APP), leukoaraiosis volume began to increase significantly 6 years 
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prior to estimated symptom onset32. Specifically, in the parietal and occipital lobe, 
leukoaraiosis was significantly increased as early as 22 years prior to estimated symptom 
onset. This offers strong support for leukoaraiosis as a core feature of AD and a potential 
biomarker as opposed to an observation that is commonly coincidental due to chance 
alone32. However, the pathological basis of leukoaraiosis has yet to be identified. While 
many studies suggest a vascular etiology for leukoaraiosis41, dysregulation of astrocytes 
in the BBB45 and genetic variation related to inflammation has also been implicated46. 
Though dysregulation of astrocytes and aberrant inflammation can certainly be initiated 
by vascular pathology, AD-related proteinopathies may also drive the dysregulation of 
glial cells and neuroinflammation, as discussed above.  While leukoaraiosis may already 
be an informative predictor for dementia, further experimentation is needed to identify the 
etiology of leukoaraiosis in the context of AD. 
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1.3 Vascular Cognitive Impairment 
Cerebrovascular disease is highly heterogeneous and the second most prevalent cause 
of dementia104,199,217. When cerebrovascular disease causes cognitive and functional 
impairment, Vascular dementia (VaD) is diagnosed. However, in many patients, 
cerebrovascular disease may result in cognitive impairment but not functional 
impairment217, analogous to MCI with cerebrovascular etiology218,219. In recognition of 
this, broader diagnostic categories have been proposed: major Canadian and US 
associations endorse vascular cognitive impairment (VCI)217,220, the International Society 
for Vascular Behavioural and Cognitive Disorders (VASCOG) endorse vascular cognitive 
disorder221, and the DSM-V uses the term vascular neurocognitive disorders115. While the 
terminology will continue to evolve in research and clinical settings, this thesis will refer 
to the term VCI to include both VCI-no dementia (VCIND)218,219 and VaD. VCIND and VaD 
exist on a spectrum of cognitive manifestations of cerebrovascular disease, with VaD only 
diagnosed when cognitive impairment causes severe functional impairment. In the 
Canadian Study of Health and Aging, following a diagnosis of VCIND, 58% died and 46% 
developed dementia within 5 years; of patients that progressed to dementia and were 
alive at follow-up, 35% had AD, 15% had mixed dementia, 42% had VaD, and 8% had an 
unclassified form of dementia222. Since effective prevention and treatment for 
cerebrovascular disease exists, there is growing interest in reliably identifying VCI to limit 
disease progression217,222.  
Unlike AD, there is not a defined set of pathological criteria for the post-mortem diagnosis 
of VaD, and clinical diagnostic criterion are applied inconsistently223. Moreover, increased 
recognition of the comorbidity of AD and VaD has made it difficult to distinguish the two 
diseases, with growing recognition of mixed dementia as the most prevalent form of 
dementia199,224. Mixed dementia will refer to the prevalent case in which both AD and 
cerebrovascular disease contribute to cognitive impairment199,224, although comorbidity of 
other forms of neurodegenerative disease are also common. 
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1.3.1 Clinical Profile of Vascular Cognitive Disorders 
Generally, VCI can result from overt symptomatic cerebrovascular disease, such as 
ischemic or hemorrhagic stroke, or from “covert” cerebrovascular disease, such as 
asymptomatic lacunar infarcts or small vessel disease199. Particularly in patients with 
covert cerebrovascular disease, thorough physical examination, neuropsychological 
assessment, and neuroimaging play an important role in diagnosing VCI. Due to the 
vascular nature of VCI, functional and cognitive impairments evolve suddenly, in contrast 
to the relatively gradual progression of impairments seen in AD. Any cognitive domain 
can be impaired and multidomain impairment is common in VCI. As the frontal lobes and 
white matter are particularly susceptible to cerebrovascular disease, executive functions 
are the most commonly affected199. Deficits in ADLs only contribute to the diagnosis of 
VCI if they are due to cognitive impairments; functional impairments as a result of any 
motor or sensory sequalae related to cerebral infarcts are not considered, emphasizing 
the cognitive component of VCI220.  
The epidemiological estimates of VCI vary greatly but offer important insights into the 
complex relationships between cerebrovascular disease and dementia. Risk factors for 
VCI are generally the same risk factors identified for stroke and cardiovascular disease: 
smoking, atrial fibrillation, hypertension, diabetes, hyperlipidemia, and ApoE ε4, while 
regular exercise confers protection220. After the age of 55, lifetime risk of stroke is 21% in 
women and 17% in men121, while estimates for the proportion of patients that develop 
cognitive impairment after a symptomatic stroke ranges greatly, from 6-41%225,226. With 
regard to covert cerebrovascular disease, 67-76% of elderly subjects without a history of 
cognitive impairment exhibit cerebrovascular pathology in post-mortem evaluation, with 
small vessel disease being the most common198,227. Thus, even in the absence of overt 
cognitive symptoms, cerebrovascular disease is highly prevalent. Both overt and covert 
cerebrovascular disease contribute to an overall prevalence of VaD in 1.6% of individuals 
over the age of 65, with prevalence increasing exponentially with age228. Though there 
are no direct studies of the lifetime risk of VaD, lifetime risk of all-cause dementia is 22% 
in women and 14% in men over the age of 65121, of which 15-20% is attributed to 
VaD225,228-230. Similarly, VaD accounts for 18% of early dementia cases diagnosed prior 
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to 65 years of age228. However, cerebrovascular disease is estimated to contribute 33% 
of the risk of all-cause dementia199,217; cerebrovascular disease is highly comorbid with 
AD, such that mixed dementia is estimated to be more prevalent than either “pure” AD or 
VCI199,224.  
 
1.3.2 Neuropathology of Vascular Cognitive Disorders: Cerebrovascular Disease 
Cerebrovascular disease, the underlying neuropathology of VCI, is very heterogeneous, 
and multiple types of cerebrovascular lesions can be observed in a single brain. 
Universally accepted neuropathological criteria for VCI do not exist221,223, and the 
correlations between the breadth of cerebrovascular disease and its range of clinical 
manifestation is an area of ongoing research226,231,232. However, it is informative to 
classify cerebrovascular disease according to major etiological categories199,226:  
• Large vessel disease or atherosclerosis: proliferation of the intima (atheroma) in 
medium and large arteries, with accumulation of cholesterol and leukocytes that 
can lead to plaque formation and calcification.  Plaques can rupture, causing local 
thrombosis and a single large brain infarct or produce emboli and multiple infarcts.  
• Small vessel disease: reduced compliance in arterioles and capillaries due to 
arteriosclerosis, lipohyalinosis, arteriolosclerosis, and amyloid angiopathy,  
resulting in lacunar infarcts, even smaller microinfarcts, small hemorrhages, and 
extravasations of blood known as microbleeds.  
• Cardiac: cardioembolic injury, commonly attributed to atrial fibrillation, as well as 
any condition that impairs cerebral perfusion such as cardiomyopathy, cardiogenic 
shock. 
• Other Systemic: sickle cell disease, autoimmune conditions such as vasculitis, 
circulatory shock. 
Cerebrovascular lesions can be further categorized according to distribution: focal, 
multifocal, or diffuse. Focal lesions can be attributed to any of the etiologies described 
above, but focal lesions that result in VCI are usually the result of an infarct in functionally 
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important regions. Focal lesions affecting the mesial temporal lobe, anterior cingulate 
cortex, caudate, thalamus, angular gyrus of the dominant hemisphere, and key white 
matter areas can result in strategic infarct dementia223. Multifocal lesions of large vessel 
etiology can result in multiple infarct dementia223. Multifocal or diffuse lesions of small 
vessel etiology are particularly heterogeneous and are seen in VCI attributed to multiple 
lacunar infarcts, Binswanger disease, hypertensive angiopathy, and cerebral amyloid 
angiopathy223. In two hereditary cerebrovascular conditions that can result in VCI, 
dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)233 
and Moya Moya disease234, both small and large vessel disease are seen in a 
multifocal/diffuse distribution. The categories of cerebrovascular pathologies outlined 
here are far from exhaustive but do capture some of the breadth of factors involved. 
Further considerations related to neuropathological staging include lesion severity, 
location(s), and sampling strategies are also in ongoing development, and will likely play 
an important role in correlating cerebrovascular disease and VCI226,231,232. 
The high co-occurrence of AD and cerebrovascular disease199,224 has generated research 
on whether the two diseases may have synergistic neuropathological and cognitive 
effects235-239. This is supported by the Nun Study, which found that AD pathology was far 
more likely to correlate with dementia if cortical infarcts or lacunar strokes were also 
present240. This has been replicated, with a recent metanalysis of 2856 from 10 studies 
finding that compared to patients with post-mortem evidence of AD, patients with both AD 
neuropathology and cerebrovascular disease were three times more likely to have had 
dementia241. In a large post-mortem study from the National Alzheimer’s Coordinating 
Centre, 80% of patients diagnosed with AD were also found to have cerebrovascular 
pathology, significantly greater than the 67% of subjects that had cerebrovascular 
pathology but no cognitive impairment198. Furthermore, a recent large cross-sectional 
study with participants of the Religious Orders Study and the Rush Memory and Aging 
Project found the odds of a clinical diagnosis of AD to be increased in participants that 
had cerebral atherosclerosis or cerebral arteriosclerosis, confirmed post-mortem239. 
Thus, the prevention and treatment of cerebrovascular disease is likely to play an 
important role in reducing the burden of dementia by addressing both AD and VCI241-243.  
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1.4 The Neurovascular Hypothesis of Alzheimer disease  
In recognition of the high comorbidity between AD and VCI, the Neurovascular 
Hypothesis of AD proposes that the interaction of amyloid pathology and cerebrovascular 
disease is a core mechanism that leads to neuronal injury and cognitive impairment236.  
The Neurovascular Hypothesis directs focus to neurovascular unit (NVU), which is 
composed of neurons, astrocytes, endothelial cells, myocytes, pericytes, crucial 
extracellular components, and resident immune cells244.  A crucial component of the NVU 
is the BBB, which segregates the interstitial microenvironment of the CNS and regulates 
the clearance of neurotoxic molecules such as Aβ. The NVU also regulates the coupling 
of blood flow and local metabolic demands, known as hyperaemia or neurovascular 
coupling203,245. Thus, the NVU is crucial to protecting the brain from both AD pathology 
and cerebrovascular disease. At the same time, the NVU can be directly disrupted by 
both of these diseases as well as systemic vascular conditions203,237,238,246-248. 
Experimental studies have generated evidence in support of the Neurovascular 
Hypothesis, identifying potential therapeutic targets that may prevent important 
neurodegenerative disease mechanisms203,237,246-251.      
 
1.4.1 The Neurovascular Unit and Blood-Brain-Barrier 
Autoregulation of large vessels maintains near-constant blood flow to a large vascular 
territory, accomplished by intravascular regulation of the luminal diameter to compensate 
for fluctuations in systemic blood pressure. In contrast, coupling occurs at the microscopic 
level of the vascular bed, accomplished through a complex coordination between NVU 
cells responding to fluctuations in the metabolic demands of the local parenchyma244. 
Myocytes are the smooth muscle cells that make autoregulation of arteries and arterioles 
possible, and myocytes communicate with downstream pericytes via gap junctions252. 
Pericytes are also contractile cells that regulate blood flow at the level of capillary beds 
and individual capillaries, and pericytes have been found to communicate with both 
endothelial cells and astrocytes244. Astrocytes are considered to be the key detector of 
abluminal metabolic demands, receiving glutamatergic signals from neurons and 
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interneurons244. To relay these signals and affect local blood flow, astrocyte endfeet 
release vasoactive substances such as eicosanoids which directly stimulate or inhibit the 
contraction of pericytes253. Additionally, astrocyte endfeet release potassium ions into 
blood vessels and onto myocytes, inducing vasodilation253. Endothelial cells also 
modulate vascular tone, and relay signals of vascular tone to astrocytes244. Importantly, 
cells of the NVU are mutually dependent on crucial extracellular trophic factors during 
both development, maintenance, and microstructural remodelling244. The NVU directs the 
formation, maintenance, and remodelling of the BBB, which regulates the passive and 
active diffusion of molecules and ions both into and out of the brain parenchyma. The 
physical barrier of the BBB is formed in part by the complex basement membrane that is 
maintained by both endothelial cells and astrocytes248. More recently, the primary 
inflammatory cells of the brain, microglia, have also been found to respond to ischemia 
and contribute to BBB and vascular remodelling by cytokine signalling.  Dysregulation of 
any of the NVU cells or microglia can contribute to a dysfunctional BBB.  
 
1.4.2 NVU Dysfunction 
The NVU maintains neurovascular coupling and the microenvironment of the CNS, 
promoting healthy CNS function. However, vascular conditions can lead to dysregulation 
of the NVU, disrupting CNS homeostasis. Hypertension, ischemic stroke, and covert or 
‘silent’ brain infarcts (SBI) are among the most prevalent vascular etiologies that can 
cause NVU dysfunction. The NVU is essentially the site at which small vessel disease 
occurs; arteriolosclerosis, lipohyalinosis, microbleeds, and microhemorrhages indicate 
profound disruption of the NVU254. Due to the diffuse nature of small vessel disease, NVU 
dysregulation is likely to exist well beyond the immediate temporal or anatomical proximity 
of detectable cerebrovascular lesions, such as SBI. Impaired coupling results in 
oligaemia, hypoxia237,  and mitochondrial-mediated oxidative stress237, with further injury 
propagated by dysregulated inflammation248,255,256. Meanwhile, a ‘leaky’ BBB can result 
in extravasation of circulating molecules and proteins that have toxic and pro-
inflammatory effects in the brain237,254. Interestingly, peripheral sources of circulating Aβ 
can enter the CNS, induce Aβ-related pathology, and disrupt neuronal function237,246,257; 
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this can be prevented by molecular interventions that target specific molecules in the 
NVU246. Thus, NVU dysfunction can exacerbate or result in AD pathology. In turn, 
abluminal pathology such as AD can also propagate dysregulation of the NVU and BBB, 
creating a self-propagating pathological cycle.  
 
1.4.2.1 Hypertension 
Hypertension is a highly prevalent condition, affecting 23% of Canadian adults, of whom 
only 68% have controlled blood pressure258. Hypertension is also recognized as a leading 
vascular risk factor for stroke and dementia259,260, including AD261-263. Experimental 
animal models of comorbid hypertension to exacerbate AD-related pathology251,264-268. 
However, while the connection between hypertension and cerebrovascular disease is well 
established259,260, it remains inconclusive whether anti-hypertensive therapy reduces AD 
incidence269-274. In addition to dysregulating cerebrovascular autoregulation, hypertension 
can also disrupt neurovascular coupling203. This was observed in an experimental 
hypertensive rodent model that had an attenuated blood low response to whisker 
stimulation275, which was further exacerbated by neocortical application of Aβ or by 
transgenic expression of pathogenic APP276. Similarly, in a clinical cohort study using 
PET imaging, hypertensive subjects demonstrated a reduced hemodynamic change 
during a memory task277. Moreover, hypertension has been shown to cause BBB 
leakiness and the pro-inflammatory activation of microglia and astrocytes278. Perivascular 
macrophages, resident immune cells that are distinct from microglia, have also been 
found to release reactive oxygen species in response to hypertension, resulting in 
neurovascular and cognitive dysfunction279. These are some of the mechanisms by which 
hypertension can disrupt the NVU and CNS function, even in the absence of detectable 
cerebrovascular disease203. 
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1.4.2.2 Ischemic Stroke and Silent Brain Infarcts  
The lifetime risk of ischemic stroke in the Framingham study was found to be 18% for 
women and 15% for men at 55 years of age280. in a recent retrospective cohort study in 
London, Ontario, cardioembolic etiology accounted for 56% and large artery 
atherosclerosis accounted for 26% of ischemic stroke cases 281. Small vessel disease 
can also result in ischemic lesions, including microinfarcts and lacunar infarcts; when 
these infarcts do not cause symptoms, they are classified as an SBI. By their nature, SBIs 
are found incidentally on neuroimaging or in post-mortem evaluation, most often affecting 
subcortical white matter, basal ganglia, thalamus, and the infratentorial region282. 
Disturbingly, SBI are found in 10-20% of the general elderly population, increasing with 
age and hypertension283,284 to as high as 62% in select elderly populations with other 
significant morbidity285. While the chronic impact of SBI on proximal intact NVUs is difficult 
to investigate, it is likely to demonstrate similar processes seen in ischemic strokes and 
small vessel disease. Following ischemic stroke, autoregulation and coupling are 
impaired even in brain regions that appear uninjured203. Similarly, in a transient middle 
cerebral artery occlusion model, BBB disruption can be observed 30 days after injury, 
even on the contralateral hemisphere286. When striatal lacunar infarcts were modelled in 
a transgenic mouse model of AD, increased APP, tau, and inflammatory microglia were 
observed in the cortex and hippocampus287. In this same study, anti-inflammatory 
treatment reduced the area and density of APP near the injury site. Thus, inflammation 
may play an important role in propagating AD-related pathology following NVU injury by 
ischemic stroke and SBI. 
 
1.4.2.3 Abluminal Injury: Alzheimer Disease Pathology  
Aβ is generally cleared from the brain by enzymatic degradation or by active clearance 
across the BBB, mediated by the low-density lipoprotein receptor-related proteins (LRP) 
pathway. Endothelial cell LRP1 binds and initiates clearance of abluminal unbound Aβ as 
well as ApoE-bound Aβ; interestingly, ApoE ε4 inhibits this active transport of Aβ out of 
the brain237. By impairing the clearance of Aβ, reduced expression of LRP1 in blood 
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vessels has been associated with AD in both preclinical and clinical studies237. However, 
Aβ can impair its own clearance by oxidizing LRP1, which was observed in the 
hippocampal tissue of AD patients288. As Aβ is toxic to virtually all cell types in the NVU, 
increased concentrations of Aβ, as seen in AD, can directly disrupt the NVU289,290. 
Additionally, dysregulated inflammation induced by AD pathology can further disrupt the 
NVU, while failure of perivascular macrophages to clear Aβ can contribute to its 
accumulation in the brain279,289,291. Thus, the disruption of the NVU may be either a cause 
of AD, a consequence of AD, or both. In any case, there is strong indication that the NVU 
has a central role in neurodegenerative disease. 
 
1.4.3 White Matter Pathology and the Neurovascular Hypothesis of Alzheimer Disease 
The Neurovascular Hypothesis offers a potential understanding of AD that is non-neuron-
centric236, as it draws attention to the important role of non-neuronal cells in the NVU. 
Similarly, the often-overlooked factor of white matter disease may also play an important 
role in the Neurovascular Hypothesis; disruption of NVUs in periventricular white matter, 
which is particularly vulnerable to cerebrovascular pathology44,47-52, may contribute to the 
accumulation of cerebral Aβ and in turn, AD. Both in preclinical and clinical studies, AD 
pathology is associated with impaired coupling235,245. Dramatic pericyte loss is observed 
in the white matter of patients that had AD, which is also accompanied with 
demyelination292. This was further investigated in transgenic mice lacking cerebral 
pericytes, which developed white matter dysfunction, white matter atrophy, hippocampal 
and cortical atrophy, and cognitive impairments292. Furthermore, a transgenic mouse 
model of AD treated with simvastatin, a cholesterol lowering drug, showed improved 
coupling and cognition293. 
The role of proinflammatory astrocytes and microglia in NVU injury, white matter integrity, 
and cognitive impairment is also strongly supported; 5 recent experimental animal studies 
showed that targeted modulation of astrocyte- and microglia-mediated inflammation 
protected white matter microstructure, white matter function, and cognition following 
chronic hypertension, hypoperfusion, and ischemic injury72-76. These studies did not 
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evaluate whether protecting white matter integrity had beneficial effects on executive 
function, but this link has been demonstrated in humans. In elderly individuals with 
hypertension and/or diabetes mellitus type 2, neurovascular coupling was measured by 
changes in blood flow velocity in the middle cerebral artery during a series of cognitive 
evaluations; more responsive coupling was correlated with better scores on cognitive 
flexibility tasks and higher white matter FA, an indicator of white matter integrity294. In the 
same study, consumption of flavanol-cocoa for 30 days improved coupling and 
behavioural flexibility scores, which was attributed to the beneficial effects of cocoa 
flavanols on systemic and cerebral vascular function294. Altogether, these studies strongly 
indicate that white matter inflammation and cerebrovascular disease play an important 
role in the pathogenesis of executive dysfunction and AD. However, with regard to 
executive function, this has yet to be evaluated in an experimental model of AD.  
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1.5 Rationale and Objectives  
White matter is highly susceptible to ageing12,85, as both amyloid pathology and 
cerebrovascular disease can initiate white matter inflammation and 
dysfunction44,68,186,215,216,292. In recent studies, microglia- and astrocyte-mediated 
inflammation of white matter was shown to impair executive function78-81, a major 
cognitive domain that is crucial for maintaining functional independence86-88. However, 
the relationship between white matter inflammation and executive function in the contexts 
of ageing or AD has not been directly evaluated, even though both increased 
inflammation and executive dysfunction are common in advanced age and 
AD68,84,116,190,191,193. Thus, we hypothesized that ageing and pathogenic APP induce 
white matter inflammation, resulting in executive dysfunction. Furthermore, as white 
matter is particularly vulnerable to cerebrovascular disease44,47-52, chronic dysfunction of 
the NVU can result in reduced clearance of Aβ237 and further exacerbation of white matter 
inflammation248,255,256. Thus, vascular injury exacerbates white matter inflammation 
and executive dysfunction induced by ageing and pathogenic APP. A transgenic rat 
model of AD was studied to test these hypotheses and address the following research 
objectives: 
1) To determine the effect of pathogenic APP on white matter inflammation and 
executive function (Chapter 2 and Chapter 3) 
2) To characterize the temporal relationship between age, pathogenic APP 
expression, white matter inflammation, and executive function (Chapter 3) 
3) To evaluate the impact of comorbid pathogenic APP and cerebrovascular stress 
(hypertension; Chapter 4) or injury (ischemia; Chapter 5) on executive function 
The attributes of the transgenic model, the TgAPP21 rat, permitted the investigation of 
pre-Aβ-plaque dysfunction295-298, modelling the early stages of AD-related pathology. 
Evaluation of inflammation was focused on microglia and astrocytes, as these cells are 
central to the neuroinflammatory processes observed in neurodegenerative disease66. 
Testing paradigms for rat behavioural flexibility have been well established100,299,300, and 
behavioural flexibility is considered to be the most integrated cognitive subdomain of 
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executive function82. Thus, evaluation of executive function in the TgAPP21 rat was 
focused on behavioural flexibility.    
32 
 
 
1.6  References 
1. Filley CM. White matter and behavioral neurology. Ann N Y Acad Sci. 2005;1064:162-183. 
2. Kumar DR, Aslinia F, Yale SH, Mazza JJ. Jean-Martin Charcot: the father of neurology. Clin Med 
Res. 2011;9(1):46-49. 
3. Filley CM. White Matter Dementia: Origin, Development, Progress, and Prospects. J 
Neuropsychiatry Clin Neurosci. 2016:appineuropsych16010003. 
4. Jakel S, Dimou L. Glial Cells and Their Function in the Adult Brain: A Journey through the History 
of Their Ablation. Front Cell Neurosci. 2017;11:24. 
5. Kaminsky N, Bihari O, Kanner S, Barzilai A. Connecting Malfunctioning Glial Cells and Brain 
Degenerative Disorders. Genomics Proteomics Bioinformatics. 2016;14(3):155-165. 
6. Matute C, Ransom BR. Roles of white matter in central nervous system pathophysiologies. ASN 
Neuro. 2012;4(2). 
7. Lundgaard I, Osorio MJ, Kress BT, Sanggaard S, Nedergaard M. White matter astrocytes in health 
and disease. Neuroscience. 2014;276:161-173. 
8. Fields RD. Neuroscience. Change in the brain's white matter. Science. 2010;330(6005):768-769. 
9. de Lange AG, Brathen AC, Grydeland H, et al. White matter integrity as a marker for cognitive 
plasticity in aging. Neurobiol Aging. 2016;47:74-82. 
10. Jones DK, Knosche TR, Turner R. White matter integrity, fiber count, and other fallacies: the do's 
and don'ts of diffusion MRI. Neuroimage. 2013;73:239-254. 
11. Soares JM, Marques P, Alves V, Sousa N. A hitchhiker's guide to diffusion tensor imaging. Front 
Neurosci. 2013;7:31. 
12. Salat DH, Tuch DS, Greve DN, et al. Age-related alterations in white matter microstructure 
measured by diffusion tensor imaging. Neurobiol Aging. 2005;26(8):1215-1227. 
13. Jung RE, Grazioplene R, Caprihan A, Chavez RS, Haier RJ. White matter integrity, creativity, and 
psychopathology: disentangling constructs with diffusion tensor imaging. PLoS One. 
2010;5(3):e9818. 
14. Gunning-Dixon FM, Raz N. The cognitive correlates of white matter abnormalities in normal aging: 
a quantitative review. Neuropsychology. 2000;14(2):224-232. 
15. Sasson E, Doniger GM, Pasternak O, Tarrasch R, Assaf Y. White matter correlates of cognitive 
domains in normal aging with diffusion tensor imaging. Front Neurosci. 2013;7(7 MAR):32. 
16. Rabin JS, Perea RD, Buckley RF, et al. Global White Matter Diffusion Characteristics Predict 
Longitudinal Cognitive Change Independently of Amyloid Status in Clinically Normal Older Adults. 
Cereb Cortex. 2018(February):1-12. 
17. Hedden T, Gabrieli JD. Insights into the ageing mind: a view from cognitive neuroscience. Nat Rev 
Neurosci. 2004;5(2):87-96. 
33 
 
 
18. Grieve SM, Williams LM, Paul RH, Clark CR, Gordon E. Cognitive aging, executive function, and 
fractional anisotropy: a diffusion tensor MR imaging study. AJNR Am J Neuroradiol. 
2007;28(2):226-235. 
19. Head D, Buckner RL, Shimony JS, et al. Differential vulnerability of anterior white matter in 
nondemented aging with minimal acceleration in dementia of the Alzheimer type: evidence from 
diffusion tensor imaging. Cereb Cortex. 2004;14(4):410-423. 
20. Van Petten C, Plante E, Davidson PS, Kuo TY, Bajuscak L, Glisky EL. Memory and executive 
function in older adults: relationships with temporal and prefrontal gray matter volumes and white 
matter hyperintensities. Neuropsychologia. 2004;42(10):1313-1335. 
21. Madden DJ, Bennett IJ, Song AW. Cerebral white matter integrity and cognitive aging: contributions 
from diffusion tensor imaging. Neuropsychol Rev. 2009;19(4):415-435. 
22. Bozzali M, Franceschi M, Falini A, et al. Quantification of tissue damage in AD using diffusion tensor 
and magnetization transfer MRI. Neurology. 2001;57(6):1135-1137. 
23. Lin YC, Shih YC, Tseng WY, et al. Cingulum correlates of cognitive functions in patients with mild 
cognitive impairment and early Alzheimer's disease: a diffusion spectrum imaging study. Brain 
Topogr. 2014;27(3):393-402. 
24. Atkinson-Clement C, Pinto S, Eusebio A, Coulon O. Diffusion tensor imaging in Parkinson's 
disease: Review and meta-analysis. Neuroimage Clin. 2017;16:98-110. 
25. Alves GS, Sudo FK, Alves CEO, et al. Diffusion tensor imaging studies in vascular disease: A 
review of the literature. Dement Neuropsychol. 2012;6(3):158-163. 
26. Metzler-Baddeley C, Cantera J, Coulthard E, Rosser A, Jones DK, Baddeley RJ. Improved 
Executive Function and Callosal White Matter Microstructure after Rhythm Exercise in Huntington's 
Disease. J Huntingtons Dis. 2014;3(3):273-283. 
27. Cesar B, Dwyer MG, Shucard JL, et al. Cognitive and White Matter Tract Differences in MS and 
Diffuse Neuropsychiatric Systemic Lupus Erythematosus. AJNR Am J Neuroradiol. 
2015;36(10):1874-1883. 
28. Smith EE, Salat DH, Jeng J, et al. Correlations between MRI white matter lesion location and 
executive function and episodic memory. Neurology. 2011;76(17):1492-1499. 
29. Clarke R, Joachim C, Esiri M, et al. Leukoaraiosis at presentation and disease progression during 
follow-up in histologically confirmed cases of dementia. Ann N Y Acad Sci. 2000;903:497-500. 
30. Pettersen JA, Sathiyamoorthy G, Gao FQ, et al. Microbleed topography, leukoaraiosis, and 
cognition in probable Alzheimer disease from the Sunnybrook dementia study. Arch Neurol. 
2008;65(6):790-795. 
31. Brickman AM, Guzman VA, Gonzalez-Castellon M, et al. Cerebral autoregulation, beta amyloid, 
and white matter hyperintensities are interrelated. Neurosci Lett. 2015;592:54-58. 
32. Lee S, Viqar F, Zimmerman ME, et al. White matter hyperintensities are a core feature of 
Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. Ann Neurol. 
2016;79(6):929-939. 
33. Kalaria RN, Akinyemi R, Ihara M. Does vascular pathology contribute to Alzheimer changes? J 
Neurol Sci. 2012;322(1-2):141-147. 
34 
 
 
34. Cai Z, Wang C, He W, et al. Cerebral small vessel disease and Alzheimer's disease. Clin Interv 
Aging. 2015;10:1695-1704. 
35. O'Sullivan M, Morris RG, Huckstep B, Jones DK, Williams SC, Markus HS. Diffusion tensor MRI 
correlates with executive dysfunction in patients with ischaemic leukoaraiosis. J Neurol Neurosurg 
Psychiatry. 2004;75(3):441-447. 
36. Altamura C, Scrascia F, Quattrocchi CC, et al. Regional MRI Diffusion, White-Matter 
Hyperintensities, and Cognitive Function in Alzheimer's Disease and Vascular Dementia. J Clin 
Neurol. 2016;12(2):201-208. 
37. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic 
resonance imaging: systematic review and meta-analysis. BMJ. 2010;341(jul26 1):c3666. 
38. Brickman AM, Provenzano FA, Muraskin J, et al. Regional white matter hyperintensity volume, not 
hippocampal atrophy, predicts incident Alzheimer disease in the community. Arch Neurol. 
2012;69(12):1621-1627. 
39. Brickman AM. Contemplating Alzheimer's disease and the contribution of white matter 
hyperintensities. Curr Neurol Neurosci Rep. 2013;13(12):415. 
40. Hachinski VC, Potter P. Leuko-Araiosis. 2015. 
41. Wardlaw JM, Valdés Hernández MC, Muñoz-Maniega S, Valdes Hernandez MC, Munoz-Maniega 
S. What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. J 
Am Heart Assoc. 2015;4(6):1140-1140. 
42. Shi Y, Wardlaw JM. Update on cerebral small vessel disease: a dynamic whole-brain disease. 
Stroke Vasc Neurol. 2016;1(3):83-92. 
43. Ter Telgte A, van Leijsen EMC, Wiegertjes K, Klijn CJM, Tuladhar AM, de Leeuw FE. Cerebral 
small vessel disease: from a focal to a global perspective. Nat Rev Neurol. 2018;14(7):387-398. 
44. Black S, Gao F, Bilbao J. Understanding white matter disease: imaging-pathological correlations 
in vascular cognitive impairment. Stroke. 2009;40(3 Suppl):S48-52. 
45. Huang J, Li J, Feng C, et al. Blood-Brain Barrier Damage as the Starting Point of Leukoaraiosis 
Caused by Cerebral Chronic Hypoperfusion and Its Involved Mechanisms: Effect of Agrin and 
Aquaporin-4. Biomed Res Int. 2018;2018:2321797. 
46. Raz N, Yang Y, Dahle CL, Land S. Volume of white matter hyperintensities in healthy adults: 
contribution of age, vascular risk factors, and inflammation-related genetic variants. Biochim 
Biophys Acta. 2012;1822(3):361-369. 
47. Raz N, Rodrigue KM, Acker JD. Hypertension and the brain: vulnerability of the prefrontal regions 
and executive functions. Behav Neurosci. 2003;117(6):1169-1180. 
48. Vicario A, Martinez CD, Baretto D, Diaz Casale A, Nicolosi L. Hypertension and cognitive decline: 
impact on executive function. J Clin Hypertens (Greenwich). 2005;7(10):598-604. 
49. Li X, Ma C, Sun X, et al. Disrupted white matter structure underlies cognitive deficit in hypertensive 
patients. Eur Radiol. 2016;26(9):2899-2907. 
50. Mandell DM, Han JS, Poublanc J, et al. Selective reduction of blood flow to white matter during 
hypercapnia corresponds with leukoaraiosis. Stroke. 2008;39(7):1993-1998. 
35 
 
 
51. Wang Y, Liu G, Hong D, Chen F, Ji X, Cao G. White matter injury in ischemic stroke. Prog 
Neurobiol. 2016;141:45-60. 
52. Markus HS, Lythgoe DJ, Ostegaard L, O'Sullivan M, Williams SC. Reduced cerebral blood flow in 
white matter in ischaemic leukoaraiosis demonstrated using quantitative exogenous contrast based 
perfusion MRI. J Neurol Neurosurg Psychiatry. 2000;69(1):48-53. 
53. Iadecola C, Park L, Capone C. Threats to the mind: aging, amyloid, and hypertension. Stroke. 
2009;40(3 Suppl):S40-44. 
54. Lin J, Wang D, Lan L, Fan Y. Multiple Factors Involved in the Pathogenesis of White Matter Lesions. 
Biomed Res Int. 2017;2017:9372050. 
55. Langdon KD, Cordova CA, Granter-Button S, et al. Executive dysfunction and blockage of brain 
microvessels in a rat model of vascular cognitive impairment. Journal of Cerebral Blood Flow & 
Metabolism. 2017:0271678X1773921-0271678X1773921. 
56. Skoog I. A review on blood pressure and ischaemic white matter lesions. Dement Geriatr Cogn 
Disord. 1998;9 Suppl 1:13-19. 
57. van Dijk EJ, Breteler MM, Schmidt R, et al. The association between blood pressure, hypertension, 
and cerebral white matter lesions: cardiovascular determinants of dementia study. Hypertension. 
2004;44(5):625-630. 
58. Oh YS, Kim JS, Lee KS. Orthostatic and supine blood pressures are associated with white matter 
hyperintensities in Parkinson disease. J Mov Disord. 2013;6(2):23-27. 
59. Wang Z, Wong A, Liu W, et al. Pulse Pressure and Cognitive Decline in Stroke Patients With White 
Matter Changes. J Clin Hypertens (Greenwich). 2015;17(9):694-698. 
60. Kim CK, Lee SH, Kim BJ, Ryu WS, Yoon BW. Age-independent association of pulse pressure with 
cerebral white matter lesions in asymptomatic elderly individuals. J Hypertens. 2011;29(2):325-
329. 
61. van Norden AG, de Laat KF, Gons RA, et al. Causes and consequences of cerebral small vessel 
disease. The RUN DMC study: a prospective cohort study. Study rationale and protocol. BMC 
Neurol. 2011;11:29. 
62. Gouw AA, Seewann A, van der Flier WM, et al. Heterogeneity of small vessel disease: a systematic 
review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry. 2011;82(2):126-
135. 
63. Joutel A, Chabriat H. Pathogenesis of white matter changes in cerebral small vessel diseases: 
beyond vessel-intrinsic mechanisms. Clin Sci (Lond). 2017;131(8):635-651. 
64. Di Benedetto B, Rupprecht R. Targeting glia cells: novel perspectives for the treatment of 
neuropsychiatric diseases. Curr Neuropharmacol. 2013;11(2):171-185. 
65. Ahmed S, Gull A, Khuroo T, Aqil M, Sultana Y. Glial Cell: A Potential Target for Cellular and Drug 
Based Therapy in Various CNS Diseases. Curr Pharm Des. 2017;23(16):2389-2399. 
66. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer 
disease. Nat Rev Neurosci. 2015;16(6):358-372. 
36 
 
 
67. Harry GJ, Kraft AD. Neuroinflammation and microglia: considerations and approaches for 
neurotoxicity assessment. Expert Opin Drug Metab Toxicol. 2008;4(10):1265-1277. 
68. Raj D, Yin Z, Breur M, et al. Increased White Matter Inflammation in Aging- and Alzheimer's 
Disease Brain. Front Mol Neurosci. 2017;10(June):206. 
69. Wolf G, Lotan A, Lifschytz T, et al. Differentially Severe Cognitive Effects of Compromised Cerebral 
Blood Flow in Aged Mice: Association with Myelin Degradation and Microglia Activation. Front 
Aging Neurosci. 2017;9:191. 
70. Hase Y, Horsburgh K, Ihara M, Kalaria RN. White matter degeneration in vascular and other 
ageing-related dementias. J Neurochem. 2018;144(5):617-633. 
71. Shobin E, Bowley MP, Estrada LI, et al. Microglia activation and phagocytosis: relationship with 
aging and cognitive impairment in the rhesus monkey. Geroscience. 2017;39(2):199-220. 
72. Lan LF, Zheng L, Yang X, Ji XT, Fan YH, Zeng JS. Peroxisome proliferator-activated receptor-
gamma agonist pioglitazone ameliorates white matter lesion and cognitive impairment in 
hypertensive rats. CNS Neurosci Ther. 2015;21(5):410-416. 
73. Fowler JH, McQueen J, Holland PR, et al. Dimethyl fumarate improves white matter function 
following severe hypoperfusion: Involvement of microglia/macrophages and inflammatory 
mediators. Journal of Cerebral Blood Flow and Metabolism2017. 
74. Qin C, Fan WH, Liu Q, et al. Fingolimod Protects Against Ischemic White Matter Damage by 
Modulating Microglia Toward M2 Polarization via STAT3 Pathway. Stroke. 2017;48(12):3336-3346. 
75. Manso Y, Holland PR, Kitamura A, et al. Minocycline reduces microgliosis and improves subcortical 
white matter function in a model of cerebral vascular disease. Glia. 2018;66(1):34-46. 
76. Miyanohara J, Kakae M, Nagayasu K, et al. TRPM2 Channel Aggravates CNS Inflammation and 
Cognitive Impairment via Activation of Microglia in Chronic Cerebral Hypoperfusion. J Neurosci. 
2018;38(14):3520-3533. 
77. von Bernhardi R, Eugenin J. Microglial reactivity to beta-amyloid is modulated by astrocytes and 
proinflammatory factors. Brain Res. 2004;1025(1-2):186-193. 
78. Kim DH, Choi BR, Jeon WK, Han JS. Impairment of intradimensional shift in an attentional set-
shifting task in rats with chronic bilateral common carotid artery occlusion. Behav Brain Res. 
2016;296:169-176. 
79. Janova H, Arinrad S, Balmuth E, et al. Microglia ablation alleviates myelin-associated catatonic 
signs in mice. J Clin Invest. 2018;128(2):734-745. 
80. Saing T, Dick M, Nelson PT, Kim RC, Cribbs DH, Head E. Frontal cortex neuropathology in 
dementia pugilistica. J Neurotrauma. 2012;29(6):1054-1070. 
81. de la Monte SM, Kril JJ. Human alcohol-related neuropathology. Acta Neuropathol. 
2014;127(1):71-90. 
82. Diamond A. Executive functions. Annu Rev Psychol. 2013;64:135-168. 
83. Tullberg M, Fletcher E, DeCarli C, et al. White matter lesions impair frontal lobe function regardless 
of their location. Neurology. 2004;63(2):246-253. 
37 
 
 
84. Harada CN, Natelson Love MC, Triebel KL. Normal cognitive aging. Vol 29: NIH Public Access; 
2013:737-752. 
85. Guttmann CR, Jolesz FA, Kikinis R, et al. White matter changes with normal aging. Neurology. 
1998;50(4):972-978. 
86. Johnson JK, Lui LY, Yaffe K. Executive Function, More Than Global Cognition, Predicts Functional 
Decline and Mortality in Elderly Women. The Journals of Gerontology Series A: Biological Sciences 
and Medical Sciences. 2007;62(10):1134-1141. 
87. Razani J, Casas R, Wong JT, Lu P, Alessi C, Josephson K. Relationship between executive 
functioning and activities of daily living in patients with relatively mild dementia. Appl Neuropsychol. 
2007;14(3):208-214. 
88. Mlinac ME, Feng MC. Assessment of Activities of Daily Living, Self-Care, and Independence. Arch 
Clin Neuropsychol. 2016;31(6):506-516. 
89. Falconer E, Bryant R, Felmingham KL, et al. The neural networks of inhibitory control in 
posttraumatic stress disorder. J Psychiatry Neurosci. 2008;33(5):413-422. 
90. Levy BJ, Anderson MC. Individual differences in the suppression of unwanted memories: the 
executive deficit hypothesis. Acta Psychol (Amst). 2008;127(3):623-635. 
91. Baler RD, Volkow ND. Drug addiction: the neurobiology of disrupted self-control. Trends Mol Med. 
2006;12(12):559-566. 
92. Penades R, Catalan R, Rubia K, Andres S, Salamero M, Gasto C. Impaired response inhibition in 
obsessive compulsive disorder. Eur Psychiatry. 2007;22(6):404-410. 
93. Arnsten AF, Rubia K. Neurobiological circuits regulating attention, cognitive control, motivation, and 
emotion: disruptions in neurodevelopmental psychiatric disorders. J Am Acad Child Adolesc 
Psychiatry. 2012;51(4):356-367. 
94. Chambers CD, Garavan H, Bellgrove MA. Insights into the neural basis of response inhibition from 
cognitive and clinical neuroscience. Neurosci Biobehav Rev. 2009;33(5):631-646. 
95. Garavan H, Ross TJ, Stein EA. Right hemispheric dominance of inhibitory control: an event-related 
functional MRI study. Proc Natl Acad Sci U S A. 1999;96(14):8301-8306. 
96. Robinson G, Shallice T, Bozzali M, Cipolotti L. The differing roles of the frontal cortex in fluency 
tests. Brain. 2012;135(Pt 7):2202-2214. 
97. Chapados C, Petrides M. Impairment only on the fluency subtest of the Frontal Assessment Battery 
after prefrontal lesions. Brain. 2013;136(Pt 10):2966-2978. 
98. Carlen M. What constitutes the prefrontal cortex? Science. 2017;358(6362):478-482. 
99. Dalley JW, Cardinal RN, Robbins TW. Prefrontal executive and cognitive functions in rodents: 
neural and neurochemical substrates. Neurosci Biobehav Rev. 2004;28(7):771-784. 
100. Bizon JL, Foster TC, Alexander GE, Glisky EL. Characterizing cognitive aging of working memory 
and executive function in animal models. Front Aging Neurosci. 2012;4:19. 
101. Robinson AL, Heaton RK, Lehman RA, Stilson DW. The utility of the Wisconsin Card Sorting Test 
in detecting and localizing frontal lobe lesions. J Consult Clin Psychol. 1980;48(5):605-614. 
38 
 
 
102. Floresco SB, Zhang Y, Enomoto T. Neural circuits subserving behavioral flexibility and their 
relevance to schizophrenia. Behav Brain Res. 2009;204(2):396-409. 
103. Chudasama Y. Animal models of prefrontal-executive function. Behav Neurosci. 2011;125(3):327-
343. 
104. Alzheimer's A. 2016 Alzheimer's disease facts and figures. Alzheimers Dement. 2016;12(4):459-
509. 
105. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's 
disease: recommendations from the National Institute on Aging-Alzheimer's Association 
workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-
269. 
106. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer 
disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp 
Neurol. 2012;71(4):266-273. 
107. Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's 
disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614-629. 
108. Huynh RA, Mohan C. Alzheimer's Disease: Biomarkers in the Genome, Blood, and Cerebrospinal 
Fluid. Front Neurol. 2017;8:102. 
109. Sabbagh MN, Lue LF, Fayard D, Shi J. Increasing Precision of Clinical Diagnosis of Alzheimer's 
Disease Using a Combined Algorithm Incorporating Clinical and Novel Biomarker Data. Neurol 
Ther. 2017;6(Suppl 1):83-95. 
110. Gauthier S, Patterson C, Chertkow H, et al. Recommendations of the 4th Canadian Consensus 
Conference on the Diagnosis and Treatment of Dementia (CCCDTD4). Can Geriatr J. 
2012;15(4):120-126. 
111. Casey DA, Antimisiaris D, O'Brien J. Drugs for Alzheimer's disease: are they effective? P T. 
2010;35(4):208-211. 
112. Herman L, Atri A, Salloway S. Alzheimer's Disease in Primary Care: The Significance of Early 
Detection, Diagnosis, and Intervention. Am J Med. 2017;130(6):756. 
113. Henneges C, Reed C, Chen YF, Dell'Agnello G, Lebrec J. Describing the Sequence of Cognitive 
Decline in Alzheimer's Disease Patients: Results from an Observational Study. J Alzheimers Dis. 
2016;52(3):1065-1080. 
114. Gold CA, Budson AE. Memory loss in Alzheimer's disease: implications for development of 
therapeutics. Expert Rev Neurother. 2008;8(12):1879-1891. 
115. American Psychiatric Association., American Psychiatric Association. DSM-5 Task Force. 
Diagnostic and statistical manual of mental disorders : DSM-5. 5th ed. Washington, D.C.: American 
Psychiatric Association; 2013. 
116. Stokholm J, Vogel A, Gade A, Waldemar G. Heterogeneity in executive impairment in patients with 
very mild Alzheimer's disease. Dement Geriatr Cogn Disord. 2006;22(1):54-59. 
117. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: 
a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63-75 e62. 
39 
 
 
118. Ridge PG, Mukherjee S, Crane PK, Kauwe JS, Alzheimer's Disease Genetics C. Alzheimer's 
disease: analyzing the missing heritability. PLoS One. 2013;8(11):e79771. 
119. Barber RC. The genetics of Alzheimer's disease. Scientifica (Cairo). 2012;2012:246210. 
120. Ridge PG, Ebbert MT, Kauwe JS. Genetics of Alzheimer's disease. Biomed Res Int. 
2013;2013:254954. 
121. Seshadri S, Wolf PA. Lifetime risk of stroke and dementia: current concepts, and estimates from 
the Framingham Study. Lancet Neurol. 2007;6(12):1106-1114. 
122. Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, 
mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106-118. 
123. Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD 
pathology. Neurobiol Aging. 2004;25(5):641-650. 
124. Michaelson DM. APOE epsilon4: the most prevalent yet understudied risk factor for Alzheimer's 
disease. Alzheimers Dement. 2014;10(6):861-868. 
125. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron. 
2009;63(3):287-303. 
126. Ridge PG, Hoyt KB, Boehme K, et al. Assessment of the genetic variance of late-onset Alzheimer's 
disease. Neurobiol Aging. 2016;41:200 e213-200 e220. 
127. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to 
Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's 
Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 
2011;7(3):270-279. 
128. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183-194. 
129. Roberts RO, Knopman DS, Mielke MM, et al. Higher risk of progression to dementia in mild 
cognitive impairment cases who revert to normal. Neurology. 2014;82(4):317-325. 
130. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia--meta-
analysis of 41 robust inception cohort studies. Acta Psychiatr Scand. 2009;119(4):252-265. 
131. Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C. Progression of mild cognitive impairment to 
dementia in clinic- vs community-based cohorts. Arch Neurol. 2009;66(9):1151-1157. 
132. Burke D. Review: long-term annual conversion rate to dementia was 3.3% in elderly people with 
mild cognitive impairment. Evid Based Med. 2009;14(3):90. 
133. Ward A, Tardiff S, Dye C, Arrighi HM. Rate of conversion from prodromal Alzheimer's disease to 
Alzheimer's dementia: a systematic review of the literature. Dement Geriatr Cogn Dis Extra. 
2013;3(1):320-332. 
134. Schott JM, Petersen RC. New criteria for Alzheimer's disease: which, when and why? Brain. 
2015;138(Pt 5):1134-1137. 
135. Tabert MH, Manly JJ, Liu X, et al. Neuropsychological prediction of conversion to Alzheimer 
disease in patients with mild cognitive impairment. Arch Gen Psychiatry. 2006;63(8):916-924. 
40 
 
 
136. Summers MJ, Saunders NL. Neuropsychological measures predict decline to Alzheimer's dementia 
from mild cognitive impairment. Neuropsychology. 2012;26(4):498-508. 
137. Kirova AM, Bays RB, Lagalwar S. Working memory and executive function decline across normal 
aging, mild cognitive impairment, and Alzheimer's disease. Biomed Res Int. 2015;2015:748212. 
138. Cloutier S, Chertkow H, Kergoat MJ, Gauthier S, Belleville S. Patterns of Cognitive Decline Prior to 
Dementia in Persons with Mild Cognitive Impairment. J Alzheimers Dis. 2015;47(4):901-913. 
139. Michaud TL, Su D, Siahpush M, Murman DL. The Risk of Incident Mild Cognitive Impairment and 
Progression to Dementia Considering Mild Cognitive Impairment Subtypes. Dement Geriatr Cogn 
Dis Extra. 2017;7(1):15-29. 
140. Li J, Wang YJ, Zhang M, et al. Vascular risk factors promote conversion from mild cognitive 
impairment to Alzheimer disease. Neurology. 2011;76(17):1485-1491. 
141. Lehallier B, Essioux L, Gayan J, et al. Combined Plasma and Cerebrospinal Fluid Signature for the 
Prediction of Midterm Progression From Mild Cognitive Impairment to Alzheimer Disease. JAMA 
Neurol. 2016;73(2):203-212. 
142. Sun Z, van de Giessen M, Lelieveldt BP, Staring M. Detection of Conversion from Mild Cognitive 
Impairment to Alzheimer's Disease Using Longitudinal Brain MRI. Front Neuroinform. 2017;11:16. 
143. Frolich L, Peters O, Lewczuk P, et al. Incremental value of biomarker combinations to predict 
progression of mild cognitive impairment to Alzheimer's dementia. Alzheimers Res Ther. 
2017;9(1):84. 
144. Smith EE, Egorova S, Blacker D, et al. Magnetic resonance imaging white matter hyperintensities 
and brain volume in the prediction of mild cognitive impairment and dementia. Arch Neurol. 
2008;65(1):94-100. 
145. Silbert LC, Dodge HH, Perkins LG, et al. Trajectory of white matter hyperintensity burden preceding 
mild cognitive impairment. Neurology. 2012;79(8):741-747. 
146. Nalivaeva NN, Turner AJ. The amyloid precursor protein: a biochemical enigma in brain 
development, function and disease. FEBS Lett. 2013;587(13):2046-2054. 
147. Uhlen M, Fagerberg L, Hallstrom BM, et al. Proteomics. Tissue-based map of the human proteome. 
Science. 2015;347(6220):1260419. 
148. Puig KL, Combs CK. Expression and function of APP and its metabolites outside the central 
nervous system. Exp Gerontol. 2013;48(7):608-611. 
149. Ferreira ST, Lourenco MV, Oliveira MM, De Felice FG. Soluble amyloid-beta oligomers as 
synaptotoxins leading to cognitive impairment in Alzheimer's disease. Front Cell Neurosci. 
2015;9:191. 
150. Frost GR, Li YM. The role of astrocytes in amyloid production and Alzheimer's disease. Open Biol. 
2017;7(12). 
151. Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological 
conditions. Physiol Rev. 2004;84(2):361-384. 
152. Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes 
with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71(5):362-381. 
41 
 
 
153. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 
1991;82(4):239-259. 
154. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-
associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta 
Neuropathol. 2006;112(4):389-404. 
155. Iaccarino L, Tammewar G, Ayakta N, et al. Local and distant relationships between amyloid, tau 
and neurodegeneration in Alzheimer's Disease. Neuroimage Clin. 2018;17:452-464. 
156. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its 
relevance for the development of AD. Neurology. 2002;58(12):1791-1800. 
157. Thal DR. Clearance of amyloid beta-protein and its role in the spreading of Alzheimer's disease 
pathology. Front Aging Neurosci. 2015;7:25. 
158. Manczak M, Reddy PH. Abnormal interaction of oligomeric amyloid-beta with phosphorylated tau: 
implications to synaptic dysfunction and neuronal damage. J Alzheimers Dis. 2013;36(2):285-295. 
159. Do TD, Economou NJ, Chamas A, Buratto SK, Shea JE, Bowers MT. Interactions between amyloid-
beta and Tau fragments promote aberrant aggregates: implications for amyloid toxicity. J Phys 
Chem B. 2014;118(38):11220-11230. 
160. Pascoal TA, Mathotaarachchi S, Shin M, et al. Synergistic interaction between amyloid and tau 
predicts the progression to dementia. Alzheimers Dement. 2017;13(6):644-653. 
161. Leyns CEG, Holtzman DM. Glial contributions to neurodegeneration in tauopathies. Mol 
Neurodegener. 2017;12(1):50. 
162. Garwood CJ, Pooler AM, Atherton J, Hanger DP, Noble W. Astrocytes are important mediators of 
Abeta-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis. 
2011;2:e167. 
163. Jack CR, Jr., Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological 
definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-562. 
164. Thal DR, von Arnim C, Griffin WS, et al. Pathology of clinical and preclinical Alzheimer's disease. 
Eur Arch Psychiatry Clin Neurosci. 2013;263 Suppl 2:S137-145. 
165. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association 
guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 
2012;8(1):1-13. 
166. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's 
Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's 
disease. Neurology. 1991;41(4):479-486. 
167. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer 
disease. Cold Spring Harb Perspect Med. 2011;1(1):a006189. 
168. Boluda S, Toledo JB, Irwin DJ, et al. A comparison of Abeta amyloid pathology staging systems 
and correlation with clinical diagnosis. Acta Neuropathol. 2014;128(4):543-550. 
169. Serrano-Pozo A, Mielke ML, Gomez-Isla T, et al. Reactive glia not only associates with plaques 
but also parallels tangles in Alzheimer's disease. Am J Pathol. 2011;179(3):1373-1384. 
42 
 
 
170. Jack CR, Jr., Wiste HJ, Lesnick TG, et al. Brain beta-amyloid load approaches a plateau. 
Neurology. 2013;80(10):890-896. 
171. Pascual O, Ben Achour S, Rostaing P, Triller A, Bessis A. Microglia activation triggers astrocyte-
mediated modulation of excitatory neurotransmission. Proc Natl Acad Sci U S A. 
2012;109(4):E197-205. 
172. Streit WJ, Xue QS, Tischer J, Bechmann I. Microglial pathology. Acta Neuropathol Commun. 
2014;2:142. 
173. Thal DR. The role of astrocytes in amyloid beta-protein toxicity and clearance. Exp Neurol. 
2012;236(1):1-5. 
174. Corbett A, Williams G, Ballard C. Drug repositioning in Alzheimer's disease. Front Biosci (Schol 
Ed). 2015;7:184-188. 
175. Calsolaro V, Edison P. Neuroinflammation in Alzheimer's disease: Current evidence and future 
directions. Alzheimers Dement. 2016;12(6):719-732. 
176. Decourt B, Lahiri DK, Sabbagh MN. Targeting Tumor Necrosis Factor Alpha for Alzheimer's 
Disease. Curr Alzheimer Res. 2017;14(4):412-425. 
177. Medeiros R, Figueiredo CP, Pandolfo P, et al. The role of TNF-alpha signaling pathway on COX-2 
upregulation and cognitive decline induced by beta-amyloid peptide. Behav Brain Res. 
2010;209(1):165-173. 
178. Krause DL, Muller N. Neuroinflammation, microglia and implications for anti-inflammatory treatment 
in Alzheimer's disease. Int J Alzheimers Dis. 2010;2010. 
179. Zhang C, Wang Y, Wang D, Zhang J, Zhang F. NSAID Exposure and Risk of Alzheimer's Disease: 
An Updated Meta-Analysis From Cohort Studies. Front Aging Neurosci. 2018;10:83. 
180. Sanz-Blasco S, Calvo-Rodriguez M, Caballero E, Garcia-Durillo M, Nunez L, Villalobos C. Is it All 
Said for NSAIDs in Alzheimer's Disease? Role of Mitochondrial Calcium Uptake. Curr Alzheimer 
Res. 2018;15(6):504-510. 
181. Kukar T, Golde TE. Possible mechanisms of action of NSAIDs and related compounds that 
modulate gamma-secretase cleavage. Curr Top Med Chem. 2008;8(1):47-53. 
182. Breitner JC, Baker LD, Montine TJ, et al. Extended results of the Alzheimer's disease anti-
inflammatory prevention trial. Alzheimers Dement. 2011;7(4):402-411. 
183. Butchart J, Brook L, Hopkins V, et al. Etanercept in Alzheimer disease: A randomized, placebo-
controlled, double-blind, phase 2 trial. Neurology. 2015;84(21):2161-2168. 
184. Andrade-Moraes CH, Oliveira-Pinto AV, Castro-Fonseca E, et al. Cell number changes in 
Alzheimer's disease relate to dementia, not to plaques and tangles. Brain. 2013;136(Pt 12):3738-
3752. 
185. Roth AD, Ramirez G, Alarcon R, Von Bernhardi R. Oligodendrocytes damage in Alzheimer's 
disease: beta amyloid toxicity and inflammation. Biol Res. 2005;38(4):381-387. 
186. Sachdev PS, Zhuang L, Braidy N, Wen W. Is Alzheimer's a disease of the white matter? Curr Opin 
Psychiatry. 2013;26(3):244-251. 
43 
 
 
187. Sjobeck M, Englund E. Glial levels determine severity of white matter disease in Alzheimer's 
disease: a neuropathological study of glial changes. Neuropathol Appl Neurobiol. 2003;29(2):159-
169. 
188. Tomimoto H, Akiguchi I, Suenaga T, et al. Alterations of the blood-brain barrier and glial cells in 
white-matter lesions in cerebrovascular and Alzheimer's disease patients. Stroke. 
1996;27(11):2069-2074. 
189. Jeong YJ, Yoon HJ, Kang DY. Assessment of change in glucose metabolism in white matter of 
amyloid-positive patients with Alzheimer disease using F-18 FDG PET. Medicine (Baltimore). 
2017;96(48):e9042. 
190. Agosta F, Pievani M, Sala S, et al. White matter damage in Alzheimer disease and its relationship 
to gray matter atrophy. Radiology. 2011;258(3):853-863. 
191. Migliaccio R, Agosta F, Possin KL, Rabinovici GD, Miller BL, Gorno-Tempini ML. White matter 
atrophy in Alzheimer's disease variants. Alzheimers Dement. 2012;8(5 Suppl):S78-87 e71-72. 
192. Bronge L, Bogdanovic N, Wahlund LO. Postmortem MRI and histopathology of white matter 
changes in Alzheimer brains. A quantitative, comparative study. Dement Geriatr Cogn Disord. 
2002;13(4):205-212. 
193. Zhang Y, Schuff N, Jahng GH, et al. Diffusion tensor imaging of cingulum fibers in mild cognitive 
impairment and Alzheimer disease. Neurology. 2007;68(1):13-19. 
194. Maier-Hein KH, Westin CF, Shenton ME, et al. Widespread white matter degeneration preceding 
the onset of dementia. Alzheimers Dement. 2015;11(5):485-493 e482. 
195. Pierpaoli C, Barnett A, Pajevic S, et al. Water diffusion changes in Wallerian degeneration and their 
dependence on white matter architecture. Neuroimage. 2001;13(6 Pt 1):1174-1185. 
196. Song SK, Sun SW, Ramsbottom MJ, Chang C, Russell J, Cross AH. Dysmyelination revealed 
through MRI as increased radial (but unchanged axial) diffusion of water. Neuroimage. 
2002;17(3):1429-1436. 
197. Goldberg MP, Ransom BR. New light on white matter. Stroke. 2003;34(2):330-332. 
198. Toledo JB, Arnold SE, Raible K, et al. Contribution of cerebrovascular disease in autopsy confirmed 
neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain. 
2013;136(Pt 9):2697-2706. 
199. Smith EE. Clinical presentations and epidemiology of vascular dementia. Clin Sci (Lond). 
2017;131(11):1059-1068. 
200. Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. 
Alzheimer Dis Assoc Disord. 1999;13 Suppl 3:S115-123. 
201. Groves WC, Brandt J, Steinberg M, et al. Vascular dementia and Alzheimer's disease: is there a 
difference? A comparison of symptoms by disease duration. J Neuropsychiatry Clin Neurosci. 
2000;12(3):305-315. 
202. de la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, 
and dialectics. The Lancet Neurology. 2004;3(3):184-190. 
44 
 
 
203. Girouard H, Iadecola C. Neurovascular coupling in the normal brain and in hypertension, stroke, 
and Alzheimer disease. J Appl Physiol (1985). 2006;100(1):328-335. 
204. Rodrigue KM. Contribution of cerebrovascular health to the diagnosis of Alzheimer disease. JAMA 
Neurol. 2013;70(4):438-439. 
205. Moody DM, Brown WR, Challa VR, Ghazi-Birry HS, Reboussin DM. Cerebral microvascular 
alterations in aging, leukoaraiosis, and Alzheimer's disease. Ann N Y Acad Sci. 1997;826:103-116. 
206. de la Torre JC. Alzheimer Disease as a Vascular Disorder: Nosological Evidence. Stroke. 
2002;33(4):1152-1162. 
207. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke. 1997;28(3):652-659. 
208. Wardlaw JM, Sandercock PA, Dennis MS, Starr J. Is breakdown of the blood-brain barrier 
responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke. 2003;34(3):806-812. 
209. Basile AM, Pantoni L, Pracucci G, et al. Age, hypertension, and lacunar stroke are the major 
determinants of the severity of age-related white matter changes. The LADIS (Leukoaraiosis and 
Disability in the Elderly) Study. Cerebrovasc Dis. 2006;21(5-6):315-322. 
210. Conklin J, Silver FL, Mikulis DJ, Mandell DM. Are acute infarcts the cause of leukoaraiosis? Brain 
mapping for 16 consecutive weeks. Ann Neurol. 2014;76(6):899-904. 
211. Bernbaum M, Menon BK, Fick G, et al. Reduced blood flow in normal white matter predicts 
development of leukoaraiosis. J Cereb Blood Flow Metab. 2015;35(10):1610-1615. 
212. Diaz JF, Merskey H, Hachinski VC, et al. Improved recognition of leukoaraiosis and cognitive 
impairment in Alzheimer's disease. Arch Neurol. 1991;48(10):1022-1025. 
213. Stout JC, Jernigan TL, Archibald SL, Salmon DP. Association of dementia severity with cortical 
gray matter and abnormal white matter volumes in dementia of the Alzheimer type. Arch Neurol. 
1996;53(8):742-749. 
214. Ble A, Ranzini M, Zurlo A, et al. Leukoaraiosis is associated with functional impairment in older 
patients with Alzheimer's disease but not vascular dementia. J Nutr Health Aging. 2006;10(1):31-
35. 
215. van Westen D, Lindqvist D, Blennow K, et al. Cerebral white matter lesions - associations with 
Abeta isoforms and amyloid PET. Sci Rep. 2016;6:20709. 
216. Pietroboni AM, Scarioni M, Carandini T, et al. CSF beta-amyloid and white matter damage: a new 
perspective on Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2018;89(4):352-357. 
217. Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and 
Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 
2006;37(9):2220-2241. 
218. Stephan BC, Matthews FE, Khaw KT, Dufouil C, Brayne C. Beyond mild cognitive impairment: 
vascular cognitive impairment, no dementia (VCIND). Alzheimers Res Ther. 2009;1(1):4. 
219. Roman GC, Sachdev P, Royall DR, et al. Vascular cognitive disorder: a new diagnostic category 
updating vascular cognitive impairment and vascular dementia. J Neurol Sci. 2004;226(1-2):81-87. 
45 
 
 
220. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and 
dementia: a statement for healthcare professionals from the american heart association/american 
stroke association. Stroke. 2011;42(9):2672-2713. 
221. Sachdev P, Kalaria R, O'Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a 
VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206-218. 
222. Wentzel C, Rockwood K, MacKnight C, et al. Progression of impairment in patients with vascular 
cognitive impairment without dementia. Neurology. 2001;57(4):714-716. 
223. Korczyn AD, Vakhapova V, Grinberg LT. Vascular dementia. J Neurol Sci. 2012;322(1-2):2-10. 
224. Korczyn AD. Mixed Dementia-the Most Common Cause of Dementia. Annals of the New York 
Academy of Sciences. 2002;977(1):129-134. 
225. Black SE. Vascular cognitive impairment: epidemiology, subtypes, diagnosis and management. J 
R Coll Physicians Edinb. 2011;41(1):49-56. 
226. Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment-a critical update. Front 
Aging Neurosci. 2013;5:17. 
227. Neuropathology Group. Medical Research Council Cognitive F, Aging S. Pathological correlates of 
late-onset dementia in a multicentre, community-based population in England and Wales. 
Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study 
(MRC CFAS). Lancet. 2001;357(9251):169-175. 
228. van der Flier WM, Scheltens P. Epidemiology and risk factors of dementia. J Neurol Neurosurg 
Psychiatry. 2005;76 Suppl 5:v2-7. 
229. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: A 
collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research 
Group. Neurology. 2000;54(11 Suppl 5):S4-9. 
230. Canadian study of health and aging: study methods and prevalence of dementia. CMAJ. 
1994;150(6):899-913. 
231. Kalaria RN, Kenny RA, Ballard CG, Perry R, Ince P, Polvikoski T. Towards defining the 
neuropathological substrates of vascular dementia. J Neurol Sci. 2004;226(1-2):75-80. 
232. Kalaria RN. Neuropathological diagnosis of vascular cognitive impairment and vascular dementia 
with implications for Alzheimer's disease. Acta Neuropathol. 2016;131(5):659-685. 
233. Choi EJ, Choi CG, Kim JS. Large cerebral artery involvement in CADASIL. Neurology. 
2005;65(8):1322-1324. 
234. Yamashita M, Oka K, Tanaka K. Histopathology of the brain vascular network in moyamoya 
disease. Stroke. 1983;14(1):50-58. 
235. Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular 
dysfunction in Alzheimer disease. Nat Rev Neurosci. 2017;18(7):419-434. 
236. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 
2005;28(4):202-208. 
46 
 
 
237. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other 
disorders. Nat Rev Neurosci. 2011;12(12):723-738. 
238. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev 
Neurosci. 2004;5(5):347-360. 
239. Arvanitakis Z, Capuano AW, Leurgans SE, Bennett DA, Schneider JA. Relation of cerebral vessel 
disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross-sectional 
study. Lancet Neurol. 2016;15(9):934-943. 
240. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction 
and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277(10):813-817. 
241. Azarpazhooh MR, Avan A, Cipriano LE, Munoz DG, Sposato LA, Hachinski V. Concomitant 
vascular and neurodegenerative pathologies double the risk of dementia. Alzheimer's & Dementia. 
2018;14:148-156. 
242. Pase MP, Satizabal CL, Seshadri S. Role of Improved Vascular Health in the Declining Incidence 
of Dementia. Stroke. 2017;48(7):2013-2020. 
243. Hachinski V, Sposato LA. Dementia: from muddled diagnoses to treatable mechanisms. Brain. 
2013;136(Pt 9):2652-2654. 
244. Muoio V, Persson PB, Sendeski MM. The neurovascular unit - concept review. Acta Physiol (Oxf). 
2014;210(4):790-798. 
245. Tarantini S, Tran CHT, Gordon GR, Ungvari Z, Csiszar A. Impaired neurovascular coupling in aging 
and Alzheimer's disease: Contribution of astrocyte dysfunction and endothelial impairment to 
cognitive decline. Exp Gerontol. 2017;94:52-58. 
246. Deane R, Singh I, Sagare AP, et al. A multimodal RAGE-specific inhibitor reduces amyloid beta-
mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest. 2012;122(4):1377-
1392. 
247. Halliday MR, Rege SV, Ma Q, et al. Accelerated pericyte degeneration and blood-brain barrier 
breakdown in apolipoprotein E4 carriers with Alzheimer's disease. J Cereb Blood Flow Metab. 
2016;36(1):216-227. 
248. Zenaro E, Piacentino G, Constantin G. The blood-brain barrier in Alzheimer's disease. Neurobiol 
Dis. 2017;107:41-56. 
249. Jin SJ, Liu Y, Deng SH, et al. Protective effects of activated protein C on neurovascular unit in a 
rat model of intrauterine infection-induced neonatal white matter injury. J Huazhong Univ Sci 
Technolog Med Sci. 2015;35(6):904-909. 
250. D. Williams P, V. Zlokovic B, H. Griffin J, E. Pryor K, P. Davis T. Preclinical Safety and 
Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke. 
Current Pharmaceutical Design. 2012;18(27):4215-4222. 
251. Carnevale D, Mascio G, D'Andrea I, et al. Hypertension induces brain beta-amyloid accumulation, 
cognitive impairment, and memory deterioration through activation of receptor for advanced 
glycation end products in brain vasculature. Hypertension. 2012;60(1):188-197. 
47 
 
 
252. Borysova L, Wray S, Eisner DA, Burdyga T. How calcium signals in myocytes and pericytes are 
integrated across in situ microvascular networks and control microvascular tone. Cell Calcium. 
2013;54(3):163-174. 
253. MacVicar BA, Newman EA. Astrocyte regulation of blood flow in the brain. Cold Spring Harb 
Perspect Biol. 2015;7(5). 
254. Rosenberg GA. Extracellular matrix inflammation in vascular cognitive impairment and dementia. 
Clin Sci (Lond). 2017;131(6):425-437. 
255. Thurgur H, Pinteaux E. Microglia in the Neurovascular Unit: Blood–Brain Barrier–microglia 
Interactions After Central Nervous System Disorders. Neuroscience. 2018. 
256. Barakat R, Redzic Z. The Role of Activated Microglia and Resident Macrophages in the 
Neurovascular Unit during Cerebral Ischemia: Is the Jury Still Out? Med Princ Pract. 2016;25 Suppl 
1:3-14. 
257. Bu XL, Xiang Y, Jin WS, et al. Blood-derived amyloid-beta protein induces Alzheimer's disease 
pathologies. Mol Psychiatry. 2017. 
258. Padwal RS, Bienek A, McAlister FA, Campbell NR, Outcomes Research Task Force of the 
Canadian Hypertension Education P. Epidemiology of Hypertension in Canada: An Update. Can J 
Cardiol. 2016;32(5):687-694. 
259. Tzourio C. Hypertension, cognitive decline, and dementia: an epidemiological perspective. 
Dialogues Clin Neurosci. 2007;9(1):61-70. 
260. Kennelly SP, Lawlor BA, Kenny RA. Blood pressure and dementia - a comprehensive review. Ther 
Adv Neurol Disord. 2009;2(4):241-260. 
261. Oveisgharan S, Hachinski V. Hypertension, executive dysfunction, and progression to dementia: 
the canadian study of health and aging. Arch Neurol. 2010;67(2):187-192. 
262. Iadecola C. Hypertension and dementia. Hypertension. 2014;64(1):3-5. 
263. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 
2017;390(10113):2673-2734. 
264. Diaz-Ruiz C, Wang J, Ksiezak-Reding H, et al. Role of Hypertension in Aggravating Abeta 
Neuropathology of AD Type and Tau-Mediated Motor Impairment. Cardiovasc Psychiatry Neurol. 
2009;2009:107286. 
265. Gentile MT, Poulet R, Di Pardo A, et al. Beta-amyloid deposition in brain is enhanced in mouse 
models of arterial hypertension. Neurobiol Aging. 2009;30(2):222-228. 
266. Csiszar A, Tucsek Z, Toth P, et al. Synergistic effects of hypertension and aging on cognitive 
function and hippocampal expression of genes involved in beta-amyloid generation and 
Alzheimer's disease. Am J Physiol Heart Circ Physiol. 2013;305(8):H1120-1130. 
267. Cifuentes D, Poittevin M, Dere E, et al. Hypertension accelerates the progression of Alzheimer-like 
pathology in a mouse model of the disease. Hypertension. 2015;65(1):218-224. 
268. Carnevale D, Perrotta M, Lembo G, Trimarco B. Pathophysiological Links Among Hypertension 
and Alzheimer's Disease. High Blood Press Cardiovasc Prev. 2016;23(1):3-7. 
48 
 
 
269. Lithell H, Hansson L, Skoog I, et al. The Study on COgnition and Prognosis in the Elderly (SCOPE); 
outcomes in patients not receiving add-on therapy after randomization. J Hypertens. 
2004;22(8):1605-1612. 
270. Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the 
Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-
blind, placebo controlled trial. Lancet Neurol. 2008;7(8):683-689. 
271. McGuinness B, Todd S, Passmore P, et al. Blood pressure lowering in patients without prior 
cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database 
Syst Rev. 2009(4):CD004034-CD004034. 
272. Sörös P, Whitehead S, Spence JD, et al. Antihypertensive treatment can prevent stroke and 
cognitive decline. Nat Rev Neurol. 2013;9(3):174-178. 
273. Perrotta M, Lembo G, Carnevale D. Hypertension and Dementia: Epidemiological and 
Experimental Evidence Revealing a Detrimental Relationship. Int J Mol Sci. 2016;17(3):347. 
274. Walker V, Davies N, Kehoe P, Martin R. Can treatments for hypertension be repurposed for the 
treatment of dementia? Revue d'Épidémiologie et de Santé Publique. 2018;66:S262-S262. 
275. Kazama K, Wang G, Frys K, Anrather J, Iadecola C. Angiotensin II attenuates functional hyperemia 
in the mouse somatosensory cortex. Am J Physiol Heart Circ Physiol. 2003;285(5):H1890-1899. 
276. Faraco G, Park L, Zhou P, et al. Hypertension enhances Abeta-induced neurovascular dysfunction, 
promotes beta-secretase activity, and leads to amyloidogenic processing of APP. J Cereb Blood 
Flow Metab. 2016;36(1):241-252. 
277. Jennings JR, Muldoon MF, Ryan C, et al. Reduced cerebral blood flow response and compensation 
among patients with untreated hypertension. Neurology. 2005;64(8):1358-1365. 
278. Setiadi A, Korim WS, Elsaafien K, Yao ST. The role of the blood-brain barrier in hypertension. Exp 
Physiol. 2018;103(3):337-342. 
279. Faraco G, Sugiyama Y, Lane D, et al. Perivascular macrophages mediate the neurovascular and 
cognitive dysfunction associated with hypertension. J Clin Invest. 2016;126(12):4674-4689. 
280. Seshadri S, Beiser A, Kelly-Hayes M, et al. The lifetime risk of stroke: estimates from the 
Framingham Study. Stroke. 2006;37(2):345-350. 
281. Bogiatzi C, Hackam DG, McLeod AI, Spence JD. Secular trends in ischemic stroke subtypes and 
stroke risk factors. Stroke. 2014;45(11):3208-3213. 
282. Vilar-Bergua A, Riba-Llena I, Nafria C, et al. Blood and CSF biomarkers in brain subcortical 
ischemic vascular disease: Involved pathways and clinical applicability. J Cereb Blood Flow Metab. 
2016;36(1):55-71. 
283. Fanning JP, Wong AA, Fraser JF. The epidemiology of silent brain infarction: a systematic review 
of population-based cohorts. BMC Med. 2014;12:119. 
284. Vermeer SE, Longstreth WT, Jr., Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet 
Neurol. 2007;6(7):611-619. 
285. Nakagawa T, Sekizawa K, Nakajoh K, Tanji H, Arai H, Sasaki H. Silent cerebral infarction: a 
potential risk for pneumonia in the elderly. J Intern Med. 2000;247(2):255-259. 
49 
 
 
286. Garbuzova-Davis S, Haller E, Williams SN, et al. Compromised blood-brain barrier competence in 
remote brain areas in ischemic stroke rats at the chronic stage. J Comp Neurol. 2014;522(13):3120-
3137. 
287. Whitehead SN, Massoni E, Cheng G, et al. Triflusal reduces cerebral ischemia induced 
inflammation in a combined mouse model of Alzheimer's disease and stroke. Brain Res. 
2010;1366:246-256. 
288. Owen JB, Sultana R, Aluise CD, et al. Oxidative modification to LDL receptor-related protein 1 in 
hippocampus from subjects with Alzheimer disease: implications for Abeta accumulation in AD 
brain. Free Radic Biol Med. 2010;49(11):1798-1803. 
289. Erickson MA, Banks WA. Blood-brain barrier dysfunction as a cause and consequence of 
Alzheimer's disease. J Cereb Blood Flow Metab. 2013;33(10):1500-1513. 
290. Veszelka S, Toth AE, Walter FR, et al. Docosahexaenoic acid reduces amyloid-beta induced 
toxicity in cells of the neurovascular unit. J Alzheimers Dis. 2013;36(3):487-501. 
291. Hawkes CA, JoAnne M. Selective targeting of perivascular macrophages for clearance of β-amyloid 
in cerebral amyloid angiopathy. 2009;106(4):1261-1266. 
292. Montagne A, Nikolakopoulou AM, Zhao Z, et al. Pericyte degeneration causes white matter 
dysfunction in the mouse central nervous system. Nat Med. 2018;24(3):326-337. 
293. Tong XK, Lecrux C, Rosa-Neto P, Hamel E. Age-dependent rescue by simvastatin of Alzheimer's 
disease cerebrovascular and memory deficits. J Neurosci. 2012;32(14):4705-4715. 
294. Sorond FA, Hurwitz S, Salat DH, Greve DN, Fisher ND. Neurovascular coupling, cerebral white 
matter integrity, and response to cocoa in older people. Neurology. 2013;81(10):904-909. 
295. Agca C, Klakotskaia D, Schachtman TR, Chan AW, Lah JJ, Agca Y. Presenilin 1 transgene addition 
to amyloid precursor protein overexpressing transgenic rats increases amyloid beta 42 levels and 
results in loss of memory retention. BMC Neurosci. 2016;17(1):46. 
296. Agca C, Fritz JJ, Walker LC, et al. Development of transgenic rats producing human beta-amyloid 
precursor protein as a model for Alzheimer's disease: transgene and endogenous APP genes are 
regulated tissue-specifically. BMC Neurosci. 2008;9:28. 
297. Rosen RF, Fritz JJ, Dooyema J, et al. Exogenous seeding of cerebral beta-amyloid deposition in 
betaAPP-transgenic rats. J Neurochem. 2012;120(5):660-666. 
298. Silverberg GD, Miller MC, Pascale CL, et al. Kaolin-induced chronic hydrocephalus accelerates 
amyloid deposition and vascular disease in transgenic rats expressing high levels of human APP. 
Fluids Barriers CNS. 2015;12(1):2. 
299. Brady AM, Floresco SB. Operant procedures for assessing behavioral flexibility in rats. J Vis Exp. 
2015(96):e52387. 
300. Floresco SB, Block AE, Tse MTL. Inactivation of the medial prefrontal cortex of the rat impairs 
strategy set-shifting, but not reversal learning, using a novel, automated procedure. Behav Brain 
Res. 2008;190(1):85-96. 
 
50 
 
 
Chapter 2: The Cognitive and Neuroinflammatory Profile of 
the TgAPP21 Rat  
This study set out to determine the effect of pathogenic APP on white matter inflammation 
and executive function (Objective 1) and is currently under review for Scientific Reports.  
 
2.1  Abstract 
Executive dysfunction and white matter pathology continue to be relatively understudied 
in Alzheimer’s disease (AD). The TgAPP21 rat model of AD expresses hAPP with swe/ind 
mutations but does not spontaneously develop plaques; however, previous studies of this 
model suggest a spontaneous impairment of behavioural flexibility, an important 
subdomain of executive function. In this study, 7 – 8-month-old male TgAPP21 rats were 
tested for behavioural flexibility, learning, and memory using an operant conditioning 
chamber and the Morris Water Maze (MWM). TgAPP21 rats demonstrated a regressive 
behavioral inflexibility during set shifting in an operant conditioning chamber, and 
regressive behaviour was also demonstrated in the MWM probe test; this behavioural 
phenotype has not been previously described in the MWM. Clinical research of prodromal 
AD suggests that white matter pathology may underlie impairment of executive functions 
such as behavioural flexibility. Diffuse microglia activation was increased in the white 
matter of TgAPP21, which was found to correlate with the number of reversal errors in 
the operant conditioning chamber. TgAPP21 rats are therefore an instrumental model of 
behavioural inflexibility and plaque-independent extrahippocampal changes of early AD-
related amyloidopathy.   
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2.2  Introduction 
Patients with mild cognitive impairment that exhibit executive dysfunction are more likely 
to progress to Alzheimer’s disease (AD)1-7. Executive dysfunction can also be detected 
early in AD, even prior to diagnosis8-11. Particular subdomains of executive function that 
are important predictors of progressive cognitive decline include cognitive flexibility and 
working memory1-5. Despite this, behavioural characterization of rodent models of AD has 
largely focused on hippocampal dependent cognition such as memory and spatial 
processing12-14. To advance our understanding of the early mechanisms underlying AD 
and other dementias, further characterization of executive functions in rodent models is 
needed15.  
The TgAPP21 transgenic Fischer 344 rat (hAPP with Swedish and Indiana mutations) is 
ideal for modelling the prodromal phase of AD. TgAPP21 rats do not spontaneously 
develop plaques16,17, but while amyloid aggregates are absent in naïve TgAPP21 rats, 
aggregates can be induced by cerebral stressors16-19. No behavioural changes have been 
found in previous studies of naïve TgAPP21 rats, which have only evaluated hippocampal 
dependent spatial learning and memory17. In contrast, TgAPP21 rats with ischemic injury 
of the dorsal striatum demonstrated significantly more behavioural inflexibility than injured 
wildtype (control) rats and uninjured TgAPP21 rats, characterized by a specific increase 
of regressive errors on an extradimensional set shifting task20. While the interaction of 
ischemic striatal injury and transgene expression produced a synergistic increase of 
behavioural inflexibility, the transgene alone had an overall effect of increased regressive 
behaviour. This warrants closer investigation of spontaneous regressive behaviour in 
TgAPP21 rats. Mild cortical pathology has only been observed in naïve TgAPP21 rats 
that were aged to 18 – 19 months of age and was absent in younger rats and would 
therefore be unlikely to underlie spontaneous behavioural inflexibility in younger rats. 
However, significant dysregulation of membrane lipids has been found in TgAPP21 white 
matter by 12 months of age21. Recent clinical research on the early stages of dementia 
have found white matter pathology to be linked to executive dysfunction, including 
behavioural inflexibility22-32. As features of both white matter pathology and executive 
dysfunction have been observed independently in the TgAPP21 rat, this model may 
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present an important opportunity to study the link between white matter changes and 
executive function. 
To better characterize spontaneous behavioural changes in TgAPP21 rats, a complement 
of behavioural tests was performed in the present study. We found that TgAPP21 rat 
demonstrated behavioural inflexibility in an operant-chamber-based test of 
extradimensional set shifting33. This manifested as increased regressive behaviour and 
reversal impairments in an operant conditioning chamber. To corroborate previous 
findings of normal hippocampal-dependent function in TgAPP21 rats, the Morris Water 
Maze (MWM) was used to evaluate spatial learning, memory, and working memory34-38. 
MWM tests confirmed that TgAPP21 rats had unimpaired spatial learning and memory, 
but we were surprised to also observe a previously undescribed regressive-like behaviour 
during the MWM probe test. These observations demonstrate how tests of behavioural 
inflexibility can inform tests of hippocampal function, such as learning and memory. 
Lastly, as white matter inflammation has been linked to executive dysfunction, we 
analyzed brain tissue for activation of microglia and astrocytes in the plaque-free 
TgAPP21 rat. While astrocyte activation was not increased in TgAPP21 rat, widespread 
activation of white matter microglia was significantly increased. Microglia activation in the 
supraventricular corpus callosum (SVCC) was also significantly correlated with reversal 
impairment. Our findings identify the TgAPP21 rat as having the behavioural and 
neuropathological profile that reflects some of the earliest observable neurological 
changes that precede diagnosis of dementia.  
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2.3  Methods 
2.3.1 Animals 
Animal ethics and procedures were approved by the Animal Care Committee at Western 
University (protocol 2014-016) and are in compliance with Canadian and National Institute 
of Health Guides for the Care and Use of Laboratory Animals (NIH Publication #80-23). 
All rats used in this study were housed in facilities maintained by Western University 
Animal Care and Veterinary Services on a 12:12 hour light/dark cycle alternating at 
1AM/PM; behavioural testing was conducted during the rats’ dark cycle. Homozygous 
transgenic Fischer 344-APP21 rats (TgAPP21) were studied to model the effect of 
increased brain concentrations of amyloid protein. Developed by lentiviral infection of 
zygotes, TgAPP21 rats overexpress a pathogenic human APP sequence with Swedish 
and Indiana mutations, and produce high levels of beta-amyloid (both 1-40 and 1-42), but 
do not deposit beta-amyloid plaques16. TgAPP21 rats were bred and aged in house, 
alongside wildtype Fischer 344. TgAPP21 homozygosity was validated using tissue 
samples from pups. 10 male TgAPP21 rats and 10 male wildtype Fischer 344 (Wt) rats 
with body masses ranging from 300-430 g were aged to an average of 6.7 months (SD = 
0.3) before behavioural studies began; rats were euthanized at 7.5 months of age (SD = 
0.3). This age range was selected to allow for some age-dependent pathology of hAPP 
expression and to minimize other health variables expected in more advanced age.  
 
2.3.2 Set Shift & Reversal 
Behavioral flexibility was assessed using an operant conditioning based set-shifting task 
as developed by Floresco et al39. As described in our recent publication40, the set-shifting 
task required rats to perform an extradimensional strategy shift, in which they had to 
transition from a learned visual cue-dependent strategy to a newly-rewarding egocentric 
spatial strategy (Figure 2-1). The overall experimental series included acclimation and 
training, initial set formation (visual cue discrimination task) and finally, set-shifting 
(response discrimination task). Throughout these experimental steps, animals were 
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tested during their dark cycle at regular individual times, completing all training and testing 
in the same apparatus.  
 
2.3.2.1 Apparatus 
Two operant conditioning chambers (Med Associates; St. Albans, VT) were fitted in 
separate sound attenuating boxes. The operant conditioning chambers were equipped 
with two retractable response levers which were located on either side of a central food 
pellet receptacle. A bright stimulus light was located above each lever (Figure 2-1), and 
there was a house light at the back of the apparatus at roof level. All operant conditioning 
chamber inputs and outputs were handled using MED-PC software (Med Associates; St. 
Albans, VT) with customized programs that automated control of the chamber and data 
recording. Immediately following a correct lever press, a 45 mg sucrose pellet (Dustless 
precision pellets, Bio-Serv; Burlington, ON) was dispensed into the central pellet 
receptacle as a positive reinforcement.  
 
2.3.2.2 Food Restriction & Initial Operant Conditioning 
To ensure motivation for food reinforcement, food restriction was initiated 6 days before 
lever-press training and continued throughout testing. Feed quantity was adjusted 
individually to maintain rat body mass at 85% of initial free-feed mass. Rats were weighed 
regularly during food restriction, and there was no difference in loss of body mass 
between groups. Water was provided freely during food restriction.  
Three days prior to training, pellets were placed daily in the rat’s cage to allow for 
acclimation to the future reinforcement used in testing. Rats were habituated to the 
operant conditioning chamber for 20 min, followed by daily training of lever pressing; lever 
presses were reinforced with a pellet using a fixed-ratio 1 (FR1) schedule. Rats were 
trained under manual control of lever extension & retraction using operant conditioning 
strategies until they could consecutively alternate between 15 left and 15 right lever 
presses. They were then trained daily on an automated 90-trial program that pseudo-
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randomly alternated lever presentation; each trial allowed the rat 10 s to press an 
extended lever, followed by a 20 s inter-trial period. The training program was repeated 
daily until the rat completed 90 trials with 5 or fewer omissions.  
 
2.3.2.3 Side Bias Determination 
The side bias determination program was run immediately after training was complete. 
Both levers were presented on all trials, and rats were granted a 10 s response period 
with a 20 s inter-trial period. Initially, either lever was rewarded with a pellet, but the 
following reward would only be given when the opposite lever was pressed. This was 
repeated until the rat completed 7 pairs of lever alternations (a pair could be initiated on 
either side). A side bias was identified if one lever was pressed twice as many times as 
the other lever, otherwise the lever-side that initiated 4 or more of 7 alternation pairs was 
classified as the biased side. Each rat’s side bias was used for the response 
discrimination task, where the lever opposite the rat’s side bias was always considered 
the correct lever.  
 
2.3.2.4 Visual Cue Discrimination  
One day after completion of side bias determination, rats began the visual cue 
discrimination (VCD) task (Figure 2-1). On each trial, illumination of one stimulus light 
preceded the extension of both levers by 3 s and remained illuminated when both levers 
were extended. The rat then had 10 s to press the lever associated with the illuminated 
stimulus to receive a pellet. If no lever was pressed (omission), then no pellet was 
granted, levers were retracted, and lights were turned off. The location of the stimulus 
light was counterbalanced and presented equally over both levers during the test. All 
animals were presented with 100 trials on a testing day, with 20 s inter-trial periods. 8 
correct consecutive responses were needed to achieve test criterion, and if this was not 
met within the allotted trial limit, the animal was placed in its home cage and retested the 
next day. Omissions were not considered to disrupt a streak of correct responses.  
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2.3.2.5 Set-shifting: Response Discrimination  
On the day after the VCD task performance criterion was achieved, rats were given 20 
VCD trials to test for retention of the learned rule (i.e., “follow the light”). On the 21st trial, 
the paradigm was switched to a response discrimination (RD) task in which only the lever 
opposite the rat’s side bias was always considered correct despite the location of the 
stimulus light. The RD task continued for 120 trials, with a performance criterion set at 8 
correct consecutive responses.  
It is important to note that half of the RD task trials could be considered as ‘congruent’ 
and the other half were ‘incongruent’, occurring in a counterbalanced and pseudorandom 
sequence. ‘Congruent trials’ occurred when the visual cue distractor was illuminated 
above the correct lever, so that a rat would be rewarded whether it was responding in 
accordance with the previously-correct VCD strategy or the new RD strategy (Figure 2-1). 
Hence, success on a congruent trial was not informative of the rat’s behavioural strategy. 
In contrast, ‘incongruent trials’ occurred when the visual cue distractor was illuminated 
above the incorrect lever, so that a rat would only receive a pellet if it responded in 
accordance with the new RD strategy (Figure 2-1). Thus, success on an incongruent trial 
was informative of the rat’s behavioural strategy. In this study, we also included a 24 h 
delayed 20 trial retrieval test for response discrimination. 
 
2.3.2.6 Set-shifting Behavioural Measures  
Traditional measures for assessing set-shifting behaviour during the RD task included the 
number of trials to criterion, number of errors to criterion, and error profiling, namely by 
perseverative, never-reinforced, or regressive error types (Figure 2-1)39,40. Errors made 
on incongruent trials were deemed either perseverative or regressive. ‘Perseverative’ 
errors were scored earlier in the RD task when rats continued to adhere to the original 
VCD strategy (i.e., “follow the light”), so long as 6 or more incorrect lever responses were 
observed in a block of 8 incongruent trials (which randomly occurred over a block of 16 
trials that also included 8 interspersed congruent trials). Later in the RD task, rats 
successfully disengaged from the previously-correct VCD strategy. Once 5 or fewer 
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incorrect lever responses were observed in a block of 8 incongruent trials, all incorrect 
responses to incongruent trials in that block and on all subsequent blocks were scored 
as ‘regressive’ errors. Thus, perseverative errors were an indicator of the rat’s failure to 
inhibit the previously-learned strategy, whereas regressive errors indicated the rat’s 
failure to engage or maintain a new strategy39. Incorrect responses made on congruent 
trials, when the rat’s response did not follow either the VCD or RD strategies, were scored 
as ‘never-reinforced’ errors (Figure 2-1). Never-reinforced errors reflected the rat’s 
exploration of new operant strategies and provided an index of a rat’s ability to filter out 
non-rewarding options39. 
 
2.3.2.7 Reversal 
Immediately after the Response Discrimination Retrieval test, a 120-trial session of spatial 
reversal was initiated, wherein the opposite lever became the only rewarding lever; the 
cue light continued to pseudorandomly alternate during the reversal trials to ensure 
sufficient cognitive challenge.  
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Figure 2-1: Testing behavioral flexibility in an operant based set-shifting task 
During the final day of testing, rats were first exposed to 20 visual cue discrimination 
(VCD) trials that required them to retrieve the strategy learned the day earlier, i.e., 
pressing the lever under the randomly illuminated light for a pellet. On the 21st trial, rats 
were then challenged to shift from the original, no-longer rewarding strategy (VCD) 
towards a new strategy (lever position; response discrimination). In this shift, errors on 
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congruent trials were characterized as never-reinforced, while errors on incongruent trials 
were either perseverative or regressive. Perseverative errors occurred early in the shift, 
when rats persisted with the old strategy on 75% or more of incongruent trials, failing to 
disengage from the no-longer rewarding strategy. Regressive errors occurred later in the 
shift, when rats had already disengaged from the old strategy and followed it on less than 
75% of incongruent trials but regressed back to the old strategy, failing to fully engage 
and/or maintain the new strategy. 
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2.3.3 Morris Water Maze 
Following set shifting and recovery of normal body weight, rats were tested in the MWM. 
In a dimly lit room, a water tank (144 cm diameter) was filled with room temperature water, 
dyed with black non-toxic acrylic paint, and a target platform (12 cm diameter) was 
submerged below 3 cm of water. To allow for multiple tolerances of navigational error, the 
‘target quadrant’ and a 7.5 cm vicinity to the platform designated as the ‘platform region’ 
were both evaluated in swim path analysis (Figure 2-4A). Rats were placed in a fixed start 
location and had to locate the hidden platform to be removed from the water tank. The 
rats were given six 90 s learning trials (with 1 h inter-trial rest intervals) to learn the 
location of the submerged platform; this learning schedule was adapted from Roof et al41. 
Twenty-four hours after the last learning trial, the rats’ swim behaviour was again 
recorded during the probe test, wherein the platform was removed. 
In addition to tracking the rat’s location over time, swim strategies were analyzed 
according to swim time in key regions. Swim time in the annulus (Figure 2-4A), a 27cm 
wide ring corresponding to the location and diameter of the platform region, approximated 
the use of an egocentric strategy based on distance from the wall, also known as 
‘chaining’38. Swim time in a subset of the annulus outside of the target quadrant (Figure 
2-4A) was also analyzed to determine if egocentric navigation to a platform generalized 
to the rest of the maze. The thigmotactic region designated a 10 cm proximity to the tank 
walls; swim time in this region indicated thigmotactic behaviour. The ‘goal directed 
corridor’ was a subjective interpretation of the rats’ intended swim path, based on video 
recordings of swim behaviour and heading as judged by a blinded rater. When the corridor 
was directed at the platform location, the rater scored the amount of time that the rat 
demonstrated ‘allocentric navigation’ (Figure 2-4A)38. Working spatial memory is another 
crucial component of navigation, and can be dissociated by testing trial-dependent 
learning as in match-sample testing35,37. Three days after the probe test, 5 consecutive 
days of delayed match-sample testing assessed spatial working memory. Each day, 
during the ‘sample trial’, a new start location and a new platform location was used. 6 h 
later, the rats were tested on these new spatial parameters during the ‘match trial’ and 
were assessed for improvement in their latency to locate the platform (schematic location 
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of platforms can be found in Figure 4-5B). The 6 h delay was used to create a greater 
working memory challenge37. 
After MWM testing was complete, potentially confounding differences in visual perception 
or swim speed were evaluated on 4 cued trials (2 different start locations for 2 different 
platform locations) wherein the location of the platform was visibly marked. All swim paths 
were tracked using ANYmaze tracking software, version 4.70 (Stoelting Company; Wood 
Dale, IL), with a top-view webcam (C525, Logitech, Newark, CA). The experimenter was 
not visible to the rats during testing.  
 
2.3.4 Open Field 
The day after MWM testing was complete, rat behaviour in the open field was evaluated. 
Rats were placed in a square 45 cm open field with 40 cm black walls and a black floor 
and permitted to explore freely for 20 mins. A top-view webcam was used for behavioural 
tracking with ANYmaze software, version 4.70. Active time was measured as the sum of 
time spent on both locomotor and non-locomotor movement. The experimenter was not 
visible to the rats during testing. 
 
2.3.5 Immunohistochemistry & Image Processing 
After all behavioural testing was complete, rats were euthanized with intraperitoneal 
injection of pentobaribital (Euthanyl, Bimeda MTC Animal Health Inc; Cambridge, ON) 
and after transcardiac perfusion with 200 ml of 0.01 PBS followed by 200 ml of freshly 
depolymerized and buffered 4% paraformaldehyde solution (PFA), brain tissue was 
collected and stored in 4% PFA for 24 h before transfer to 30% sucrose solution (n = 10 
for both groups). 30 µm coronal sections were prepared using a cryostat (CryoStar NX50, 
Thermo Fischer Scientific; Ottawa, ON) and stored in cryoprotectant until all tissue was 
available for IHC. Standard protocols were followed for DAB-mediated IHC of free floating 
sections, using an ABC-HRP kit (Thermo Fischer Scientific #32020; Ottawa, ON), a 
1:1000 concentration of OX6 primary antibody to identify activated microglia (BD 
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Pharmingen #554926; Mississauga)42, and a 1:2000 concentration of GFAP primary 
antibody to identify reactive astrocytes (Sigma-Aldrich #G3893; Oakville, ON)43. Stained 
brain sections were mounted onto slides (VWR #16004-368; Mississauga, ON), air-dried, 
dehydrated in baths of progressive concentrations of ethanol and Xylene, and cover-
slipped with DePex mounting medium (BDH Chemicals; Mississauga, ON).  
Stitched micrographs of slides were prepared using a 10x objective lens on an upright 
microscope (Nikon Eclipse Ni-E, Nikon DS Fi2 colour camera, NIS Elements Imaging; 
Mississauga, ON); light source intensity, exposure, aperture, and diaphragm parameters 
were fixed for all imaging. Prior to each scan, white balance was automated using an off-
tissue reference point and a focus plane was programmed for the micrograph. Anatomical 
regions of interest (Figure 2-7A; forceps minor, cingulum, corpus callosum, internal 
capsule, hippocampus) were captured at coronal sections: Bregma +3.00mm, +2.00mm, 
+0.00mm, -3.00mm, and -5.50mm44. The subset of the corpus callosum, the 
supraventricular corpus callosum (SVCC), was of particular interest and outlined on the 
anterior two coronal planes of the corpus callosum, excluding the portion of the corpus 
callosum that was medial to the lateral ventricles. Micrographs were processed and 
analyzed using ImageJ, version 1.50b; after regions of interest were outlined using the 
polygon tool, images were converted to 8-bit, processed using the subtract background 
command, and then thresholded with a fixed grayscale cut-off value of 237. Area 
coverage (%) was recorded for each region of interest. For anatomical regions that 
spanned multiple coronal sections (corpus callosum, cingulum, hippocampus), an 
average area coverage was calculated, weighted by cross-sectional area at each coronal 
plane. 
 
2.3.6 Data Analyses 
Graphpad Prism 7.0 software was used to generate figures and for statistical 
comparisons of group means; equal variances were not assumed for group comparisons 
(Welch’s t-test), which were corrected for multiplicity using the Holm-Sidak method. 
Bonferroni correction was used for one-sample t-tests. Where dependent measures were 
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repeated over time, 2-way repeated measures ANOVA was performed, followed by 
Sidak’s post hoc tests. IBM SPSS, version 23, was used for regression and partial 
correlation analysis. Group statistics were summarized in figures as means with error 
bars = SEM; all errors noted in text indicate SEM. Significance was determined with α = 
0.05. The datasets generated and analysed for the current study are available from the 
corresponding author on reasonable request.  
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2.4 Results 
2.4.1 Set Shift & Reversal 
Attentional set shifting, an important component of behavioural flexibility, was tested in 
an operant conditioning chamber using appetitive conditioning with sucrose pellet 
reinforcement. Wt and TgAPP21 rats were first food restricted until they respectively lost 
13.5 +/- 0.7% and 13.8 +/- 0.3% of ad libitum weight. On the visual cue discrimination 
task, rats were first trained to press the lever that was associated with a cue light. This 
cue light would be activated on every trial above one of two levers, alternating sides in 
pseudorandom fashion (Figure 2-2A). The number of trials needed to achieve a learning 
criterion of 8 correct consecutive lever presses was not significantly different between 
groups (Figure 2-2B), indicating no differences in learning. 24 h after the learning criterion 
was achieved, a 20-trial test was run for retrieval of visual cue discrimination. Again, no 
group differences were observed on this visual cue retrieval test (Figure 2-2C), 
suggesting that visual cue memory was unimpaired in the TgAPP21 rats. No group 
differences in the number of omissions were observed throughout discrimination trials, 
indicating no group differences in motivation to lever press.   
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Figure 2-2: TgAPP21 rats demonstrate unimpaired learning and memory of visual 
cue discrimination   
(A) When a rat pressed the lever associated with the cue light, which pseudorandomly 
alternated sides, they were rewarded with a sucrose pellet.  
(B) The number of learning trials needed to achieve a criterion of 8 correct consecutive 
responses and (C) the number of correct lever presses (out of 20 trials) after a 24 h delay 
were not significantly different between Wt and TgAPP21 rats.  
n = 10 for both groups, error bars = SEM.  
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Immediately after the 20 trials of the visual cue retrieval test, attentional set shifting was 
evaluated over 120 response discrimination trials wherein sucrose pellet reinforcement 
was now determined by a spatial strategy. This extradimensional shift challenged rats to 
ignore the cue light, which continued to pseudorandomly alternate sides, and learn that 
only one of the levers would yield a food pellet. No group differences were observed in 
the number of trials needed to achieve the learning criterion of 8 correct consecutive 
responses during response discrimination (Figure 2-3A).  We then evaluated the types of 
errors committed, which can be categorized as never reinforced, perseverative, or 
regressive21. Never reinforced errors occur when a lever press follows neither the 
previously learned rewarding visual cue strategy (i.e., “follow the light”) nor the new spatial 
strategy (e.g., “always press the left lever”). Never reinforced errors tend to occur in the 
early-middle trials of response discrimination and reflect a failure to filter out non-
rewarding operant behaviour. Perseverative errors occur early during response 
discrimination, when rats persist in following the no-longer rewarding visual cue strategy. 
Once rats disengage from the visual cue strategy, that is, when <75% of responses follow 
the old strategy, subsequent errors following the old strategy are considered regressive. 
TgAPP21 rats demonstrated a nonsignificant trend for fewer perseverative errors, which 
were negatively correlated with regressive errors (r = -0.81, p = 0.005, F(1,8) = 15.11; no 
correlation seen in Wt rats). This shift in the error profile of TgAPP21 rats reflected a 
significant increase in the number regressive errors (Figure 2-3B; p = 0.046, t = 2.256, df 
= 10.9). Furthermore, TgAPP21 rats committed significantly more errors even after 
achieving the response discrimination learning criterion of 8 correct consecutive trials 
(Figure 2-3C; p = 0.01, t = 2.793, df = 15.66). Errors after reaching criterion are uncommon 
and suggest a very aberrant regressive behavioural phenotype.  
To test for retrieval of response discrimination, a retrieval test of 20 trials was run after a 
24 h delay; no group differences were observed in the proportion of correct lever presses 
(Figure 2-3D). Immediately after the response discrimination retrieval test, 120 trials of a 
spatial reversal task were run, wherein the rewarding lever was now on the side opposite 
to the previously rewarding lever. As the cue light continued to alternate pseudorandomly 
during this task, profiling the errors types was not possible. However, TgAPP21 rats 
performed significantly more total errors on this task (Figure 2-3E; p = 0.02, t = 2.538, df 
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= 15.25). No group differences in the number of omissions were observed throughout 
response discrimination and reversal trials, indicating no group differences in motivation 
to lever press.  
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Figure 2-3: TgAPP21 rats demonstrate increased regressive behaviour during 
extradimensional set shifting and impaired spatial reversal 
Immediately after visual cue retrieval, rats were challenged to ignore the cue light, which 
continued to pseudorandomly alternate sides, and learn that only one of the levers would 
always yield a food pellet.  
(A) The number of trials required to achieve 8 correct consecutive responses under the 
new spatial strategy was not different between Wt and TgAPP21 rats.  
(B) However, the types of errors committed over the 120 trials allotted for the set shift 
differed. Never reinforced errors were committed when a rat’s response was not in 
accordance with the visual cue strategy or the new correct spatial strategy and reflect a 
failure to filter out non-rewarding operant behaviour. Perseverative errors were committed 
when a rat continued to follow the no-longer rewarding visual cue strategy. Once a rat 
had begun to disengage from the visual cue strategy (<75% of responses following the 
old strategy), subsequent responses following the visual cue strategy were considered 
regressive errors; TgAPP21 rats committed significantly more regressive errors.  
(C) This paralleled a significant increase in the subset of regressive errors that were 
committed after criterion for response discrimination was met (8 correct consecutive 
responses), further suggesting a highly regressive behavioural phenotype.  
(D) After a 24 h delay, there was no difference in the retrieval of response discrimination, 
as inferred by the correct number of responses out of 20 trials.  
(E) When the rewarding strategy was again changed, so that only the opposite lever 
would now yield a sucrose pellet on all trials (reversal), TgAPP21 rats committed more 
errors.  
n = 10 for both groups, error bars = SEM.   
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2.4.2 Morris Water Maze 
To test for spatial learning capacity, rats were trained on a modified MWM protocol41. Six 
90 s learning trials with 1 h intervals allowed both Wt and TgAPP21 rats to learn the 
location of the submerged platform (Figure 2-4B). No differences in MWM learning 
efficiency was observed; navigational strategies were similar except TgAPP21 
demonstrated a greater reliance on egocentric navigation during trials 4-6 (Figure 2-5D; 
p = 0.049, F(1,18) = 4.421).  
The probe test identified clearer distinctions in navigational behaviour. 24 h after the last 
learning trial, the platform was removed, and the rats’ memory of the platform location 
during a 90 s probe test was inferred by latency to enter the platform region and 
preference for the target quadrant in which the platform was previously located (Figure 
2-4C). No significant differences were observed in the latency to enter the platform region, 
suggesting that TgAPP21 rats have no spatial memory impairments; 1 outlier Wt rat is 
not represented in Figure 2-4C (ROUT method, Q = 0.1%), but was still included in all 
statistical analyses. Both groups showed a significant preference for the target quadrant 
(Wt: p = 0.04, t = 2.758, df = 9; Tg: p = 0.01, t = 4.27, df = 9; compared to a chance value 
of 25% of swim time), indicating that both groups formed a true allocentric map of the 
MWM38. However, when the probe test was parsed into 30 s segments, TgAPP21 rats 
demonstrated a significantly increased preference for the target quadrant during the last 
30 s segment of the probe test (Figure 2-4D; see supplementary online files for 
representative video recordings; Appendix B). This behaviour was unusual in that a 
preference for the target quadrant should normally remain level or extinguish over the 
course of the probe test.  
During the probe test, TgAPP21 rats also demonstrated abnormal search strategies that 
further indicate impairments of behavioural flexibility. No group differences were observed 
in thigmotaxis during the learning trials (Figure 2-5A), but while Wt rats showed an 
increase of thigmotaxis during the probe test, TgAPP21 rats did not (Figure 2-4E, Figure 
2-5E; p = 0.004, t = 3.597, df = 18). Furthermore, TgAPP21 rats spent significantly more 
time in both egocentric search for the platform (time spent in the annulus) and allocentric 
platform-directed swim (Figure 2-4E). Only in the final 30 s segment of the probe test, 
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TgAPP21 rats normalized the proportion of time in egocentric navigation, though they 
continued to favour allocentric search for the platform (p = 0.001, t = 3.773, df = 54). The 
group differences in egocentric and allocentric navigation help characterize the group 
differences in thigmotactic response; TgAPP21 rats continued to navigate according to 
the allocentric and egocentric cues associated with the learned platform location, while 
Wt rats employed a broader search strategy which involved more swim time in the 
thigmotactic region.  
Comparing across behavioural testing paradigms, the TgAPP21 rats’ impairment on 
spatial reversal (Figure 2-3E) and greater adherence to search strategies favouring the 
last known platform location despite platform removal (Figure 2-4E) indicate impairments 
of behavioural flexibility. More specifically, the TgAPP21 rats’ regressive behaviour on 
response discrimination (Figure 2-3BC) and increased target quadrant preference late in 
the probe test (Figure 2-4D) identifies a primarily regressive inflexibility.  
No significant group differences were observed in average swim time improvement on 
match-sample testing (Figure 2-5F), so working memory is unlikely to have played a role 
in behavioural differences seen in MWM navigational behaviour. After MWM tests were 
completed, potentially confounding differences in visual perception or swim speed were 
evaluated on 4 cued trials wherein the location of the platform was visibly marked.  No 
differences were observed in swim time to the platform, and no differences in swim speed 
were observed  
71 
 
 
 
Figure 2-4: TgAPP21 rats demonstrate regressive inflexibility during the Morris 
Water Maze probe test 
(A) Apparatus schematic of start location, region designations, and platform location; the 
platform (grey) was submerged below 3 cm of water. The schematic is not to scale.  
(B) Wt and TgAPP21 showed no significant differences in learning to locate the platform. 
(C) During the 24 h delayed probe test, the platform was removed before observation of 
swim behaviour. Recall of the learned platform location, as inferred by latency to enter 
the platform region, was not significantly different between Wt and TgAPP21 rats.  
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(D) TgAPP21 rats spent more swim time in the target quadrant during the last 30 s 
segment of the probe test. * The TgAPP21 rats’ increased preference in this final segment 
of the test was significant in comparison to the first two segments (p < 0.02) and in 
comparison with the Wt rats (p = 0.03). The dotted horizontal line indicates the time in the 
target quadrant that would be expected by chance.  
(E) TgAPP21 rats demonstrated atypical swim strategies following the removal of the 
platform during the delayed probe test: TgAPP21 rats did not increase swim time in the 
thigmotaxis region; TgAPP21 rats spent more time in egocentric navigation to the platform 
region, as demonstrated by the greater preference for both the annulus and the annulus 
outside of the target quadrant; TgAPP21 rats spent more time in allocentric navigation to 
the learned platform location.  
The increased preference for the target quadrant (D) and swim strategies favouring the 
platform’s last known location (E) indicate a regressive inflexibility in the TgAPP21 rats.  
n = 10 for both groups, error bars = SEM.   
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Figure 2-5: Supplementary MWM behavioural analysis 
(A) During MWM learning trials, repeat exposure had a significant effect on thigmotactic 
behaviour, progressively reducing thigmotaxis in both groups (p < .0001, F(5,90) = 56.73). 
Wt and TgAPP21 showed no significant differences in (B) allocentric navigation or (C-D) 
egocentric navigation during learning. However, TgAPP21 rats did tend to spend more 
time in the annulus outside of the target quadrant; while this trend was not statistically 
significant across all learning trials (p = 0.053), it was significant when only trials 4 – 6 
were analyzed (p = 0.049, F(3,36) = 4.421). This suggests that TgAPP21 have an 
increased reliance on egocentric spatial navigation as this measure captures a search 
strategy that relies on swimming a fixed distance from the maze wall, even when outside 
of the target quadrant. 
74 
 
 
(E) Thigmotaxis over the full 90 s of the probe test was significantly affected by genotype 
(p = 0.002, F(1,18) = 12.8). Over the course of the probe test, all rats demonstrated 
increasing thigmotaxis (p = 0.04, F(2,36) = 3.63). 
(F) On delayed match-sample testing for working memory, no group differences were 
observed.  
n = 10 for both groups, error bars = SEM. 
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2.4.3 Open Field 
Potentially confounding behavioural variables such as exploratory behaviour and anxiety 
were evaluated in the open field. The day after MWM testing was complete, rat behaviour 
in the open field was evaluated; the first 5 min of the 20 min test are considered to be 
relatively more anxiogenic for the rats. TgAPP21 demonstrated reduced exploration in 
the open field with significantly less travel distance over the full 20 min duration of the test 
(p < 0.0001, t = 6.981, df = 36), and reduced active time during both the first 5 min (p = 
0.003, t = 3.421, df = 36) and full 20 min duration of the test (p = .002, t = 3.691, df =36; 
Figure 2-6AB). A generalized reduction in exploratory behaviour may be a relevant factor 
in the TgAPP21 rats’ MWM target quadrant preference during the probe test, but distance 
travelled in the target quadrant during the MWM probe had no correlation with distance 
travelled in the open field. Moreover, reduced exploration would not explain the increased 
goal-oriented return to the target quadrant and no rat was immobile at any time in MWM 
testing. 
 Group differences in anxiety are unlikely to have affected operant conditioning chamber 
or MWM behaviour, as no differences in anxiety were observed in the open field (Figure 
2-6C). TgAPP21 rats showed a nonsignificant trend (p = 0.06) for reduced time in the 
open field centre during the full 20 min test period; this is more likely to be due to the 
TgAPP21 rats’ reduced locomotion than an increased level of anxiety, as time in the 
centre of the field correlated with total distance travelled (r = 0.69, p = 0.0008; F(1,18) = 
16.26). The absence of group differences in open field centre avoidance disputes the 
possibility that Wt rats exhibited more thigmotaxis during the MWM probe (Figure 2-4E) 
test suggesting increased levels of anxiety; time spent in the centre of the open field did 
not correlate with thigmotactic swim time. 
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Figure 2-6: TgAPP21 rats exhibited less exploratory behaviour in the open field 
 (A) TgAPP21 rats demonstrated reduced locomotion over the full 20 min test and (B) 
reduced active time during both the first 5 min and the full 20 min test, indicating reduced 
exploratory behaviour.  
(C) The relatively exposed centre of the open field is considered to be anxiogenic, 
particularly during initial exploration of the open field. No significant group differences 
were observed for the avoidance of the centre, suggesting no differences of anxiety in 
response to novel environments.  
n = 10 for both groups, error bars = SEM. 
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2.4.4 Activated Microglia in White Matter 
Qualitative observations of increased concentrations of activated OX6-positive 
microglia42 informed which anatomical regions of interest to analyze quantitatively (Figure 
2-7AB): the forceps minor, corpus callosum, cingulum, internal capsule, and 
hippocampus. A subset of the corpus callosum, the supraventricular corpus callosum 
(SVCC; immediately superior and anterior to the lateral ventricles) was also analyzed 
separately, as it was observed to have particularly increased concentrations of OX6-
positive microglia in TgAPP21 rats. Interestingly, this same region has also been found 
to have some of the greatest age-dependent dysregulation of membrane lipids21. 
Significantly more area coverage by OX6-positive microglia was observed in the white 
matter tracts of TgAPP21 rats (Figure 2-7D): corpus callosum, SVCC, cingulum, and 
internal capsule. Nonsignificant trends for increased OX6-positive microglia area 
coverage was also observed for the forceps minor (p = 0.08, t = 2.26, df = 18) and 
hippocampus (p = 0.08, t = 2.025, df = 18). Within individual brains, increased microglia 
activation was highly correlated across anatomical regions, even when controlling for 
genotype (Table 2-1). This suggests a pro-inflammatory cue that is diffuse, consistent 
with broad over-expression of pathogenic hAPP. To avoid collinearity in modelling 
relationships between white matter microglia activation and behavioural findings, 
stepwise regression was used to identify the most informative predictors. Only reversal 
errors in the operant conditioning chamber were found to be significantly related to white 
matter area coverage by OX6-positive microglia, for which the SVCC was identified as 
the most informative predictor (Figure 2-7C; R2 = 0.42, p = 0.002, F(1,18) = 12.794). 
Independently, both genotype and SVCC microglia activation were significant predictors 
of reversal errors (β = 0.513, p = 0.02, t = 2.538, df =18, ; β = 0.645, p = 0.002, t = 3.577, 
df = 18). When genotype and SVCC microglia activation were both included in a linear 
regression model, SVCC microglia activation was still a significant predictor of reversal 
errors (β = 0.544, p = 0.04, t = 2.212, df = 17) while genotype was not, suggesting that 
the relationship between genotype and reversal errors was primarily mediated by white 
matter microglia activation (p = 0.005, Sobel statistic = 2.600). No group differences in 
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morphology or area coverage by reactive GFAP-positive astrocytes43 were observed 
(Figure 2-7E).   
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Table 2-1: Global activation of microglia across anatomical regions 
 Forceps Minor 
Corpus 
Callosum SVCC Cingulum 
Internal 
Capsule Hippocampus 
Forceps 
Minor - 
0.62 
0.005 
0.55 
0.014 
0.56 
0.014 
0.61 
0.005 
0.47 
0.044 
Corpus 
Callosum  - 
0.95 
<0.0001 
0.85 
<0.0001 
0.73 
<0.0001 
0.56 
0.013 
SVCC   - 
0.78 
<0.0001 
0.63 
0.004 
0.48 
0.0383 
Cingulum    - 
0.70 
0.001 
0.70 
0.001 
Internal 
Capsule     - 
0.61 
0.006 
Hippocampus      - 
Strong positive partial correlations indicate that microglia activation increased globally 
within individual rats’ brains; values shown indicate Pearson’s r and corresponding p 
values for correlations of OX6+ microglia activation (% Area) between anatomical regions 
of interest. These correlations were controlled for genotype, so increases in microglia 
activation were seen globally for both Wt and TgAPP21 rats. n = 20. SVCC = 
Supraventricular Corpus Callosum 
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Figure 2-7: Increased microglia activation in TgAPP21 white matter correlates with 
reversal impairments 
(A) Representative coronal sections developed with DAB-immunohistochemistry and an 
OX6 primary antibody, with anatomical regions of interest outlined on the left hemisphere 
and digitally processed images overlaid on the right hemisphere; FM = forceps minor, CC 
= corpus callosum, Cing = cingulum, IC = internal capsule, HCP = hippocampus. The 
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supraventricular corpus callosum (SVCC) was a subsection of the corpus callosum that 
was directly superior and anterior to the lateral ventricles. Scale bar = 2 mm.  
(B) Representative DAB-immunohistochemistry image of corpus callosum tissue with 
1.3% area coverage by OX6-positive microglia. Scale bar = 50 µm. (C) A significant linear 
relationship was found between OX6-positive microglia area coverage in the SVCC and 
the number of spatial reversal errors in the operant conditioning chamber (R2 = 0.42, p = 
0.002). Microglia activation throughout the brain was highly correlated (Table 2-1) and 
using stepwise linear regression, OX6+ microglia area coverage in the SVCC was 
identified as the most informative predictor of reversal errors.  
(D) Microglia activation was significantly increased in the white matter tracts of TgAPP21 
rats; cross-sectional area coverage by OX6+ microglia was increased in the corpus 
callosum, SVCC, cingulum, and internal capsule.  
(E) No group differences were observed for cross-sectional area occupied by GFAP-
positive astrocytes.  
n = 10 for both groups, error bars = SEM. 
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2.5 Discussion 
Our findings replicate the absence of learning and memory deficits in naïve TgAPP21 rats 
but capture a spontaneous increase of regressive behavioural inflexibility, reversal 
impairments, a reduction of exploratory locomotor behaviour. Although TgAPP21 rats do 
not develop amyloid plaques16-20, we have found a spontaneous increase of white matter 
activation of microglia.  Microglia activation in the supraventricular corpus callosum was 
also a significant mediator of reversal impairment, even when accounting for genotype. 
The globally increased activation of white matter microglia suggests that TgAPP21 rats 
spontaneously develop an inflammatory response to the widespread overexpression of 
pathogenic hAPP, which may have precipitated the cognitive impairments and 
amyloidopathy seen in previous studies when TgAPP21 rats were exposed to cerebral 
stressors18-20. The initiation of pathology at the axon is consistent with previous findings 
of neurofibrillary tangles appearing spontaneously in 18 – 19-month-old TgAPP21 rats17.  
Microglia activation in the white matter of TgAPP21 is also consistent with clinical studies 
that have found increased white matter pathology in early stages of AD30,31, which likely 
involves inflammatory processes23,29,31,32.  
The TgAPP21 rats’ increased reversion to the learned target quadrant during the final 
third of the MWM probe test paralleled our observations of regressive behaviour during 
response discrimination. To our knowledge, this behaviour in the MWM probe test has 
not been previously reported, perhaps because of previous recommendations to perform 
probe tests for only 30 – 60 s to avoid extinction34,45. One possible interpretation is 
informed by our finding that TgAPP21 rats exhibited reduced exploration in the open field, 
so it is possible that TgAPP21 rats were less motivated to explore the water maze during 
the probe test. However, TgAPP21 rats were never immobile during the probe test and a 
reduced exploratory drive would not explain the increased goal-oriented return to the 
target quadrant during the last third of the probe test. Another interpretation is that 
TgAPP21 rats had a more accurate spatial recall of the platform location. This is unlikely 
as there were no group differences in the time required to swim to the platform region and 
both groups demonstrated a significant preference for the target quadrant. Moreover, this 
would not account for the TgAPP21 rats’ significantly increased preference for the target 
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quadrant in only the last third of the probe test. It is the timing of the TgAPP21 rats’ 
preference for the target quadrant that is particularly indicative of a regressive behavioural 
inflexibility, whereas a persistently greater preference could be expected with 
perseverative behavioural inflexibility. The increase in thigmotaxis in Wt rats was more 
likely a consequence of a swim strategy that involved more ‘random search’ and 
‘scanning’, as evidenced by reduced ‘direct swim’ and ‘chaining’ patterns of swim. 
Random search and scanning patterns of swim result in more crossing into the 
thigmotactic region, but are still generally successful strategies for finding new platform 
locations46. In contrast, TgAPP21 demonstrated less navigational flexibility following the 
removal of the platform. Our MWM probe results highlight how behavioural inflexibility in 
rodents could lead to misinterpretation of increased target quadrant preference as an 
indication of better memory. Tests for behavioural flexibility can inform performance on 
memory tests38, and our findings reaffirm the need to develop a better understanding of 
how executive dysfunction can confound measures of memory.  
We demonstrate in this study that the TgAPP21 rat is a highly relevant model as it 
demonstrates both executive dysfunction and white matter pathology, which have been 
linked in the early stages of neurodegenerative diseases22-32. While cerebral amyloid 
deposits are not observed spontaneously in TgAPP21 rats across their lifespan18, we 
have shown that TgAPP21 rats have increased microglia activation in white matter and 
impairments of behavioural flexibility by the age of 7 – 8 months. Therefore, the TgAPP21 
rat is useful to the study of these early disease processes that precede the canonical 
features of AD.  
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Chapter 3: Behavioural Inflexibility and White Matter 
Inflammation Across the TgAPP21 Lifespan 
This chapter expands the experiments described in Chapter 2 to an additional 3 age 
points, characterizing the temporal relationship between age, pathogenic APP 
expression, white matter inflammation, and executive function (Objective 1 & 2). Data 
from the 8-month-old rats in Chapter 2 was included in this study. While delayed matching 
to sample testing in the MWM was performed in this study, it could not be completed in 
the oldest cohort and no informative results were observed in the younger cohorts, thus 
delayed matching to sample test results are not presented in this chapter. The manuscript 
of this study is under review for publication in the Journal of Neuroscience.  
 
3.1  Abstract 
Neuroinflammation and behavioural inflexibility are common in late adulthood but far more 
profound in Alzheimer disease (AD). To investigate the relationship between 
neuroinflammation, behavioural flexibility, ageing, and AD, male wildtype Fischer 344 and 
the TgAPP21 rats were aged to 4, 8, 13, and 22 months and evaluated for 
neuroinflammation and cognitive impairment. TgAPP21 rats overexpress a pathogenic 
variant of the human amyloid precursor protein (Swedish and Indiana mutations) but do 
not spontaneously develop overt pathology related to AD. In both genotypes, learning 
and memory were similarly impaired in older rats. However, at 8 months of age, TgAPP21 
rats demonstrated behavioural inflexibility in set shifting, reversal, and the Morris Water 
Maze, while wildtype rats showed inflexibility at 13 and 22 months of age. This early 
inflexibility in TgAPP21 rats was accompanied by a precocious increase in activated 
microglia within the corpus callosum; 8- and 13-month-old TgAPP21 rats had similar 
levels of microglia activation as 13- and 22-month-old wildtype rats, respectively. 
However, while neuroinflammation within the white matter continued to progress with age, 
behavioural inflexibility peaked in 8-month old TgAPP21 rats. These findings suggest that 
prior to the onset of learning and memory impairments, age-dependent white matter 
inflammation has an important but dynamic effect on behavioural inflexibility.   
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3.2  Introduction 
Executive functions are necessary for maintaining functional independence1. Inhibition, 
working memory, and behavioural flexibility are core subdomains of executive function, 
but these cognitive subdomains decline with age2,3. This has been linked to disruptions 
of white matter integrity, which are observed even in “healthy” elderly individuals4-7, as 
white matter tract integrity is important for executive function6,8. White matter volume also 
shows a greater age-dependent decline than grey matter volume9, emphasizing the 
importance of white matter changes in ageing. Therefore, developing a better 
understanding of the processes that affect white matter integrity will be crucial to 
supporting healthier aging.  
Experimental studies have found that white matter microgliosis is associated with 
disruption of white matter integrity, resulting in cognitive impairments10-17. Age-associated 
dysregulation of microglia leads to a pro-inflammatory environment in the brain18, and this 
process appears to be particularly pronounced in white matter19. While this association 
has been well established, the specific processes that incite dysregulation of microglia 
remains unclear. Since amyloid pathology is highly prevalent and also progresses with 
age20, amyloid has been widely considered a common culprit in age-associated microglial 
dysregulation18,21,22. This may account for the observations of neuroinflammation19,23, 
white matter disruption24,25, and executive dysfunction26-29 in the early stages of Alzheimer 
disease (AD). To determine the temporal sequence and molecular links between 
dysregulation of amyloid and microglia, longitudinal preclinical studies are needed.  
Previous studies of microglia-mediated disruption of white matter integrity were limited in 
investigating impairments of executive function, such as behavioural flexibility. Although 
experimental animal studies have demonstrated a strong association between white 
matter microgliosis, disruption of white matter integrity, and cognitive impairments, the 
combined role of age and pathogenic human amyloid precursor protein (hAPP) in white 
matter microgliosis is not clear. The transgenic APP21 (TgAPP21) rat was developed 
from the Fischer 344 strain and overexpresses a pathogenic variant of hAPP30. TgAPP21 
rats do not spontaneously develop AD-associated pathology but are more vulnerable to 
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acute cerebral stressors, which can induce amyloid aggregation and a regressive form of 
behavioural inflexibility31-33. 
In this study, male wildtype Fischer 344 (Wt) and TgAPP21 rats were aged to 4, 8, 13, 
and 22 months of age and evaluated for cognitive impairments and white matter microglia 
activation. As amyloid can trigger the activation of microglia and chronic 
neuroinflammation localizes to white matter in the aging brain19, we predicted an earlier 
increase in the activation of microglia in the white matter of TgAPP21 rats. Accordingly, 
microglia-mediated disruption of white matter integrity would cause impairments of 
behavioural flexibility in TgAPP21 rats at a younger age. Indeed, we found a precocious 
age-dependent increase of microglia activation in the corpus callosum of TgAPP21 rats, 
and in an operant-conditioning chamber, regressive forms of behavioural inflexibility 
during set shifting and reversal impairments peaked in TgAPP21 rats at 8 months of age. 
Regressive target quadrant preference in the MWM also peaked in 8-month-old TgAPP21 
rats. These findings suggest that pathogenic hAPP expression can accelerate white 
matter microgliosis and affect behavioural flexibility, a core component of executive 
function. 
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3.3  Methods 
3.3.1 Animals 
Animal ethics and procedures were approved by the Animal Care Committee at Western 
University (protocol 2014-016) and are in compliance with Canadian and National Institute 
of Health Guides for the Care and Use of Laboratory Animals (NIH Publication #80-23). 
All rats used in this study were housed in facilities maintained by Western University 
Animal Care and Veterinary Services on a 12:12 hour light/dark cycle alternating at 
1AM/PM; behavioural testing was conducted during the rats’ dark cycle. Homozygous 
transgenic Fischer 344-APP21 (TgAPP21) rats were studied to model the effect of 
increased brain concentrations of amyloid protein. Developed by lentiviral infection of 
zygotes, TgAPP21 rats overexpress a pathogenic hAPP with Swedish and Indiana 
mutations and produce high levels of beta-amyloid (both 1-40 and 1-42) but do not 
spontaneously develop β-amyloid plaques30. hAPP homozygosity was validated using 
tissue samples from pups. 
Male TgAPP21 and wildtype (Wt) Fischer 344 rats were bred and aged to form four 
different age cohorts (n = 10 – 13 for each genotype at each age cohort; see  
 
 
Table 3-1 for sample size details). From herein, the four age points will be referred to as 
4M, 8M, 13M, and 22M, corresponding to the mean age in months at which the cohorts 
were euthanized. Ages were well matched between genotypes, with no significant 
differences in the age at which behavioural testing was initiated or the age at which rats 
were euthanized and brain tissue was collected ( 
 
 
Table 3-1). Rats that failed training, visual cue discrimination (VCD), or did not achieve at 
least 75% correct lever presses on VCD retrieval trials would be excluded from all set 
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shifting analyses, as these rats’ motivation to lever press and for food could not be 
ensured. Additionally, 22M rats that were not resilient to the stress of food restriction and 
behavioural testing were excluded from subsequent behavioural testing.  
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Table 3-1: Experimental group characteristics 
Cohort 
4M 8M 13M 22M 
Wt Tg Wt Tg Wt Tg Wt Tg 
N 12 12 11 12 13 13 9 10 
Age at set shifting 3.2 
(0.3) 
3.0 
(0.3) 
6.6 
(0.4) 
7.0 
(0.1) 
12.6 
(0.3) 
12.5 
(0.3) 
21.3 
(0.3) 
21.5 
(0.2) 
Age at perfusion 3.8 
(0.3) 
3.7 
(0.3) 
7.4 
(0.4) 
7.7 
(0.1) 
13.4 
(0.3) 
13.3 
(0.3) 
21.9 
(0.8) 
22.2 
(0.6) 
Included in  
VCD analysis 11 12 11 10 13 13 8 9 
Included in  
RD analysis 11 12 11 10 13 12 8 8 
Included in 
Reversal results 8 11 5 7 10 8 4 6 
Included in  
MWM analysis 12 12 11 12 13 13 5 9 
Included in  
OF analysis 12 12 11 12 13 13 6 10 
Values in parenthesis indicate SD. 
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3.3.2 Set Shift & Reversal 
The set shifting protocol, which includes side bias determination, is detailed in 2.3.2 Set 
Shift & Reversal on page 53. Briefly, rats were food restricted and maintained at 85-87% 
of free-feed mass to ensure motivation for 45 mg sucrose pellets (Dustless precision 
pellets, Bio-Serv; Burlington ON) during behavioural reinforcement in a sound-attenuated 
operant-conditioning chamber (Med Associates; St. Albans, VT). During all training and 
testing, each correct lever press was reinforced with a single sucrose pellet (fixed-ratio 1 
schedule). Habituation to the operant-conditioning chamber was followed by initial lever-
press training; rats were required to lever press on at least 85 of 90 trials of lever 
presentations, pseudorandomly alternating sides, before progressing to VCD.  
Twenty-four h after initial training, rats were given 100 trials to learn the VCD task. In each 
trial, both levers were extended but only the lever paired with the cue light, which 
pseudorandomly alternated sides, would yield a sucrose pellet reward when pressed. The 
passing criterion for visual discrimination was 8 correct consecutive responses, based on 
methods used by Floresco et al34. Twenty-four h after meeting criterion, a VCD retrieval 
session of 20 trials was run to evaluate retention. Immediately after the VCD retrieval 
session, 120 trials of response discrimination (RD) were initiated: only one lever would 
yield a sucrose pellet on all trials, even though the cue light continued to alternate sides. 
For each rat, the lever opposite a previously determined side bias was selected to be 
rewarding during RD (as described previously)33. This challenged the rats to ignore the 
previously learned VCD strategy and to acquire a spatial strategy, constituting an extra-
dimensional set shift. As described previously33, RD trials were binned into 16 trials of 8 
congruent and 8 incongruent trials. Perseverative errors were scored when rats reverted 
to the VCD strategy on incongruent trials; once rats demonstrated disengagement from 
VCD (5 or fewer errors in a block of 8 incongruent trials), subsequent reversions to the 
VCD strategy on incongruent trials was scored as regressive errors. Incorrect lever 
presses on congruent trials were scored as never-reinforced errors. The passing criterion 
for RD was 8 correct consecutive responses. We departed from common approaches to 
operant-conditioning chamber based set shifting35 in that we allowed rats to complete all 
120 trials of RD instead of removing them from the chamber once they achieved criterion. 
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This allowed us to quantify the number of errors committed after criterion, offering a more 
complete measure of regressive behaviour. We also conducted a 24 h delayed 20 trial 
RD retrieval test. This was immediately followed by a 120-trial session of spatial reversal, 
wherein the opposite lever became the only rewarding lever; the cue light continued to 
pseudorandomly alternate during the reversal trials to ensure sufficient cognitive 
challenge.  
During all discrimination tests (VCD, RD, reversal), rats were granted a 10 s response 
period during which the chamber was illuminated. If the correct lever was pressed, the 
chamber remained illuminated for another 4 s so that rats could retrieve the sucrose pellet 
reward. This was followed by a dark inter-trial period so that trials lasted a total of 30 s. 
Cue lights were presented 3 s before lever extension and extinguished upon lever press 
or the end of the 10 s response period. Omissions (no lever press) were not treated as 
errors and did not reset a count of correct consecutive lever presses. 
In this chapter, rats that failed to achieve a correct lever press rate of at least 75% on the 
visual cue discrimination (VCD) retrieval test were excluded from all set-shifting results, 
whereas results in Chapter 2 focused only on rats that could achieve the higher threshold 
of at least 80%. This parameter was modified to maintain sufficient sample size in the 
oldest cohort; 5/17 22MO rats achieved only 75%. Similarly, only rats that achieved at 
least 75% correct lever press on the response discrimination (RD) retrieval trials were 
evaluated in reversal. Exclusions are detailed in 3.4.1.5 Exclusions & Outliers on page 
108 and Table 3-2. 
 
3.3.3 Morris Water Maze 
Following set shift & reversal, rats’ body weights were restored to ad libitum feed levels 
(5 – 7 days), before proceeding to MWM testing. In a dimly lit room, a water tank (144 cm 
diameter) was filled with room temperature water, dyed with black non-toxic acrylic paint, 
and a target platform (12 cm diameter) was submerged below 3 cm of water. Rats were 
placed in a fixed start location and had to locate the hidden platform to be removed from 
the water tank. The rats were given six 90 s learning trials (with 1 h inter-trial rest intervals) 
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to learn the location of the submerged platform; this learning schedule was adapted from 
Roof et al36. Twenty-four hours after the last learning trial, the rats’ swim behaviour was 
again recorded during the probe test, wherein the platform was removed. To allow for 
multiple tolerances of navigational error, the ‘target quadrant’ and a 7.5 cm vicinity to the 
platform location designated as the ‘platform region’ were both evaluated in swim path 
analysis. 
After MWM testing was complete, potentially confounding differences in visual perception 
or swim speed were evaluated on 4 cued trials (2 different start locations for 2 different 
platform locations) wherein the location of the platform was visibly marked. All swim paths 
were tracked using ANYmaze tracking software, version 4.70 (Stoelting Company; Wood 
Dale, IL), with a top-view webcam (C525, Logitech; Newark, CA). The experimenter was 
not visible to the rats during testing. Several 22M rats were not fit for MWM testing (failure 
to restore ad libitum body weight after food restriction for set shifting or failure to swim 
safely) and were excluded from analysis (4 Wt rats and 1 TgAPP21 rat), leaving a reduced 
sample size of n = 5 Wt and n = 9 TgAPP21 rats from the 22M cohort.  
 
3.3.4 Open Field 
The day after MWM testing was complete, rat behaviour in the open field was evaluated. 
Rats were placed in a square 45 cm open field with 40 cm black walls and a black floor 
and permitted to explore freely for 20 mins. A top-view webcam was used for behavioural 
tracking with ANYmaze software, version 4.70 (Stoelting Company). Active time was 
measured as the sum of time spent on both locomotor and non-locomotor movement. 
The experimenter was not visible to the rats during testing. 
 
3.3.5 Immunohistochemistry & Image Processing 
After all behavioural testing was complete, rats were euthanized with intraperitoneal 
injection of pentobaribital (Euthanyl, Bimeda MTC Animal Health Inc; Cambridge, ON) 
and after transcardiac perfusion with 200 ml of 0.01 PBS followed by 200 ml of freshly 
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depolymerized and buffered 4% paraformaldehyde solution (PFA), brain tissue was 
collected and stored in 4% PFA for 24 h before transfer to 30% sucrose solution (n = 5 
for all 8 groups). 30 µm coronal sections were prepared using a cryostat (CryoStar NX50, 
Thermo Fischer Scientific; Ottawa, ON) and stored in cryoprotectant until all tissue was 
available for IHC. Standard protocols were followed for DAB-mediated IHC of free floating 
sections, using an ABC-HRP kit (Thermo Fischer Scientific #32020; Ottawa, ON), a 
1:1000 concentration of OX6 primary antibody for MHC II to identify activated microglia 
(BD Biosciences #554926; Mississauga, ON37), and a 1:2000 concentration of GFAP 
primary antibody to identify reactive astrocytes (Sigma-Aldrich #G3893; Oakville, ON38). 
Stained brain sections were mounted onto slides (VWR #16004-368; Mississauga, ON), 
air-dried, dehydrated in baths of progressive concentrations of ethanol and Xylene, and 
cover-slipped with DePex mounting medium (BDH Chemicals; Mississauga, ON).  
Stitched micrographs of slides were prepared using a 10x objective lens on an upright 
microscope (Nikon Eclipse Ni-E, Nikon DS Fi2 colour camera, NIS Elements Imaging; 
Mississauga, ON); light source intensity, exposure, aperture, and diaphragm parameters 
were fixed for all imaging. Prior to each scan, white balance was automated using an off-
tissue reference point and a focus plane was programmed for the micrograph. Anatomical 
regions of interest (forceps minor, cingulum, corpus callosum, internal capsule, 
hippocampus) were captured at coronal sections: Bregma +3.00, +2.00, +0.00, -3.00, and 
-5.50 mm39. The subset of the corpus callosum, the supraventricular corpus callosum 
(SVCC), was of particular interest40 and outlined on the anterior two coronal planes of the 
corpus callosum, excluding the portion of the corpus callosum that was medial to the 
lateral ventricles. Micrographs were processed and analyzed using ImageJ, version 
1.50b; after regions of interest were outlined using the polygon tool, images were 
converted to 8-bit, processed using the subtract background command, and then 
thresholded with a fixed grayscale cut-off value of 237. Percentage of area coverage was 
recorded for each region of interest. For anatomical regions that spanned multiple coronal 
sections, an average area coverage was calculated, weighted by cross-sectional area at 
each coronal plane; the corpus callosum and cingulum were analyzed across 3 coronal 
planes (Bregma +2.00, +0.00, and -3.00 mm) and the hippocampus was analyzed across 
2 coronal planes (Bregma -3.00 and -5.50 mm). 
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3.3.6 Data Analysis 
Two-way ANOVA were used to test the effects of age and genotype on outcome 
measures using GraphPad Prism 7.0 software (La Jolla, CA). The conservative Dunnett’s 
post-hoc analysis was used to compare outcome measures across age cohorts within 
either genotype. When comparing genotype groups at a given age, Sidak’s post-hoc 
analysis was used. Microglia activation in separate brain regions were also analyzed with 
two-way MANOVA models using IBM SPSS version 23 (Armonk, NY). Partial correlations 
between outcome measures, controlling for age and genotype, were also calculated in 
SPSS; outcome measures were evaluated for normality to determine whether Spearman 
or Pearson correlations were more appropriate. Binary outcome measures such as 
exclusions and meeting test criteria were analyzed in SPSS using logistic regression with 
age and genotype as independent variables. Any exclusion of outliers from figures or 
analyses is noted; statistical outliers on any outcome measures were identified using the 
robust regression and outlier method (ROUT)41.  All errors bars shown in figures indicate 
standard error of the mean (SEM); probability values of statistical tests were only reported 
for significant comparisons.   
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3.4  Results 
3.4.1 Set Shift 
3.4.1.1 Visual Cue Discrimination 
Learning and memory were analyzed in an operant-conditioning chamber. On VCD, food 
reward would be given when rats pressed the lever associated with a visual cue, which 
would pseudorandomly present over the left or the right lever. VCD learning was impaired 
only in 22M rats (Figure 3-1A); genotype did not affect VCD performance, but age was a 
significant factor (p = 0.0001, F(3,79) = 7.9; 2-Way ANOVA). The age-dependent 
impairment of VCD learning was significant in TgAPP21 rats, as 22M TgAPP21 rats 
required significantly more trials to reach VCD criterion than 4M TgAPP21 (p = 0.002, q 
= 3.454, df = 78), 8M TgAPP21 (p = 0.003, q = 3.371, df = 78), and 13M TgAPP21 rats 
(p = 0.0001, q = 4.394, df = 78; Dunnett’s post-hoc test). A similar trend was observed for 
22M Wt rats but was not significant. The exclusion of a single statistical outlier within the 
8M Wt group (identified as an outlier using the ROUT method with Q = 0.5%) this did not 
alter the interpretation of any statistical comparisons.  
Similarly, on the 24 h delayed VCD retrieval trials, only 22M rats demonstrated an 
impairment of memory (Figure 3-1B). Again, only age was a significant factor (p < 0.0001, 
F(3,79) = 10.22; 2-Way ANOVA). The age-dependent impairment on VCD retrieval was 
significant in both 22M Wt rats (compared to 4M Wt: p = 0.05, q = 2.398, df = 79; and 
13M Wt rats: p = 0.004, q = 3.288, df = 79) and in 22M TgAPP21 rats (compared to 4M 
TgAPP21: p = 0. 0005, q = 3.963, df = 79; and 13M TgAPP21 rats: p = 0.0009, q = 3.973, 
df = 79; Dunnett’s post-hoc test). Although this indicates a memory impairment in 22M 
rats, all rats included in these results were still able to press the correct lever on at least 
75% of the 20 trials. The exclusion of rats that failed to meet the 75% criterion (Table 3-2) 
did not alter findings of statistical significance in either VCD learning or retrieval, but these 
rats were still excluded from all set shifting and reversal results as their motivation to lever 
press was uncertain; exclusion was not associated with age (Wald’s χ2(3) = 1.082; logistic 
regression). Thus, although 22M rats performed significantly worse on the VCD retrieval 
trials, they could still access learned memory that enabled VCD.   
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Figure 3-1: Impaired visual cue discrimination learning & memory in aged rats. 
(A) Learning performance on VCD was scored by the number of trials needed to reach a 
criterion of 8 correct consecutive lever presses. Only age had an effect on learning 
performance (p = 0.0001). ** 22M TgAPP21 rats required more trials to criterion than all 
younger TgAPP21 rats (p < 0.01); a similar but non-significant trend was observed for 
22M Wt rats.  
(B) Memory of VCD was evaluated after a 24 h delay on a 20-trial test, scoring the 
proportion of correct lever presses. Again, only age had a significant effect on the 24 h 
delayed retrieval test (p < 0.0001). * 22M Wt rats performed worse than the 4M and 13M 
Wt rats (p < 0.05); *** and 22M TgAPP21 rats also performed worse than 4M and 13M 
TgAPP21 rats (p < 0.001). This indicated a memory impairment in 22M rats but not a 
complete absence of memory for VCD as all rats included in these results pressed the 
correct lever on at least 75% of the 20 trials.  
Rats that did not press the correct lever on at least 75% of VCD retrieval (n = 4/91) were 
excluded from all analyses of set shifting and reversal behaviour. Error bars indicate SEM; 
n = 8 – 13.   
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3.4.1.2 Response Discrimination 
Immediately after VCD retrieval, rats were challenged to ignore the visual cue and learn 
that only one of the levers would yield a food reward on all trials (RD); the rats’ ability to 
demonstrate RD depended on their ability to shift between attentional sets. Wt and 
TgAPP21 performed similarly in RD, as the number of trials needed to achieve the 
criterion of 8 correct consecutive responses did not differ between Wt and TgAPP21 rats 
(Figure 3-2A). However, age was a significant factor in the number of trials to reach 
criterion (p = 0.03, F(3,77) = 3.096, 2-Way ANOVA). Unexpectedly, 22M TgAPP21 rats 
required significantly fewer trials to reach criterion than 4M (p = 0.04, q = 2.534, df = 77) 
and 13M TgAPP21 rats (p = 0.02, q = 2.690, df = 77; Dunnett’s post-hoc test). This was 
not observed in Wt rats. Age was also the only significant factor in the total number of 
errors committed over the entire 120-trial RD session (Figure 3-2B; p = 0.01, F(3,77) = 
3.782; 2-Way ANOVA). Again, 22M TgAPP21 rats unexpectedly committed a fewer total 
amount of errors than 4M (p = 0.004, q = 3.286, df = 77) and 13M TgAPP21 rats (p = 
0.02, q = 2.708, df = 77; Dunnett’s post-hoc test). The reduced number of trials and errors 
to RD criterion was attributed to the 22M rats’ partially impaired memory for VCD, which 
therefore presented less interference in engaging the spatially-determined reward 
strategy.  
Despite age-dependent differences in RD performance, no significant differences were 
observed in performance on the 24 h delayed RD retrieval task (Figure 3-2C). While 22M 
rats demonstrated partial memory impairments in VCD retrieval, they did not demonstrate 
any impairment in RD retrieval. This may indicate a dissociable impairment for distinct 
forms of memory (visual cue association vs spatial association) or may reflect the reduced 
level of locomotor effort required with a spatially-fixed rewarding lever. A total of 26 rats 
failed to press the correct lever on at least 75% of RD retrieval trials (Table 3-2). As RD 
is more challenging than VCD, and the focus of RD testing is on set shifting, these rats 
were still included in the analyses of RD results and were excluded only from subsequent 
reversal results & analyses. 
Though genotype did not have an overall effect on the number of RD errors committed, 
genotype did play a role in the types of errors committed. Early in RD, persistence in 
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following the visual cue constitutes a perseverative error; once a rat has already begun 
to disengage from VCD, subsequent errors are deemed regressive. Thus, errors 
committed after criterion, which should indicate complete disengagement from VCD, are 
a particularly aberrant form of regressive error. Never-reinforced errors occur when rats 
follow neither the visual nor spatial strategy, indicating a failure to filter out non-rewarding 
options. Age had no overall effect on the different types of errors committed during 
response discrimination (Figure 3-3). However, genotype was a significant factor in the 
number of errors after criterion (p = 0.05, F(3,77) = 4.013; 2-Way ANOVA; Figure 3-3D). 
Unexpectedly, the number of regressive errors peaked in 8M TgAPP21 rats and then 
decreased in older TgAPP21 cohorts (compared to 22M TgAPP21: p = 0.03, q = 2.66, 
df=77; Dunnett’s test). Though the number of regressive errors was not increased in all 
TgAPP21 age cohorts, the persistently greater number of errors committed after criterion 
still indicates a generally regressive phenotype in TgAPP21 rats.  
The number of perseverative errors and regressive errors were negatively correlated, 
even when controlling for age and genotype (p < 0.0001, Spearman’s ρ = -0.447, df = 81). 
This suggests that there is a generalizable trade-off between errors committed early and 
late in RD; a rat that initially appears to shift away from the VCD strategy more quickly (a 
decrease in perseverative errors) is likely to require more time to fully acquire response 
discrimination (an increase in regressive errors).   
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Figure 3-2: Set shifting in aged transgenic rats facilitated by impaired memory of 
visual cue discrimination. 
Rats’ set shifting performance during response discrimination was measured by (A) the 
number of trials needed before 8 correct consecutive responses and (B) the total number 
of errors committed across all 120 trials. Age was a significant factor in both the number 
of trials needed to achieve criterion and the total number of errors (p < 0.05). * 22M 
TgAPP21 rats required fewer trials to achieve criterion than 4M and 13M rats (p < 0.05), 
and * 22M TgAPP21 rats committed fewer errors than 4M and 13M rats (p < 0.05).  
(C) Neither genotype nor age were significant factors in the number of correct lever 
presses during the 24 h delayed RD retrieval session.  
Error bars indicate SEM; n = 8 – 13.  
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Errors made during RD can be categorized as (A) perseverative, (B) never reinforced, 
or (C) Regressive. * 8M TgAPP21 rats committed more regressive errors than 22M 
TgAPP21 rats (p < 0.05). 
(D) Regressive inflexibility is also quantified by the number of errors committed after 
achieving RD criterion (8 consecutive correct responses). Genotype was a significant 
factor in the number of errors committed after criterion (p = 0.05).  
n= 8 – 13; error bars = SEM  
Figure 3-3: Regressive inflexibility in transgenic rats peaked at 8 months of age 
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3.4.1.3 Reversal 
Neither age nor genotype were had significant overall effect on the number of errors 
committed during reversal. However, 8M TgAPP21 committed significantly more reversal 
errors than 4M (p = 0.02, q = 2.729, df = 51) and 22M TgAPP21 rats (p = 0.05, q = 2.432, 
df = 51; Dunnett’s post-hoc test; Figure 3-4A). In contrast, Wt rats committed more 
reversal errors with age, demonstrating a significant linear trend (R2 = 0.16, p = 0.04, 
F(1,23) = 4.599; post-hoc test for linear trend). Due to the high rate of omission trials 
during reversal (Figure 3-5), especially in Wt rats, the error rate on reversal as a 
proportion of non-omission trials was also evaluated (Figure 3-4B). This yielded similar 
results, but with a more robust effect of age in Wt rats (R2 = 0.32, p = 0.003) and an error 
rate significantly increased in 22M Wt compared to 4M Wt rats (p = 0.03, q = 2.477, df = 
51; Dunnett’s post-hoc test). Only age was a significant predictor for meeting the criterion 
of 8 correct consecutive lever presses on the reversal task (Figure 3-4C; p = 0.004, Wald’s 
χ2(3) = 13.223; Logistic Regression). Reversal results & analyses included only the rats 
that pressed the correct lever on at least 75% of RD retrieval trials. The peak reversal 
impairment in 8M TgAPP21 rats, with a concurrent peak in regressive errors, further 
suggests that TgAPP21 rats’ behavioural inflexibility was greatest at 8 months of age.  
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Figure 3-4: Reversal impairment in transgenic rats peaked at 8 months of age, 
increased with age in wildtype rats 
(A) While Wt rats demonstrated a linear trend for a greater number of errors with age (R2 
= 0.16, p = 0.04), * reversal impairment peaked in 8M TgAPP21 rats, committing 
significantly more reversal errors than 4M and 22M TgAPP21 rats (p < 0.05).  
(B) To correct for a high frequency of omission trials, error rates were calculated as the 
proportion of lever presses that were incorrect, excluding omission trials. With this 
correction, the age-dependent linear trend for Wt rats became more robust (R2 = 0.32, p 
= 0.003) and * 22M Wt rats showed a significantly greater error rate than 4M Wt rats (p < 
0.05). * Reversal impairment in TgAPP21 rats still peaked in the 8M group, which had a 
greater error rate than 4M TgAPP21 rats (p < 0.05). 
(C) Age, but not genotype, was a significant factor in meeting the reversal criterion of 8 
correct consecutive lever presses (p = 0.008).  
Error bars indicate SEM; n = 4 – 11.  
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3.4.1.4 Omission Trials 
To verify whether motivation might have played a role in set shifting, especially in aged 
rats, rates of omission trials were analyzed. When rats did not press either lever on a 
given trial, the trial was scored as an omission; omission trials can indicate indecision, 
stress, anxiety, or a lack of motivation to lever press or for food reward. Omissions were 
more common towards the end of a testing session, such as the combined 140 trials of 
VCD retrieval followed by RD learning. No groups omitted significantly more trials at any 
specific stage of set shifting (Figure 3-5). Individual corrections for omissions did not alter 
any findings of significant differences in VCD nor RD but did reveal a clear age-dependent 
trend in reversal (Figure 3-4B). Overall, motivation as measured by omission trials did not 
confound the effects of age nor genotype.   
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Figure 3-5: Neither genotype nor age affected frequency of omission trials. 
When rats did not press either lever on a given trial, the trial was scored as an omission; 
omission trials can indicate either a lack of motivation, indecision, stress, or anxiety. 
Neither age nor genotype had a significant effect on the frequency of omission trials.  
Error bars indicate SEM; n = 4 – 13. 
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3.4.1.5 Exclusions & Outliers 
As failing any of the set shifting criteria would impact performance on subsequent stages, 
once a rat was excluded from a given stage, it was also excluded from subsequent stages 
(Table 3-2). Rats did not advance to VCD learning if they could not complete initial lever 
press training. All rats that began VCD learning were able to achieve VCD criterion. A 
single statistical outlier in the 8M Wt group that required 308 trials to criterion on VCD 
learning (identified as an outlier using the ROUT method with Q = 0.5%) was excluded 
from analyses of VCD learning only; this did not alter the interpretation of any statistical 
comparisons but clarified behavioural trends. A single 13M TgAPP21 rat that did not meet 
RD criterion and 1 22M TgAPP21 rat that was not active during RD (88 omission trials 
out of 120 RD trials) were excluded from all RD and reversal results & analyses. Twenty-
six rats failed to press the correct lever on at least 75% of RD retrieval trials but these 
were only excluded from reversal results & analyses. The rates of exclusion did not 
significantly associate with either genotype or any of the age cohorts for any of the set 
shifting stages or overall.  
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Table 3-2: Stage of Exclusion from Set Shifting Results 
Cohort 
4M 8M 13M 22M 
Wt Tg Wt Tg Wt Tg Wt Tg 
Initial Training    1     
VCD* 1  1 1   1 1 
RD Learning      1  1 
Reversal 
(Failed RD 
Retrieval) 
3 1 6 3 3 4 4 2 
 
Once a rat was excluded, it was also excluded in the analyses of subsequent stages.  
* Rats that did not press the correct lever on at least 75% of the 20 trials of VCD retrieval, 
a relatively simple task, were excluded from all set shifting and reversal results & analyses 
including VCD learning, as these rats’ motivation to lever press was uncertain.  
Tg = TgAPP21 
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3.4.2 Morris Water Maze 
3.4.2.1 Navigational Learning 
Learning performance was measured by the rats’ latencies to find the hidden platform 
across trials 2-6 only, as the first trial reflected the rats’ chance discovery of the platform 
location. Age was the only significant factor in MWM learning (Figure 3-6; p < 0.0001, 
F(3,79) = 25.162; 2-Way RM-ANOVA). Compared to 4M rats, both 13M (Wt p = 0.0003, 
q = 4.103, df = 79; TgAPP21 p = 0.001, q = 3.722, df = 79) and 22M rats (Wt p < 0.0001, 
q = 5.171, df = 79; TgAPP21 p < 0.0001, q = 5.970, df =79; Dunnett’s post-hoc test) 
required more time to reach the platform when averaging swim time on trials 2-6. 
However, only 22M rats failed to show any improvement even by trial 6; 13M Wt still 
reduced swim time by trial 5 (p = 0.002, q = 3.586, df = 395) and 13M TgAPP21 by trial 3 
(p = 0.0006, q = 3.906, df = 395; Dunnett’s post-hoc test). Thus, while age impaired MWM 
learning performance, all but 22M rats demonstrated significant improvement in swim 
time. 
 
3.4.2.1 Navigational Memory 
While no genotype differences were observed in MWM learning, genotype differences on 
the 24 h delayed probe test were observed. During the probe test, the platform was 
removed, and rat swim behaviour was observed during a 90 s probe. Latency to swim to 
the platform region, a 7.5 cm vicinity to the learned platform location, was analyzed to 
evaluate spatial memory. With age, both Wt and TgAPP21 rats required more time to 
locate the platform (Figure 3-7A; p < 0.0001, F(3,79)=8.761; 2-Way ANOVA). Genotype 
was not a significant factor, but the age-dependent trend for increasing latency to the 
platform region was more robust in TgAPP21 rats (R2 = 0.30, p < 0.0001) than Wt rats 
(R2 = 0.17, p = 0.009; post-hoc test for linear trend). Only 22M TgAPP21 rats 
demonstrated a significant latency increase over 4M TgAPP21 rats (p < 0.0001, q = 4.875, 
df = 79; Dunnett’s post-hoc test).  
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Memory was also evaluated by analyzing the proportion of time spent in the target 
quadrant, that is, the quadrant of the MWM in which the platform was previously located. 
Both age (p = 0.03, F(3,79) = 3.187) and genotype (p = 0.05, F(1,79) = 4.140; 2-Way 
ANOVA) had a significant effect on the proportion of time spent in the target quadrant 
(Figure 3-7B), with TgAPP21 rats demonstrating a greater preference for the target 
quadrant in the 4M, 8M, and 13M groups. 13 MO Wt, 22M Wt, and 22M TgAPP21 rats 
did not spend more than 25% of swim time in the target quadrant (one-sample t-tests), 
the expected proportion of swim time in the absence of a target preference. 22M 
TgAPP21 rats showed a significant decrease in target quadrant preference in comparison 
to 4M TgAPP21 (p = 0.02, q = 2.774, df = 79) and 8M TgAPP21 rats (p = 0.003, q = 2.137, 
df = 79; Dunnett’s post-hoc test). However, none of the groups demonstrated a significant 
increase in the time needed to locate the platform region (Figure 3-7A) in comparison to 
the time needed to locate the platform on the last MWM learning trial (Figure 3-6). This 
makes it less likely that any of the groups failed to recall a learned platform location. 
Rather, the 22M rats’ failure to learn the platform location precluded any preference for 
the platform region or target quadrant. When only 4M, 8M, and 13M rats were compared 
on the probe test, genotype was still a significant factor with TgAPP21 rats spending more 
time in the target quadrant (p = 0.002, F(1,67) = 10.900; 2-Way ANOVA). Thus, so long 
as TgAPP21 rats were able to learn and recall the platform location, they would 
demonstrate a greater target quadrant preference. The traditional interpretation of target 
preference would suggest that TgAPP21 rats demonstrated a better recall of the platform 
location.  
 
3.4.2.3 Regressive Platform Search 
Just as in the previous study that focused on 8M rats only, it was observed again that 
some rats would demonstrate an increased preference for the target quadrant in the late 
segment of the probe test. This was unexpected, as preference for the target quadrant 
should extinguish, not strengthen, during the course of the probe test. To evaluate the 
role of regressive behavioural inflexibility in target quadrant preference, the proportion of 
swim time in the target quadrant in the last 30 s segment of the probe test was analyzed 
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(Figure 3-7C). Age was a significant factor in this late preference (p = 0.02, F(3,79) = 
3.404; 2-Way ANOVA), driven by the difference between 8M and 22M TgAPP21 rats (p 
= 0.002, q = 3.474, df = 79; Dunnett’s post-hoc test). Since the 22M rats never 
demonstrated that they learned the platform location, a sub-analysis that excluded 22M 
rats was also performed. When only 4M, 8M, and 13M rats were compared, only genotype 
was a significant factor with TgAPP21 rats demonstrating a greater late preference for 
the target quadrant (p = 0.02, F(1,67) = 5.177; 2-Way ANOVA). Thus, across the ages at 
which the rats could learn the platform location, TgAPP21 demonstrated a greater 
preference for the target quadrant in the last 30 s segment of the probe test. For TgAPP21 
rats, the late preference for the target quadrant peaked at 8M of age just as the number 
of regressive errors and errors after criterion in RD peaked in 8M TgAPP21 rats.  
To more accurately capture the regressive nature of a late target quadrant preference, it 
was important to analyze how this compared to target quadrant preferences 
demonstrated earlier in the probe test. To do this, the Regressive Index was calculated 
for each rat as the difference between the proportion of time in the target quadrant during 
the last 30 s and the first 60 s of the probe test. Although genotype nor age had significant 
overall effects on the Regressive Index, 8M TgAPP21 (p = 0.02, t = 3.796, df = 11) and 
13M Wt rats (p=0.002, t = 5.258, df = 12) both demonstrated a significant non-zero 
Regressive Index (one sample-test with Bonferroni correction; Figure 3-7D). This 
regressive behaviour in the MWM peaked in both genotypes prior to the development of 
navigational learning impairments, just as TgAPP21 regressive behaviour in RD peaked 
at 8 months of age prior to the onset of learning and memory impairments in the operant-
conditioning chamber.  
For both genotypes, the age-dependent trends for the regressive index (Figure 3-7D) 
replicated the regressive error trends observed in response discrimination (Figure 3-3C). 
To test whether the regressive-like behaviour in the MWM probe test was related to 
regressive behaviour in response discrimination, the relationships between regressive 
error frequency and late target quadrant preference & regressive index scores were 
analyzed (Figure 3-8). Regressive error frequency was strongly correlated with both late 
target quadrant preference (p = 0.009, R2 = 0.71, F(1,6) = 14.76) and the regressive index 
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(p = 0.03, R2 = 0.55, F(1,6) = 7.481). This reaffirms the interpretation of late target 
quadrant preference as a regressive behaviour. Altogether, the increased target quadrant 
preference demonstrated by TgAPP21 rats in the probe is more indicative of a regressive 
inflexibility than an improved memory. In TgAPP21 rats, regressive inflexibility in the 
probe test peaked at 8 months of age, paralleling observations in set shifting and reversal, 
and in Wt rats, regressive inflexibility was observed at 13 months of age.  
 
3.4.2.4 Cued Trials & Swim Speed 
Distal visual cues enabled the rats to navigate the MWM, assuming that the rats’ vision 
was not a confounding variable. To test this assumption, cued trials were performed at 
the conclusion of MWM testing, wherein a visible marker was placed on a new platform 
location with the platform slightly elevated above the water level. Neither age nor 
genotype were significant factors in the latency or swim distance to the platform, even 
when correcting for swim speed as a covariate. Thus, vision was unlikely to be a 
confounding factor in MWM observations. Similarly, neither age nor genotype were 
significant factors in swim speeds, averaged across all MWM trials.  
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Learning performance was evaluated across trials 2-6. Age had a significant effect on 
swimming time to platform (p < 0.0001).  
Compared to 4M Wt rats, *** 13M Wt (p < 0.001) and **** 22M Wt rats (p < 0.0001) 
required more time to locate the platform.  
Compared to 4M TgAPP21 rats, ** 13M TgAPP21 (p < 0.01) and **** 22M TgAPP21 (p < 
0.0001) rats also required more time to locate the platform.  
Only 22M rats failed to show any improvement even by trial 6; 13M Wt still reduced swim 
time by trial 5 (p = 0.002) and 13M TgAPP21 by trial 3 (p = 0.0006).  
Error bars indicate SEM; n = 5 – 13.  
Figure 3-6: Age impaired Morris Water Maze learning 
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24 h after MWM learning, the platform was removed, and rat swim behaviour was 
observed during a 90 s probe trial.  
(A) Latency to swim to the platform region, a 7.5 cm vicinity to the learned platform 
location, was analyzed to evaluate spatial memory. With age, both Wt and TgAPP21 rats 
required more time to locate the platform (p < 0.0001). However, **** only 22M TgAPP21 
rats showed a significant increase compared to 4M TgAPP21 rats (p<0.0001).  
(B) Time in the target quadrant is another commonly used metric to evaluate spatial 
memory; the dotted line marks the 25% proportion of swim time that would be expected 
if rats had no bias for the target quadrant. Both age (p = 0.03) and genotype (p = 0.05) 
were significant factors in the proportion of time spent in the target quadrant. * 22M 
TgAPP21 rats spent less time in the target quadrant than 4M and 8M TgAPP21 rats (p < 
0.05). Traditional interpretation of target preference would suggest that 4M, 8M, and 13M 
TgAPP21 rats demonstrated a stronger memory for the platform location than age-
matched Wt rats.  
(C) Age was a significant factor in target quadrant preference during the last 30 s segment 
of the probe test (p = 0.02). This was driven by a ** significantly greater preference in 8M 
TgAPP21 rats (p = 0.002, compared to 22M TgAPP21 rats).  
(D) To score the relative increase of a regressive-like preference for the target quadrant, 
the Regressive Index measures the difference between the proportion of time spent in 
the target quadrant during the last 30 s segment and the first 60 s segment of the probe 
Figure 3-7: Age-dependent memory impairment in the Morris Water Maze probe 
was preceded by a regressive-like inflexibility 
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test. * 8M TgAPP21 (p < 0.05) and ** 13M Wt rats (p < 0.01) both demonstrated a 
regressive-like preference for the target quadrant.  
Error bars indicate SEM; n = 5 – 13. 
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Figure 3-8: Regressive behaviour consistent across response discrimination and 
Morris Water Maze probe 
The group-wise number of regressive errors were significantly correlated with two 
different measures of regressive like-behaviour in the Morris Water Maze probe: (A) the 
proportion of time spent in the target quadrant last 30 s segment of the probe (p = 0.009, 
Pearson’s R2 = 0.71), and (B) the regressive index, which is calculated by the difference 
between the proportion of time spent in the target quadrant during the last 30 s segment 
compared to the first 60 s of the probe test (p = 0.03, Pearson’s R2 = 0.55).  
Error bars indicate SEM; dotted lines indicate 95% confidence interval of linear 
regression.  
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3.4.3 Open Field 
The open field evaluates rats’ locomotor exploration and avoidance of the anxiogenic field 
centre. Older and transgenic rats demonstrated less locomotor exploration, with both age 
and genotype having a significant effect on the total distance travelled during both the 
first 5 min (Figure 3-9A; Age: p < 0.0001, F(3,81) = 14.12; Genotype: p < 0.0001, F(1,81) 
= 54.48; 2-Way ANOVA) and the full 20 min duration of the open field (Figure 3-9A; Age: 
p < 0.0001, F(3,81) = 24.73; Genotype: p < 0.0001, F(1,81) = 71.48; 2-Way ANOVA). 
There was also a significant interaction between age and genotype (p = 0.003, F(3,81) = 
5.2; 2-Way ANOVA), with Wt rats showing a greater age-dependent decline in total 
distance travelled. Overall, TgAPP21 rats demonstrated a profound reduction in 
locomotor exploration. Avoidance of the centre of the open field is an indicator of anxiety. 
Neither age nor genotype were significant factors in this measure of anxiety (Figure 3-9B), 
thus anxiety is unlikely to have confounded behavioural tests.  
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Figure 3-9: Decreased open field exploration in aged and transgenic Rats 
(A) Total distance travelled in the open field is a measure of locomotor exploration. Age 
and genotype were both significant factors in the total distances travelled during both the 
first 5 min (p < 0.0001) and the full 20 min duration of the open field (p < 0.0001); older 
and transgenic rats demonstrated less locomotor exploration. There was also a significant 
interaction between age and genotype (p = 0.003), with Wt rats showing a greater age-
dependent decline in total distance travelled. For both the first 5 min and the full 20 min 
duration of the test, TgAPP21 rats demonstrated significantly less locomotor exploration 
at the 4M, 8M, and 13M age points (p < 0.004), but not at 22 months of age.  
(B) Avoidance of the centre of the open field is an indicator of anxiety. Neither age nor 
genotype were significant factors in this measure of anxiety.  
Error bars indicate SEM; n = 6-13. 
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3.4.4 Activated Microglia 
The activation of microglia indicates a pro-inflammatory environment. The OX6 antibody 
for MHC II was used to identify activated microglia. Major white matter tracts, such as the 
corpus callosum (Figure 3-10A), and the hippocampus were found to be common sites 
for microglial activation. Though OX6 positive microglia were also observed in the cortex, 
thalamus, and striatum, their presence was highly sporadic and qualitative observation 
did not indicate any association with genotype. Thus, only major white matter tracts and 
the hippocampus were evaluated quantitively. Older rats demonstrated a significant 
increase in the cross-sectional area coverage by OX6 positive microglia in the forceps 
minor, corpus callosum, cingulum, and internal capsule (Figure 3-10B-G; p < 0.0001, 
Wilk’s Λ = 0.057, F(24,73.109) = 5.112; 2-way MANOVA). TgAPP21 rats demonstrated 
greater activated microgliosis (p < 0.0001, Wilk’s Λ = 0.285, F(8,25) = 7.847), and there 
was a significant interaction between age and genotype (p = 0.01, Wilk’s Λ = 0.223, 
F(24,73.109) = 2.067; 2-Way MANOVA). This interaction was most apparent in the corpus 
callosum (Figure 3-10D; p = 0.004, F(3,32) = 5.518) and the supraventricular sub-region 
of the corpus callosum (Figure 3-10C; p = 0.002, F(3,32) = 6.130; 2-Way ANOVA). Within 
these two regions, the age-dependent increase activated microglia was precocious in 
TgAPP21 rats, so that 8M TgAPP21 rats had as much microglia activation as 13M Wt 
rats, and 13M TgAPP21 rats had as much microglia activation as 22M Wt rats (Figure 
3-10CD). This precocious white matter inflammation was not observed in the forceps 
minor, cingulum, or internal capsule, but 22M TgAPP21 rats did demonstrate significantly 
greater activated microglia area coverage than 22M Wt rats in all white matter regions (p 
< 0.01; Sidak’s post-hoc test).  
In the hippocampus, only age was a significant factor in microglia activation (Figure 
3-10G; p = 0.02, Wilk’s Λ = 0.543, F(9,73.163) = 2.319; 2-Way MANOVA). While 22M 
TgAPP21 rats demonstrated more neuroinflammation throughout the hippocampus than 
4M rats and 22M Wt did not, there was no significant difference between the 22M 
TgAPP21 and 22M Wt rats. However, in the pooled results for the posterior dorsal and 
ventral sub-regions of the hippocampus, genotype was a significant factor (p = 0.005, 
F(1,32) = 8.989) and interacted significantly with age (p = 0.0009, F(3,32) = 6.997; 2-Way 
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ANOVA), such that 22M TgAPP21 rats demonstrated greater neuroinflammation than 
22M Wt rats in the posterior hippocampus (p < 0.0001, t = 5.384, df = 32; Sidak’s post-
hoc test).  
Wt rats demonstrated a greater increase of microglia activation in the anterior corpus 
callosum than the posterior corpus callosum (p = 0.04, F(1,32) = 4.84; 2-Way ANOVA). 
In TgAPP21 rats, microglia activation was more widely and diffusely increased, so that 
there was not a significant anterior-posterior gradient of inflammation in the corpus 
callosum. This replicates patterns of white matter disruptions observed in healthy elderly 
control subjects and patients with AD42.  
 
 
  
122 
 
 
 
 
123 
 
 
 
IHC for the OX6 primary antibody for MHC II identified activated pro-inflammatory 
microglia; white matter areas and the hippocampus were identified as regions with high 
microglia activation.  
(A) The schematic shows one of the coronal planes on which the corpus callosum was 
analyzed (Bregma +2.0 mm). Representative images of 30 µm thick sections were taken 
from the dotted outline; 200 µm scale bar.  
(B-G) Cross-sectional area coverage by activated microglia was quantified in major white 
matter tracts and the hippocampus. (B-F) Age and genotype were significant factors for 
microglia activation in white matter (p < 0.0001). The interaction between age and 
genotype was also significant (p = 0.01); this interaction was especially apparent in the 
supraventricular corpus callosum and the corpus callosum (p < 0.004). In these regions, 
the age-dependent increase of white matter inflammation was precocious in TgAPP21 
rats, so that 8M and 13M TgAPP21 rats had as much microglia activation as 13M and 
22M Wt rats, respectively.  
(G) Only age was a significant factor in the activation of microglia in the hippocampus (p 
= 0.02); this also applied to the three subregions of the hippocampus analyzed: anterior 
dorsal, posterior dorsal, and ventral (p < 0.007). ** p < 0.01, *** p < 0.001, **** p < 0.0001: 
significant increases compared to 4M rats of the same genotype.  
Error bars indicate SEM, n = 5. 
  
Figure 3-10: Precocious corpus callosum inflammation in transgenic rats 
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3.4.5 Reactive Astrocytes 
To evaluate whether there was an increase of reactive astrocyte in regions with increased 
microglia activation, cross-sectional area coverage by GFAP-positive astrocytes was 
evaluated in the same regions (Figure 3-11). Age was a significant factor in astrocyte 
reactivity in the forceps minor (Figure 3-11B); p = 0.01, F(1,32) = 4.478), which was also 
the only region in which genotype was a significant factor (p = 0.05, F(1,32) = 4.346; 2-
way ANOVA). In the forceps minor, 22M TgAPP21 demonstrated a significant decrease 
in cross sectional area coverage by GFAP-positive astrocytes compared to 8M TgAPP21 
(p = 0.004, q = 3.491, df = 32; Dunnett’s post-hoc test; Figure 3-11B). This pattern of 
group differences was significantly correlated with the number of regressive errors 
committed during response discrimination (group-wise correlation; p = 0.03, Pearson’s R2 
= 0.57, F(1,6) = 8.036; Figure 3-12).  This relationship was particularly strong in TgAPP21 
rats (p = 0.03, Pearson’s R2 = 0.93, F(1,2) = 27.33). Thus, increased astrocyte reactivity 
in the forceps minor may have played an important role in the 8M TgAPP21 rats’ 
regressive inflexibility.  
Age was a significant factor in hippocampal astrocytosis (Figure 3-11G; p < 0.0001, Wilk’s 
Λ = 0.330, F(9,73.163) = 4.695; 2-Way MANOVA), but without a clear trend and no 
differences between the genotypes. This was also observed in the posterior dorsal 
hippocampus (p = 0.003, F(3,32) = 5.816) and ventral hippocampus (p < 0.0001, F(3,32) 
= 10.439; 2-Way ANOVA), but not the anterior dorsal hippocampus.   
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DAB mediated IHC with a primary antibody for GFAP identified reactive astrocytes. 
(A) The schematic shows the coronal planes on which the forceps minor was analyzed 
(Bregma +3.0 mm). Representative images of 30 µm thick sections were taken from the 
dotted outline; 200 µm scale bar. 
(B-G) Cross-sectional area coverage by reactive astrocytes was quantified in regions with 
increased microglia activation. (B-F) Neither age nor genotype were significant factors in 
astrocyte reactivity across most white matter regions except for the forceps minor, in 
which both age (p = 0.01) and genotype (p = 0.05) were significant factors in reactive 
astrocyte area coverage. ** In the forceps minor, 22M TgAPP21 rats had a decreased 
area coverage by reactive astrocytes compared to 8M TgAPP21 rats (p < 0.01).  
(G) Age was a significant factor in reactive astrocyte area coverage in the hippocampus 
(p < 0.0001).  
Error bars indicate SEM, n = 5.  
Figure 3-11: Reduced forceps minor astrocyte reactivity in aged TgAPP21 
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Figure 3-12: Significant positive correlation between regressive errors and 
astrocyte reactivity in the forceps minor. 
The group-wise relationship between the number of regressive errors committed during 
response discrimination and GFAP-positive reactive astrocyte area coverage in the 
forceps minor was significant (p = 0.03, Pearson’s R2 = 0.57).  
Error bars indicate SEM; dotted lines indicate 95% confidence interval of linear 
regression. 
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3.5  Discussion 
The profound acceleration of age-dependent white matter microglia activation builds on 
previous observations of increased inflammation in the TgAPP21 rats’ white matter (2.4.4 
Activated Microglia in White Matter on page 77). Concurrently, the TgAPP21 
demonstrated a regressive behavioural phenotype, committing a greater number of errors 
after criterion during set shifting. This was further evidenced by a greater regressive-like 
preference for the MWM target quadrant. However, TgAPP21 rats did not show a 
persistent or progressive increase in regressive behavioural inflexibility across all 
measures. Instead, behavioural inflexibility peaked in 8M TgAPP21 rats, as measured by 
the number of regressive errors on set shifting, reversal errors, and the MWM Probe 
Regressive Index score. Though learning and memory impairments in 22M rats may 
account for an apparent decrease in inflexibility in 22M TgAPP21 rats, the relative 
reduction of inflexibility in 13 M TgAPP21 would still be unexpected. Previous studies 
have observed that environmental enrichment promotes a relatively greater increase of 
neurogenesis in older than younger rodents43, and that environmental enrichment can 
promote functional compensation in rodent models of neurodegeneration44. This raises 
the question of whether older TgAPP21 rats may have developed compensatory 
pathways, which has been described in AD patients with increased paradoxical neural 
activation45; this would need to be investigated with positron emission tomography or 
functional magnetic resonance imaging. 
The TgAPP21 rats’ regressive inflexibility could not be attributed directly to their 
precocious white matter inflammation. However, the amount of astrocytosis in the forceps 
minor did strongly correlate with the number of regressive errors observed during 
response discrimination. This complements recent findings that correlated performance 
on the Stroop color-naming task with white matter integrity in the forceps minor, as 
measured by fractional anisotropy46. In healthy human subjects, fractional anisotropy is 
negatively correlated with age, particularly in the frontal lobe, and is associated with 
poorer cognitive performance on an attention-switching task5. Our results suggest that 
pathogenic amyloid and astrocytes may also play important roles in frontal white matter 
integrity and its behavioural correlates. 
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Reduced locomotor exploration, as demonstrated by TgAPP21 rats, has been reported 
in other rodent models of Alzheimer disease47. This reduced exploratory behaviour was 
observed in all age cohorts, and 4M TgAPP21 rats explored the field as little as 22M Wt 
rats did. Interestingly, in a study on bilateral carotid artery stenosis and white matter injury 
in aged mice, myelin degradation and microglia activation were associated with reduced 
social exploration14. Another study found that mice with white matter injury after bilateral 
carotid artery stenosis recovered normal exploratory behaviour of a novel object when 
microglia were inactivated by minocycline and TRPM2 knock-out17. These studies 
support the interpretation that white matter inflammation in TgAPP21 rats may have 
mediated reduced exploratory behaviour.  
Several behavioural testing design parameters were crucial to characterizing the 
TgAPP21 rat, although they are not standard in rodent studies. Allowing rats to continue 
lever pressing in the operant-conditioning chamber even after achieving criterion allowed 
us to measure the number of errors committed after criterion during RD. Our MWM test 
was 90 s long, allowing us to capture a regressive-like target quadrant preference in 8M 
TgAPP21 and 13M Wt rats. Both the Regressive Index and the time spent in the target 
quadrant during the last third of the probe test correlated significantly with the number of 
regressive errors committed during response discrimination learning. This reiterates the 
potentially confounding role that behavioural flexibility can have on memory testing in the 
MWM probe. The inherent challenge of maintaining animal wellness in aged rats presents 
an important limitation in our results; 22M behaviour and neuroinflammation may have 
been confounded by insidious health factors. Future work should focus on identifying the 
specific microglia populations that are activated in vivo in response to hAPP expression 
and the specific molecular pathways that link the expression of pathogenic hAPP and 
microglia activation. Targeted anti-inflammatory intervention or pro-inflammatory 
challenges will be important for confirming potentially causal links.  
The observation of precocious microglia activation in the corpus callosum of TgAPP21 
rats reinforces the central role of neuroinflammation in early AD. Increased activation of 
white matter microglia presented independently of amyloid plaque formation, as amyloid 
deposits do not develop spontaneously in the TgAPP21 rat31,32,48. Moreover, the onset of 
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behavioural inflexibility preceded impairments of hippocampal-dependent behaviour, 
such as spatial and memory impairments. This presents important considerations for 
future experimental and clinical studies of behavioural inflexibility related to ageing and 
dementia. In particular, these findings warrant closer investigation of white matter 
inflammation and regressive forms of inflexibility in the earliest stages of cognitive 
impairment associated with amyloid pathology. 
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Chapter 4: The Role of Hypertension in Executive Function 
and White Matter Astrocytosis 
This study set out to evaluate the impact of comorbid pathogenic APP and 
cerebrovascular stress on executive function (Objective 3). The experiments in this study 
were conducted prior to our development of set-shifting methodology, thus evaluation of 
behavioural flexibility was limited to delayed match-sample testing in the MWM, which 
evaluates both working memory and behavioural flexibility. A manuscript of this study is 
under review for publication in Hypertension.    
 
4.1  Abstract 
Hypertension is recognized as a risk factor for Alzheimer disease (AD), but the causal 
link remains undetermined. Although astrocytes and microglia play an important role in 
maintaining the neurovascular unit, astrocytes and microglia have been understudied in 
comorbid models of hypertension and AD. In this study, male transgenic Fischer 344 rats 
(TgAPP21) overexpressing a pathogenic human amyloid precursor protein received 8 
weeks of chronic Angiotensin II (AngII) infusion to increase blood pressure, and the rats 
were evaluated for astrocytosis, microgliosis, and cognitive function. A linear relationship 
between astrocytosis and blood pressure was observed in the corpus callosum and 
cingulum of wildtype rats, with hypertensive wildtype rats matching the elevated baseline 
astrocytosis seen in normotensive transgenic rats. In contrast, hypertensive transgenic 
rats did not demonstrate a further increase of astrocytosis, indicating a deficient response. 
AngII infusion did not affect activation of microglia, which were elevated in the white 
matter and hippocampus of transgenic rats. AngII infusion did impair both wildtype and 
transgenic rats’ executive functions in the Morris Water Maze. These results present 
important implications for the interaction between hypertension and pathogenic human 
amyloid precursor protein expression, as AngII infusion produced cognitive impairments 
in both genotypes, but transgenic rats were additionally impaired in developing a normal 
astrocytic response to elevated blood pressure.  
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4.2  Introduction 
Cerebrovascular pathology is commonly observed in all types of dementia. In addition to 
vascular dementia, this is also apparent in Alzheimer disease (AD), with 80% of cases 
showing coincident cerebrovascular pathology on autopsy1. Hypertension is recognized 
as a leading vascular risk factor for AD2-4, but the causal link between hypertension and 
AD has not been identified. Moreover, it remains inconclusive whether anti-hypertensive 
therapy can offer cognitive protection5-10. Observed interactions between AD and vascular 
pathology has given rise to the Neurovascular Hypothesis of AD11-13. The Neurovascular 
Hypothesis proposes that cerebrovascular dysregulation, such as systemic hypertension, 
disrupts amyloid and tau protein homeostasis, leading to neuronal injury and cognitive 
impairment. At the same time, amyloid- and tau-mediated injury can disrupt 
neurovascular coupling. Central to this bi-directional pathology is the neurovascular unit, 
maintained in part by astrocytes and microglia, which are responsive to hypertension14-
16.  
The importance of hypertension as a risk factor for AD is further supported by the close 
link between hypertension and leukoaraiosis, also known as white matter 
hyperintensities17. Leukoaraiosis is associated with disruptions of white matter 
integrity18,19 and is an important predictor for dementias including AD20. These white 
matter disruptions can cause impairments of executive functions such as working memory 
and behavioural flexibility18, which is also seen in patients with hypertension21-23. 
Hypertension disrupts astrocytic polarity and the blood-brain barrier24-27, which may be 
an initiating factor in the development of leukoaraiosis28. Thus, white matter pathology 
plays an important role in the cognitive effects of hypertension.  
Previous animal models of comorbid hypertension and AD have demonstrated that 
hypertension does exacerbate amyloidopathies and cognitive impairment29-34, but these 
studies did not present data on white matter disruption, executive function, astrocytes, or 
microglia. In the present study, we investigated the impact of hypertension on the 
transgenic Fischer 344 rat (TgAPP21) which overexpresses a pathogenic variant of the 
human amyloid precursor protein (hAPP)35, focusing on astrocytes, microglia, and 
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executive function. Cerebral amyloid pathology does not occur spontaneously in 
TgAPP21 but can be induced35-37, thus TgAPP21 are ideal for modelling the roles of 
hypertension and glial cells in the early pre-plaque stages of AD. For 8 weeks, 8 – 10-
month-old male wildtype and transgenic rats were chronically infused with either normal 
saline (Wt & Tg rats) or Angiotensin II (AngII; Wt-AngII & Tg-AngII rats) to elevate blood 
pressure and model the effects of hypertension38-40. We expected increased astrocytosis 
particularly in the white matter regions of Wt-AngII and Tg-AngII, accompanied by 
executive dysfunction, as both white matter and executive function are particularly 
vulnerable to hypertension21-23. As both hypertension and high levels of amyloid activate 
astrocytes and microglia12,14-16,41-43, we expected the greatest amount of glial activity in 
the comorbid Tg-AngII rats. 
Indeed, after 8 weeks of blood pressure elevation, we found greater astrocyte reactivity 
in the corpus callosum and cingulum of Wt-AngII rats. The level of white matter 
astrocytosis in Wt-AngII rats was similar to Tg rats, which appeared to have an elevated 
baseline level of reactive astrocytes. However, Tg-AngII rats did not demonstrate a further 
increase of astrocytosis. AngII infusion did impair both Wt-AngII and Tg-AngII rats in the 
Morris Water Maze (MWM) adaptation of a delayed match-sample test, a spatial task that 
also tests working memory and behavioural flexibility. These results present important 
implications for the interactive effects of hypertension and genetic risk factors for AD, as 
AngII infusion produced cognitive impairments in both genotypes, but Tg-AngII were 
additionally impaired in developing a normal astrocytic response to elevated blood 
pressure.  
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4.3  Methods 
4.3.1 Animals 
Animal ethics and procedures were approved by the Animal Care Committee at Western 
University (protocol 2014-016) and are in compliance with Canadian and National Institute 
of Health Guides for the Care and Use of Laboratory Animals (NIH Publication #80-23). 
Homozygous TgAPP21 rats were studied to model the effect of increased brain 
concentrations of pathogenic hAPP35. 26 male wildtype Fischer 344 rats and 29 male 
TgAPP21 rats were aged to 7.25 months (SD = 0.55 months), weighing an average of 
367 g (SD =  38 g), before osmotic pumps were implanted to deliver saline or AngII for 8 
weeks.  Behavioural testing was performed during the last 2 weeks of saline or AngII 
infusion.  
 
4.3.2 Blood Pressure Elevation & Measurement 
With random allocation, 13 wildtype and 14 TgAPP21 rats were infused with normal saline 
(Wt, Tg); 13 Wt and 15 TgAPP21 rats were infused with AngII to elevate blood pressure 
(Wt-AngII, Tg-AngII)38-40. Osmotic pumps (Alzet, model 2004; Cupertino, CA) were filled 
with a saline-angiotensin II solution (Sigma Aldrich, A9525; Oakville, Ontario) or with 
normal saline. The angiotensin II solutions were diluted according to lot-specific osmotic 
pump flow rates and individual rat weight to deliver 10 000 ng/kg/h. The pumps were 
implanted subcutaneously on the medial dorsum at the level of the scapulae. The pump 
reservoir allowed for drug or saline delivery for only 4 weeks, so pumps were replaced 
once to allow delivery for a total of 8 weeks. Volume pressure reading tail cuffs were used 
to measure arterial tail blood pressure (Kent Scientific, CODA High Throughput)44,45. In 
between pump implantation and behavioural tests, blood pressure was measured weekly, 
so that there were 6 measurements during the 8-week period of angiotensin II or normal 
saline infusion.  
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4.3.3 Morris Water Maze 
On the 7th week of osmotic pump infusion of either normal saline or AngII, rats began 
behavioural testing. In a dimly lit room, a water tank (144 cm diameter) was filled with 
room temperature water, dyed with black non-toxic acrylic paint, and a target platform (12 
cm diameter) was submerged below 3 cm of water. Rats were placed in a fixed start 
location and had to locate the hidden platform to be removed from the water tank (Figure 
5A). The rats were given six 90 s learning trials (with 1 h inter-trial rest intervals) to learn 
the location of the submerged platform, aided by large distal visual cues; this learning 
schedule was adapted from Roof et al46. Twenty-four hours after the last learning trial, 
the rats’ memory for the platform location was evaluated on a test trial. Rats were also 
evaluated on a 5-day series of delayed match-sample testing, to test for performance in 
more challenging spatial shifts (Figure 5B)47,48. Each day, during the ‘sample trial’, a new 
start location and a new platform location was used. The rats are tested on these new 
spatial parameters 6 h later during the ‘match trial’ and were assessed for improvement 
in their latency to find the platform. The 6 h delay was used to create a greater working 
memory challenge48. This was repeated with new start and platform locations each day 
over 5 days. 
After MWM testing was complete, potentially confounding differences in visual perception 
or swim speed were evaluated on cued trials, wherein the location of the platform was 
visibly marked. All swim paths were tracked using ANYmaze tracking software, version 
4.70 (Stoelting Company; Wood Dale, IL), with a top-view webcam (C525, Logitech; 
Newark, CA). The experimenter was not visible to the rats during testing.  
 
4.3.4 Open field 
The day after MWM testing was completed, rat exploratory behaviour and anxiety was 
evaluated in the open field. Rats were placed in a square 45 cm open field with 40 cm 
black walls and a black floor and permitted to explore freely for 20 mins. A top-view 
webcam was used for behavioural tracking with ANYmaze software, version 4.70 
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(Stoelting Company; Wood Dale, IL). The experimenter was not visible to the rats during 
testing. 
 
4.3.5 Immunohistochemistry & Image Processing  
Immediately after all behavioural testing was complete, before pump reservoirs were 
depleted, rats were euthanized, perfused with 200 ml of 0.01 PBS followed by 200 ml of 
freshly depolymerized and buffered 4% paraformaldehyde solution (PFA), and brain 
tissue was collected and stored in 4% PFA for 24 h before transfer to 30% sucrose 
solution. 30 µm thick coronal sections were prepared from a subset of brains from each 
group (n = 8 – 10) using a cryostat (CryoStar NX50, Thermo Fischer Scientific; Ottawa, 
ON). DAB-mediated IHC of free floating sections was performed with an ABC-HRP kit 
(Thermo Fischer Scientific #32020; Ottawa, ON), a 1:1000 concentration of OX6 primary 
antibody for MHC II to identify activated microglia (BD Biosciences #554926; 
Mississauga, ON)49, and a 1:2000 concentration of GFAP primary antibody to identify 
reactive astrocytes (Sigma-Aldrich #G3893; Oakville, ON)50.  
Stitched micrographs of slides were prepared using a 10x objective lens on an upright 
microscope (Nikon Eclipse Ni-E, Nikon DS Fi2 colour camera, NIS Elements Imaging; 
Mississauga, ON). Anatomical regions of interest (cingulum, corpus callosum, internal 
capsule, hippocampus) were captured at coronal sections: Bregma +2.00, +0.00, and -
3.00 mm51. Micrographs were processed and analyzed using ImageJ, version 1.50b; after 
regions of interest were outlined using the polygon tool, images were converted to 8-bit, 
processed using the subtract background command, and then thresholded with a fixed 
grayscale cut-off value of 237. Percentage of area coverage by DAB-positive cells was 
recorded for each region of interest. The corpus callosum and cingulum were analyzed 
across 3 coronal planes and an average area coverage was calculated, weighted by 
cross-sectional area at each plane.  
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4.3.6 Data Analysis 
Two-Way ANOVA and linear regressions were used to evaluate the effects of genotype 
and AngII infusion using GraphPad Prism 7.0 software (La Jolla, CA). ANCOVA models 
were used to evaluate the effect of blood pressure as a continuous predictor variable with 
IBM SPSS version 23 (Armonk, NY).  The conservative Sidak’s post-hoc analysis was 
used to compare outcome measures within genotype and infusate factors. 
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4.4  Results 
4.4.1 Blood Pressure Elevation and Measurement 
Average MAP was significantly elevated during the 8 weeks of AngII infusion (Figure 4-1; 
p < 0.0001, F(1,51) = 31.52; 2-Way ANOVA). There were no genotype differences in 
response to AngII infusion and its effects on MAP, DBP, and SBP. Post-hoc comparisons 
found a significant MAP increase of 17 +/- 5 mmHg and 22 +/- 6 mmHg in Wt-AngII and 
Tg-AngII rats, respectively (+/- SE of difference; Wt-AngII: p = 0.004, t = 3.307, df=51, 
Tg-AngII: p < 0.0001, t = 4.673, df = 51; Sidak’s test). DBP and SBP demonstrated the 
same pattern of significant changes; DBP respectively increased by 12 +/- 5 mmHg and 
21 +/- 5 mmHg in Wt-AngII and Tg-AngII rats (Wt-AngII: p = 0.04, t = 2.446, df = 51; Tg-
AngII: t= 4.547, df = 51), while SBP respectively increased by 19 +/-5 mmHg and 21 +/- 
5 mmHg Wt-AngII and Tg-AngII rats (Wt-AngII: p = 0.004, t = 4.039, df = 51; Tg-AngII: p 
<0.0001, t= 4.604, df = 51; Sidak’s test). There were no group differences in baseline 
blood pressures, measured prior to pump implantation.  
  
142 
 
 
 
 
 
 
Figure 4-1: Mean Arterial Pressure during 8 weeks of normal saline or AngII 
infusion. 
AngII infusion had a significant effect on mean arterial pressure (p < 0.0001). There were 
no differences in the genotypes’ response to AngII.  
n = 13 – 15; error bars indicate SEM.  
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4.4.2 Reactive Astrocytes 
Reactive astrocytes were found throughout white matter, cortical, subcortical, and 
hippocampal regions. However, qualitative observations identified more variable degrees 
of astrocytosis in major white matter tracts (corpus callosum, cingulum, internal capsule) 
and the hippocampus, so these regions were selected for closer investigation (Figure 
4-2). AngII infusion was found to have a significant effect on astrocyte activity in the 
corpus callosum and cingulum (Figure 4-2B; corpus callosum: p=0.05, F(1,34) = 4.265; 
cingulum: p=0.03, F(1,34) = 4.973; 2-Way ANOVA). This was driven by significant 
differences between Wt and Wt-AngII rats (corpus callosum: p=0.03, t= 2.537, df = 34; 
cingulum: p=0.04, t = 2.426, df = 34; Sidak’s test). While area coverage by reactive 
astrocytes increased in the corpus callosum and cingulum of Wt-AngII rats, Tg rats also 
had elevated astrocytosis that did not increase further in Tg-AngII rats. Astrocytosis in the 
corpus callosum and cingulum was linearly correlated with MAP in wildtype rats (Figure 
4-2C; R2 = 0.52, p=0.0007, df = 18), but not in transgenic rats. Regardless of whether the 
corpus callosum and cingulum were pooled or analyzed separately, similar significant 
relationships were identified and the slopes of the regressions between astrocytosis and 
MAP were significantly different between wildtype and transgenic rats. Moreover, 
genotype, MAP, and their interaction were found to have significant effects on 
astrocytosis in the corpus callosum and cingulum in an ANCOVA model that substituted 
infusate allocation with MAP as a continuous predictor (genotype: p = 0.009, F(1,34) = 
7.568; MAP: p = 0.03, F(1,34) = 4.893; genotype*MAP: p = 0.02, F(1,34) = 6.407; 
ANCOVA). The same findings of significance were observed when the corpus callosum 
and cingulum were analyzed separately. Absolute MAP was found to be more informative 
than individual increases of MAP (as compared to baseline measurements prior to pump 
implantation), as relative changes in MAP was not a significant predictor of astrocytosis. 
In Wt rats, blood pressure elevation increased white matter astrocyte reactivity to levels 
matching Tg and Tg-AngII rats. These findings suggest that white matter astrocyte 
reactivity was already saturated in Tg rats and could not increase further in response to 
elevated blood pressure.  
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In Wt-AngII rats, reactive astrocytes had extensive processes wrapping around blood 
vessels (Figure 4-2A). In contrast, Tg-AngII rats showed some increase of reactive 
astrocyte processes wrapping around blood vessels, but not as consistently as Wt-AngII. 
In comparison to Wt-AngII, astrocytic processes were qualitatively observed to be 
reduced in Tg-AngII across blood vessels ranging from 4 – 50 µm in diameter. This further 
supports the interpretation that astrocytes in Tg rats were already reactive at maximum 
capacity and could not respond to elevated blood pressure in Tg-AngII rats.  
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Figure 4-2: Increased white matter reactive astrocytosis in transgenic rats is 
unresponsive to blood pressure elevation. 
Reactive astrocytes were identified using DAB-mediated IHC with a primary antibody for 
GFAP.  
(A) The schematic shows one of the coronal planes on which the corpus callosum was 
analyzed (Bregma +2.0 mm). Representative images of 30 µm thick sections were taken 
from the dotted outline; 200 µm scale bar. Black triangles identify representative blood 
vessels with extensive astrocyte wrapping, as commonly observed in Wt-AngII rats; in 
comparison, white triangles identify representative blood vessels with relatively 
incomplete astrocyte wrapping, as observed in Tg-AngII rats.  
(B) AngII infusion was found to have a significant effect on astrocyte activity in the corpus 
callosum and cingulum (p < 0.05). This was driven by significant differences between Wt 
and Wt-AngII rats only.  
(C) Elevated mean arterial pressure linearly increased reactive astrocytosis in wildtype 
rats (R2 = 0.52, p=0.0007), but not transgenic rats. n = 9 – 10; error bars indicate SEM.  
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4.3.3 Activated Microglia 
Activated microglia were found infrequently in Wt and Wt-AngII rats but they did appear 
consistently in major white matter tracts and the hippocampus of Tg and Tg-AngII rats 
(Figure 4-3A). Both Tg and Tg-AngII rats demonstrated a significant increase of microglia 
activation in the corpus callosum, cingulum, internal capsule, and hippocampus (Figure 
4-3B; corpus callosum: p < 0.0001, F(1,33) = 22.02; cingulum: p = 0.006, F(1,33) = 14.26; 
internal capsule: p = 0.0005, F(1,33) = 15.33; hippocampus: p = 0.03, F(1,33) = 5.248). 
Neither AngII infusion nor MAP had any significant relationship with microglia activation 
in these regions.  
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Figure 4-3: Increased white matter and hippocampal microglia activation in 
transgenic rats. 
(A) Representative images show activated pro-inflammatory microglia in the corpus 
callosum and cingulum, identified using DAB mediated IHC with the OX6 primary antibody 
for MHC II. 30 µm thick coronal sections; 200 µm scale bar.  
(B) Genotype was a significant factor in microglial activation in all regions analyzed.  
n = 8 – 10; error bars indicate SEM. 
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4.3.4 Open Field 
Exploratory behaviour was evaluated by measuring the total distance travelled in the open 
field test; a subanalysis also evaluated the first 5 min period of the 20 min test, during 
which relatively more exploration occurs (Figure 4-4A). Genotype was a significant factor, 
with Tg and Tg-AngII rats having demonstrated less exploration (first 5 min: p = 0.006, 
F(1,51) = 8.342; full 20 min: p < 0.0001, F(1,51) = 22.39; 2-Way ANOVA). AngII infusion 
did not have an effect on exploratory behaviour. The centre of the field is considered to 
be anxiogenic, but there were no significant group differences in the proportion of time in 
the centre during either the first 5 min period or the full 20 min test duration (Figure 4-4B). 
Thus, anxiety is unlikely to have confounded behavioural measures.  
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Figure 4-4: Reduced exploratory behaviour in transgenic rats. 
(A) Tg and Tg-AngII travelled significantly less during both the first 5 min period of the 
test and during the full 20 min test, while AngII had no significant effect on distance 
travelled.  
(B) No significant group differences were observed in avoidance of the anxiogenic centre 
of the open field.  
n = 13 – 15; error bars indicate SEM.  
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4.3.5 Morris Water Maze 
No group differences were observed in spatial learning and memory (Figure 4-5A). 
However, AngII infusion appeared to impair performance on delayed match-sample 
testing (Figure 4-5B). On the ‘sample’ trial, rats were challenged to find a new platform 
location every day from a new platform location for 5 days. Swim time improvement was 
then evaluated on a 6 h delayed ‘match’ trial. Trial-unique information of changing spatial 
parameters every day places demands on spatial reference memory, working memory, 
and behavioural flexibility47,48. Both Wt and Tg rats demonstrated significant non-zero 
swim time improvements on the match trial (Wt: p = 0.003, t = 4.482, df = 12; Tg: p = 0.03, 
t = 3.082, df = 13; one-sample t-test with Bonferonni correction). In contrast, AngII infusion 
impaired rats of both genotypes, so that Wt-AngII and Tg-AngII did not demonstrate a 
significant swim time improvement. The frequently changing spatial parameters of 
delayed match-sample testing placed greater demands on spatial reference memory, 
working memory, and behavioural flexibility47,48. However, no group differences were 
observed in spatial reference memory (Figure 4-5A), so AngII infusion is more likely to 
have impaired working memory and/or behavioural flexibility. During cued trials, no 
differences were observed in swim time to platform nor swim speed, so visual acuity nor 
mobility were unlikely to have had any confounding effect.  
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Figure 4-5: AngII infusion impaired behavioural flexibility. 
(A) With a fixed start location, rats were given 6 trials to learn the platform location; 24 h 
later, a test trial evaluated spatial memory. No significant group differences were 
observed on the learning or test trials.  
(B) Every day for 5 days, rats were challenged to learn a new platform location from a 
new start location. The randomized start and platform locations are indicated by 
corresponding number pairs. After the first exposure to a new platform location on a 
‘sample’ trial, swim time improvement was measured on a 6 h delayed ‘match’ trial. * Wt 
and Tg rats demonstrated a significant swim time improvement on the match trial (p < 
0.03) but Wt-AngII and Tg-AngII rats did not, suggesting that AngII infusion impaired 
working memory and/or behavioural flexibility.  
n = 13 – 15; error bars indicate SEM.  
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4.5 Discussion 
Normotensive Tg rats had an elevated baseline of reactive astrocytes in the corpus 
callosum and cingulum, while Tg-AngII rats did not show a further increase of 
astrocytosis. The increase of reactive astrocytes in Wt-AngII rats was accompanied with 
extensive astrocytic processes around blood vessels, which was less consistent and 
relatively incomplete in Tg-AngII. This suggested that astrocytes in transgenic rats did not 
develop a normal response to elevated blood pressure; the role of transgenic hAPP in 
this insufficient response is supported by previous findings of amyloid overwhelming 
astrocytes and inducing senescence in astrocytes52,53. AngII infusion impaired both Wt-
AngII and Tg-AngII rats in the MWM adaptation of a delayed match-sample test, a spatial 
task that tests working memory and behavioural flexibility, consistent with the clinical 
studies on the cognitive effects of hypertension21-23.  While AngII infusion did not affect 
activation of microglia in either genotype, Tg and Tg-AngII rats demonstrated significantly 
more pro-inflammatory activation of microglia in the corpus callosum, cingulum, internal 
capsule, and hippocampus. This further indicates dysregulation in the cerebral tissue of 
TgAPP21 rats and implicates pro-inflammatory microglia as an important factor in the 
early pre-plaque stages of AD42,43. White matter microgliosis has also been identified as 
an important early factor of neurodegeneration in recent animal and human studies54,55.  
Previous studies have found detrimental histological and cognitive effects of AngII 
infusion or AngII blockade to be independent of blood pressure, which has been attributed 
to the central effects of AngII56-59. However, these studies did not present data on white 
matter pathology in particular. In contrast, we observed a linear astrocytic response to 
blood pressure elevation in the corpus callosum and cingulum of wildtype rats. While 
pathogenic amyloid may have obscured a linear relationship between blood pressure and 
white matter astrocytosis in the TgAPP21 rats, as it might in clinical studies, our finding 
suggests that the neurological benefit of AngII blockade may still be dependent on 
adequate blood pressure reduction when it comes to white matter integrity. This is 
particularly important for the ongoing research on therapeutic targets in the management 
of high blood pressure.  
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Perspectives  
White matter and executive function are particularly vulnerable to hypertension, which is 
reinforced by the findings of the present study. Future preclinical research on the cerebral 
and cognitive effects of hypertension should evaluate more specific metabolic parameters 
of white matter function and the specific cognitive subdomains of executive function. The 
comorbidity of hypertension and pathogenic amyloid may also have an overwhelming 
effect on astrocytes, which are central to the maintenance of the neurovascular unit. Thus, 
identifying specific molecular targets in the astrocyte, such as cell signalling factors, may 
prove to be crucial to managing the intersection of cerebrovascular and AD-related 
pathology. Characterizing these dysregulations induced by hypertension and amyloid will 
be crucial to refining ongoing research on the neuroprotective effects of antihypertensive 
treatment.   
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Chapter 5: Striatal Ischemic Injury Exacerbates Behavioural 
Inflexibility 
This study set out to evaluate the impact of comorbid pathogenic APP and 
cerebrovascular injury on executive function (Objective 3) and was conducted in close 
collaboration with Aaron M Regis, Vineeth Bhoadi, and Dr Seung-Hun Oh. The findings 
presented here reflect my contribution which focused on behavioural evaluation, namely 
set shifting. This study was published in Behavioural Brain Research. 
 
5.1  Abstract 
Alzheimer disease (AD) and stroke coexist and interact; yet how they interact is not 
sufficiently understood. Both AD and basal ganglia stroke can impair behavioural 
flexibility, which can be reliably modeled in rats using an established operant based set-
shifting test. Transgenic Fischer 344-APP21 rats (TgAPP21) overexpress pathogenic 
human amyloid precursor protein (hAPP) but do not spontaneously develop overt 
pathology, hence TgAPP21 rats can be used to model the effect of vascular injury in the 
prodromal stages of Alzheimer disease. We demonstrate that the injection of endothelin-
1 (ET1) into the dorsal striatum of TgAPP21 rats (Tg-ET1) produced an exacerbation of 
behavioural inflexibility with a behavioural phenotype that was distinct from saline-injected 
wildtype & TgAPP21 rats as well as ET1-injected wildtype rats (Wt-ET1). In addition to 
profiling the types of errors made, interpolative modeling using logistic exposure-
response regression provided an informative analysis of the timing and efficiency of 
behavioural flexibility. During set-shifting, Tg-ET1 committed fewer perseverative errors 
than Wt-ET1. However, Tg-ET1 committed significantly more regressive errors and had 
a less efficient strategy change than all other groups. Thus, behavioural flexibility was 
more vulnerable to striatal ischemic injury in TgAPP21.  
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5.2  Introduction 
It is well established that Alzheimer disease (AD) and stroke are frequently coincident 
and interact mechanistically1-9. Stroke is not only a significant risk factor for AD2-5, but the 
progression of AD is exacerbated in patients who had previously experienced a stroke6,9. 
In addition to verbal and episodic memory deficits, AD is associated with impairments in 
the cognitive processes underlying executive function, such as attention, working memory 
and behavioral flexibility10-17. Separately, executive dysfunction can also occur in 
association with vascular dementia induced by stroke18,19, including covert or ‘silent’ 
strokes in the basal ganglia19-22. In cases of comorbid stroke in AD patients, it is known 
that lacunar infarcts, which affect the basal ganglia, thalamus, or deep white matter, 
increase the odds of dementia at lower Braak stages1,23. At present, however, it is unclear 
whether behavioural flexibility, an important component of executive function, is affected 
by subcortical cerebrovascular injury coupled with AD-related pathology. 
Over the past decade, a variety of preclinical rodent models have been developed to 
investigate the comorbidity of AD and stroke, with focus on characterizing the behavioral 
deficits associated with learning and memory-based tasks24-27. Conversely, behavioural 
testing of executive function has not been comprehensively investigated in these models 
even though, clinically, executive dysfunction plays a key role in the cognitive impairment 
of both AD and stroke. Using operant conditioning-based paradigms, it is possible to 
screen rodents for executive dysfunction, such as impairments in behavioral flexibility, 
using tasks requiring set-shifting. Consistent with patients performing the Wisconsin Card 
Sorting Test (WCST), a neuropsychological assessment of behavioral flexibility, these 
set-shifting tasks challenge rodents to update their goal-directed strategies when the rules 
governing what constitutes a correct behavioral response are suddenly changed28. Within 
this context, it is reasonable to predict that a comorbid rodent model of AD and striatal 
stroke would lead to significant deficits in behavioral flexibility because AD patients have 
been found to perform worse on the WCST than age-matched control subjects29-33, and 
patients with clinical features of stroke in their basal ganglia show an inability to shift 
strategies during the WCST34,35. Consequently, establishing a preclinical model of 
executive dysfunction in a comorbid rodent model of AD and stroke will facilitate future 
160 
 
 
investigations into the underlying mechanisms and offer a platform for evaluating potential 
therapeutic strategies. 
In the present study, we endeavored to characterize behavioral flexibility following focal 
striatal ischemic injury in aged Fischer 344 rats expressing pathogenic human amyloid 
precursor protein (hAPP); the transgenic Fischer 344-APP21 rat (TgAPP21) 
overexpresses hAPP with Swedish and Indiana mutations36. TgAPP21 rats do not 
develop amyloid plaques spontaneously, but do develop amyloid deposits under 
physiological cerebral stress 37,38, making this an ideal model to investigate the prodromal 
phases of AD pathogenesis. An operant conditioned lever-pressing task 39,40 was used to 
assess the set-shifting ability of 16-month old TgAPP21 rats 3 months after unilateral 
striatal ischemia was induced with endothelin-1 (ET1) injection. The striatum was selected 
for ischemic injury due to the clinical link between subcortical lacunar infarcts and post-
stroke cognitive impairment in the presence of amyloid pathology [1,9]. To characterize 
behavioral flexibility, the overall performance and associated error profile of ET1-injected 
TgAPP21 rats was compared to that of TgAPP21 rats without striatal ET1 injection, as 
well as age-matched wildtype rats with and without ET1 injection.  
Consistent with clinical studies of AD patients, we predicted that the TgAPP21 rats would 
commit an increased number of errors and show increased perseverance (i.e., a failure 
to suppress their actions associated with the previously-correct strategy) compared to 
wildtype controls, and that these deficits in behavioural flexibility would be exacerbated 
by a unilateral striatal ischemic injury. However, in contrast to our prediction, the ET1-
injected TgAPP21 rats committed more regressive errors. We further characterized this 
unexpected yet robust behavioral phenotype with a logistic exposure-response curve to 
interpolate group-wise error rates, providing an additional estimate for the efficiency and 
timing of strategy change. Ultimately, we demonstrated that the combined stress of focal 
striatal ischemic injury and mutant hAPP overexpression caused an exacerbation of 
behavioral inflexibility in our comorbid rat model.  
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5.3 Methods 
5.3.1 Animals  
Animal ethics and procedures were approved by the Animal Care Committee at Western 
University (protocol 2014-016) and are in compliance with Canadian and National Institute 
of Health Guides for the Care and Use of Laboratory Animals (NIH Publication #80-23). 
All rats used in this study were housed in facilities maintained by Western University 
Animal Care and Veterinary Services on a 12:12 hour light/dark cycle alternating at 
1AM/PM; behavioural testing was conducted during the rats’ dark cycle. To model 
increased brain concentrations of amyloid protein, we used homozygous transgenic 
Fischer 344-APP21 rats (TgAPP21). Developed by lentiviral infection of zygotes, 
TgAPP21 rats overexpress a pathogenic human APP sequence with Swedish and 
Indiana mutations, and produce high levels of beta-amyloid (both 1-40 and 1-42)36. 
TgAPP21 rats were bred and aged in house, alongside wildtype Fischer 344. TgAPP21 
homozygosity was validated using tissue samples from pups. In total, 22 transgenic male 
(Tg) and 18 male wildtype (Wt) rats with body mass ranging from 340-450g, aged 13 
months, were used in this study.  
 
5.3.2 Endothelin-1 Focal Ischemic Injury 
Focal striatal ischemia was modelled using a unilateral injection of ET1, a potent 
vasoconstrictor, into the dorsal striatum of the right hemisphere41. Wildtype (Wt) and 
transgenic (Tg) rats were randomly selected for ET1 or saline injection: n = 8 Wt; n = 10 
Wt-ET1; n = 9 Tg; and n = 13 Tg-ET1. Surgery was performed with isoflurane anaesthetic 
(Baxter Corporation, Missisauga, Canada; 4% with 2.0 L/min of oxygen for induction, 
shifted to 2% isoflurane once in surgical plane). Prior to surgery, 0.03 mg/kg 
buprenorphine diluted in 0.9% sterile sodium chloride (saline) was administered 
subcutaneously. Anaesthetized rats were secured in a Kopf stereotaxic frame and a 
single injection of ET1 (60 pmol dissolved in 3 µl sterile 0.9% saline) was injected 
unilaterally over 5 min into the right dorsal striatum (AP: +0.5 mm, ML: 3.0 mm, DV: 5.0 
162 
 
 
mm relative to Bregma) using a 32-guage Hamilton syringe (Hamilton Company, Reno, 
NV). Rats injected with equal volume of sterile saline underwent identical procedures with 
equivalent time under isoflurane anaesthesia, pre- and post-operative care. Following 
ET1 or saline injection, rats were injected with 0.03 mL of antibiotic (intramuscular 
enrofloxacin/Baytril, Bayer Inc., Toronto, Canada), monitored during recovery, single 
housed, and observed for 3 months. Strategy set shifting tests began 3 months after 
surgery at 16 months of age, followed by euthanasia at 17 months of age.  
 
5.3.3 Thionine Histochemistry 
Thionine staining was used to detect cellular Nissl substance and regions of glial scarring 
and cell loss due to ischemic injury42. 4 months after saline or ET1 injection (following 
behavioural testing), brain tissue was collected after transcardiac perfusion with freshly 
depolymerized and buffered 4% paraformaldehyde solution (PFA). The tissue was post-
fixed in PFA for 24 h before transfer to 30% sucrose cryoprotectant. 30 µm coronal brain 
sections were first washed in 0.01 M PBS to remove residual cryoprotectant. Sections 
were mounted using 0.3% gelatin on SuperFrost Plus slides (VWR International, PA, 
USA) and left to dry for 24 h prior to staining. Mounted sections were rehydrated from 
100% ethanol to ddH20, followed by 30 s exposure to a solution of 0.25% thionine (0.25% 
thionine acetate salt, 0.28% NaOH, 0.9% glacial acetic acid in ddH20). Slides were then 
dehydrated from 50% ethanol to Xylene, followed by cover slipping with DePex mounting 
medium (DePex, BDH Chemicals, Poole, UK). 
 
5.3.4 Microscopy and Striatal Injury Analysis  
Stained sections were analyzed using a Nikon Eclipse Ni-E upright microscope with a 
Nikon DS Fi2 colour camera head (NIS Elements Imaging), stitched photomicrographs 
using 2x and 10x objective lenses captured the region of injection, and anatomical 
identification was verified with a rat brain atlas43. Infarct area was quantified by outlining 
regions of glial scarring and cell loss; for each rat, infarct areas were averaged from two 
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adjacent coronal sections at the injection site (AP: 1.92 mm relative to Bregma). Infarct 
areas were observed in Wt-ET1 and Tg-ET1 rats, but not Wt and Tg rats (n = 6 for all 
groups). During imaging and infarct area measurement, the experimenter was blinded to 
rat ID and experimental group. 
 
5.3.5 Set-Shifting  
The set shifting protocol, which includes side bias determination, is detailed in 2.3.2 Set 
Shift & Reversal on page 53. As the experiments in this chapter were performed prior the 
experiments of Chapter 2 & 3, the response discrimination retrieval test and reversal 
sessions were not yet implemented.  
 Briefly, rats were food restricted and maintained at 85-87% of free-feed mass to ensure 
motivation for 45mg sucrose pellets (Dustless precision pellets, Bio-Serv; Burlington, ON) 
during behavioural reinforcement in a sound-attenuated operant conditioning chamber 
(Med Associates; St. Albans, VT). During all training and testing, lever presses were 
reinforced with a sucrose pellet using a fixed-ratio 1 schedule. Habituation to the operant-
chamber was followed by initial lever-press training; rats were required to lever press on 
at least 85 of 90 trials of lever presentations, pseudorandomly alternating sides, before 
progressing to visual cue discrimination.  
24 h after initial training, rats were given 100 trials to learn visual cue discrimination. In 
each trial, both levers were extended but only the lever paired with the cue light, which 
pseudorandomly alternated sides, would yield a sucrose pellet reward when pressed 
(Figure 2-1 on page 58). The passing criterion for visual discrimination was 8 correct 
consecutive responses. 24 h after meeting criterion, a retrieval session of 20 visual cue 
discrimination trials was run to evaluate retention. Immediately after the retrieval session, 
120 trials of response discrimination were initiated: only one lever would yield a sucrose 
pellet on all trials, even though the cue light continued to alternate sides. For each rat, the 
lever opposite a previously determined side bias was selected to be rewarding during 
response discrimination44. This challenged the rats to ignore the previously learned visual 
cue discrimination and to acquire a spatial strategy, constituting an extra-dimensional set 
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shift. As described previously44, response discrimination trials were binned into 16 trials 
of 8 congruent and 8 incongruent trials. Perseverative errors were scored when rats 
reverted to visual cue discrimination on incongruent trials; once rats demonstrated 
disengagement from visual cue discrimination (5 or fewer errors in a block of 8 
incongruent trials), subsequent reversion to visual cue discrimination on incongruent trials 
was scored as regressive errors. Incorrect lever presses on congruent trials were scored 
as never-reinforced errors. Omissions (no lever press) were not treated as an error. The 
passing criterion for response discrimination was 8 correct consecutive responses. We 
departed from common approaches to operant conditioning chamber based set shifting45 
in that we allowed rats to complete all 120 trials of response discrimination instead of 
removing them from the chamber once they achieved criterion. This allowed us to quantify 
the number of errors committed after criterion, offering a more complete measure of 
regressive behaviour.  
During all discrimination tests (visual cue, response), rats were granted a 10 s response 
period during which the chamber was illuminated. If the correct lever was pressed, the 
chamber remained illuminated for another 4 s so that rats could retrieve the sucrose pellet 
reward. This was followed by a dark inter-trial period so that trials lasted a total of 30 s. 
Cue lights were presented 3 s before lever extension and extinguished upon lever press 
or the end of the 10 s response period.  
In addition to profiling the types of errors committed, we also applied a logistic modelling 
of group-wise error rates. This produced an exposure-response learning curve that could 
be used to interpolate when 50% of a groups’ responses had transitioned to the new 
strategy (equivalent to the IC50 of a logistic curve) and the efficiency of this transition (Hill 
slope). Logistic modelling allowed for variable slopes and was bound by a 0% and 100% 
error rate. If a group required more trials to reach 50% strategy change (greater IC50 
value), then the group had a delayed strategy change. A shallower exposure-response 
curve (lower Hill slope), indicated a reduced efficiency of strategy change. All set-shifting 
behavioural indices are summarized in Appendix Table A-1 on page 209. 
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5.3.4 Data Analyses  
All statistical analyses were conducted using GraphPad Prism 7.0 software (GraphPad, 
La Jolla, CA). Data are summarized in figures as means ± SEM. Two-way analysis of 
variance (ANOVA) analyzed the effects of genotype (Wt/Tg) and injection (saline/ET1) 
and the interaction between these two independent factors; Tukey post-hoc tests were 
used to compare individual groups where main effects were found to be significant. 
Significance was determined with α = 0.05. 
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5.4 Results 
5.4.1 Striatal Ischemic Injury 
To quantify the extent of residual striatal ischemic injury 4 months after ET1 injection, 
thionine staining of Nissl bodies was used to identify regions of glial scarring and cell loss. 
While saline injected rats (Figure 5-1AC) displayed healthy neuronal cell populations 
visualized using a 10x microscope objective (Figure 5-1EG), scarring in ET-1 treated rats 
(Figure 5-1BD) was detected by a loss of neurons and the presence of dense populations 
of glial cells (Figure 5-1FH). No significant differences were observed between the infarct 
areas of Wt-ET1 (0.85 +/- 0.24 mm2) and Tg-ET1 (0.59 +/- 0.16 mm2) rats (Figure 5-1I; 
unpaired t-test).  
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Figure 5-1: Wt-ET1 and Tg-ET1 have equal infarct areas in the ipsilateral striatum 
Representative images of thionine stained coronal sections from Wt (A), Wt-ET1(B), Tg 
(C) and Tg-ET1 (D), captured with a 2x object lens. The black rectangles outline 
respective images captured with 10x objective lens magnification (E-H). Magnified 
images of the dorsal striatum reveal typical striatal cellular morphology in saline injected 
Wt and Tg rats (E,G) while Wt-ET1 and Tg-ET1 rats (F,H) have residual scars and cell 
loss resulting from ischemic injury; these scars are outlined by red dashes (B,D). Scale 
bar is 1 mm in 2x photomicrographs (A-D), and 200 μm in 10x photomicrographs (E-H). 
Regions of residual scarring and cell loss in ET1 injured rats were used to quantify infarct 
area in the ipsilateral striatum with n = 6 samples for both groups; mean infarct area did 
not differ between Wt-ET1 and Tg-ET1 rats (I).  
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5.4.2 Visual Cue Discrimination 
The VCD task demonstrated equal capacity for associative learning across all four 
experimental groups, as a two-way ANOVA revealed no differences in the number of trials 
needed to achieve the performance criterion (i.e., 8 correct consecutive responses) 
(Figure 5-2A). To determine whether genotype and/or injection affected memory retrieval 
of the original VCD strategy, rats were tested on 20 VCD trials the following day, just prior 
to the RD task (i.e., set-shifting). All groups accurately retrieved the original strategy, 
selecting the visual-cue paired lever on ≥ 80% 20 VCD trials (Figure 5-2B); no differences 
were found across groups on the 20 VCD retention trials (p>0.05, two-way ANOVA)   
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Figure 5-2: Visual cue discrimination learning and memory retrieval 
(A) The number of trials before criterion (8 correct consecutive responses) did not differ 
across groups, indicating no differences in learning of visual cue discrimination (VCD). 
(B) On the following day of testing, prior to response discrimination trials, a set of 20 VCD 
trials were performed. No differences were observed across groups in the number of 
correct responses, indicating a lack of effect of genotype or injection on the retention of 
the VCD strategy.  
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5.4.3 Set-shifting: Response Discrimination 
Behavioral flexibility was assessed by comparing each group’s ability to set-shift following 
the transition from the VCD task (i.e., “follow the light) to the RD task (i.e., only the lever 
opposite the rat’s side bias was always correct; Figure 2-1 on page 58). A two-way 
ANOVA found that ET1 injection caused a delay in the number of trials needed to achieve 
the performance criterion (8 correct consecutive responses; F(1,36) = 7.575, p = 0.009), 
such that Wt-ET1 and Tg-ET1 rats took longer to consistently engage the new strategy 
(Figure 5-3A). However, in contrast to our prediction, there were no group differences 
observed in either the number of errors to criterion (Figure 5-3B), errors made after 
achieving the performance criterion (Figure 5-3C), or total errors committed over the 120 
RD trials (Figure 5-3D).  
To further investigate our prediction that the TgAPP21 would demonstrate a greater 
increase in perseverance following striatal ischemic injury, we compared the error profiles 
across the treatment groups. A two-way ANOVA revealed a main effect for genotype 
whereby the transgenic rats actually performed fewer perseverative errors (F(1,36) = 
4.373, p = 0.04), yet more never-reinforced errors (F(1,36) = 9.04, p = 0.005) and more 
regressive errors (F(1,36) = 9.951, p = 0.003) compared to wildtype rats (Figure 5-4). 
Moreover, this main effect of genotype to decrease the number of perseverative errors as 
well as increase the number of regressive errors was driven by the Tg-ET1 group; these 
rats demonstrated significantly fewer perseverative errors than the Wt-ET1 group (p = 
0.04; Tukey’s post hoc test), and significantly more regressive errors than all the other 
groups (Wt p<0.0001, Wt-ET1 p = 0.02, Tg p = 0.003; Tukey’s post hoc test). Finally, 
striatal injection of ET1 also produced an overall increase in the number of regressive 
errors committed (F(1,36) = 18.15, p = 0.0001). Collectively, these results suggest an 
interactive effect of ET1 injection and pathogenic hAPP expression on the error profile; 
however, instead of increased perseverance, these comorbid rats seemed to show a 
difficulty in maintaining the new strategy as the task progressed (i.e., they continued to 
regress to the original strategy).  
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Figure 5-3: Response discrimination learning and number of errors committed 
during set-shifting 
(A) A two-way ANOVA revealed that injection of ET1 significantly increased the number 
of trials to criterion (8 correct consecutive responses; p = 0.009), indicating a broad 
impairment of cognitive flexibility in ET1 injected rats. No significant effects were observed 
on the number of errors that were made prior to criterion (B), errors committed after the 
rats had achieved the test criterion (C), or total errors made over the 120 trials (D). 
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Figure 5-4: Set-shift error profile 
The combination of transgene expression and ET1 injection drove the strongest change 
in the error profile. Among ET1 injected rats, only the Tg-ET1 group demonstrated a 
change in the number of perseverative errors (*p = 0.04, Tukey’s post hoc test). Tg-ET1 
also showed the greatest increase in regressive errors; #Tg-ET1 committed more 
regressive errors than Wt, Wt-ET1, and Tg (#p<0.0001, p = 0.02, and p = 0.003 
respectively, Tukey’s post hoc tests). Genotype had a significant main effect on the 
number of perseverative errors, never-reinforced errors, and regressive errors (p = 0.04, 
p = 0.005, and p = 0.003 respectively), whereas injection type had a significant main effect 
on regressive errors (p = 0.0001). 
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5.4.4 Logistic Modelling: Exposure-Response Curve 
The number of trials to criterion and error profiles do not capture the incremental changes 
that occur in each trial of RD. In contrast, a logistic model of mean group-wise error rates 
(Figure 5-5A) produced a behavioural exposure-response learning curve derived from all 
incongruent trial data (including omission trials), and therefore the incremental effect of 
each incongruent opportunity could be interpolated. The key indices of the exposure-
response learning curves could then characterize each experimental group: the number 
of trials to 50% strategy change (equivalent to the IC50 of the logistic curve) is an index 
of when the strategy occurred, and the Hill slope of the logistic curve is an index of how 
efficiently that strategy change occurred.  
The error rates were well modelled by a logistic curve (R2 = 0.74 - 0.92; Figure 5-5A), and 
both the number of trials to 50% strategy change and Hill Slope were significantly different 
across groups (F(6,232) = 14.98, p<0.0001). ET1 injection had a significant effect on the 
number of trials to 50% strategy change (F(1,36) = 17.36, p = 0.0007; Figure 5-5B). This 
reflects a delay in strategy change and coincides with the significant increase in the 
number of trials to RD performance criterion in Wt-ET1 and Tg-ET1 rats. However, the 
effect of injection on 50% strategy change was driven by a strong interaction with 
genotype (F(1,36) = 17.36, p = 0.0002); although ET1 injection increased the number of 
incongruent trials to 50% strategy change in wildtype rats (24.77 for Wt versus 34.46 for 
Wt-ET1), it had no effect on transgenic rats. The 50% strategy change was significantly 
greater in Wt-ET1 than all groups (Wt p<0.0001; Tg p = 0.01; Tg-ET1 p = 0.002; Tukey’s 
post hoc test). The Hill slope was also significantly affected by ET1 injection (F(1,36) = 
12.66, p = 0.0011; Figure 5-5C) and was also driven by a strong interaction between ET1 
injection and genotype (F(1,36) = 11.45, p = 0.0017). In contrast to the genotype-
dependent effect on 50% strategy change, the Hill slope was reduced in transgenic rats 
but not in wildtype rats. The Hill slope was significantly less in Tg-ET1 than all other 
groups (Wt p = 0.002; Wt-ET1 p = 0.001; Tg p<0.0001; Tukey’s post hoc test). Thus, ET1 
injection delayed strategy change in wildtype rats but not transgenic rats, and ET1 
injection reduced the efficiency of strategy change in transgenic rats but not wildtype rats.  
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Figure 5-5: Logistic modelling of incongruent trial error rates 
In wildtype rats, ET1 injection delayed strategy change, but did not impair the efficiency 
of strategy change. In transgenic rats, ET1 injection did not delay strategy change but 
slowed down the efficiency of strategy change.  
(A) Logistic exposure-response regression effectively models mean group errors rates on 
incongruent trials (R2 = 0.74 - 0.92).  
(B) Number of incongruent trials to 50% strategy change estimates how many response 
discrimination opportunities are needed for half of a group's responses to demonstrate a 
strategy change (i.e., when the strategy change occurs). ET1 injection had a significant 
effect on trials to 50% strategy change (p = 0.0007), which was driven by the significant 
difference between Wt and Wt-ET1 (p<0.0001, Tukey’s post hoc test); transgenic rats 
injected with ET1 showed no change in the mean number of trials to 50% strategy change, 
reflecting a significant interaction between genotype and injection (p = 0.0002). The Wt-
ET1 group required significantly more incongruent trials to attain 50% strategy change 
than Wt, Tg, and Tg-ET1 rats (*p<0.0001, p = 0.01, and p = 0.002 respectively, Tukey’s 
post hoc tests).  
(C) The Hill slope quantifies the steepness of an exposure-response curve, which reflects 
the efficiency of strategy change (i.e., how fast the strategy change occurs). ET1 injection 
had a significant effect on the Hill slope (p = 0.001), but there was a significant interaction 
between genotype and injection (p = 0.002) such that only transgenic rats demonstrated 
an effect of ET1 injection. Consequently, the Tg-ET1 group had a significantly lower Hill 
slope parameter than Wt, Wt-ET1, and Tg rats (#p = 0.002, p = 0.001, and p<0.0001 
respectively, Tukey’s post hoc tests).  
175 
 
 
5.5 Discussion 
In the present study, an operant conditioning-based set-shifting task was used to 
investigate behavioral flexibility in a novel model of the combined stress of focal striatal 
ischemic injury and mutant pathogenic hAPP (Swedish/Indiana) expression in aged 
Fischer 344-APP21 rats (TgAPP21). Our Tg-ET1 rats demonstrated an unexpected 
increase in regressive errors but not perseverative errors. Studies of other conditions, 
including acute stress, autism spectrum disorders, mania, and schizophrenia, have also 
found surprising results regarding behavioural flexibility46-48, including increases of 
regressive errors49-56. To develop a better understanding of regressive errors, we 
complemented traditional metrics (the number of trials/errors to criterion; scoring of error 
types) with a logistic regression model to help quantify the timing and efficiency of strategy 
change.  
 
5.5.1 Comorbidity of AD and Stroke 
Numerous preclinical rodent models have investigated the mechanisms underlying the 
sensorimotor and cognitive deficits associated with dementia, including comorbidity 
models which specifically examined the interaction between AD and stroke on the 
performance of learning and memory-based tasks (for review, see Thiel et al., 2014)9,24-
27. Consistent with previous clinical investigations, the collective findings of these rodent 
comorbidity studies have shown that the nature and extent of the cognitive impairments 
depends on the age of the animals at the time of insult and assessment, as well as the 
location and severity of ischemic injury. It is important to note, however, that despite over 
a decade of animal research devoted to examining the interaction of AD and stroke, to 
our knowledge, the present study represents the first investigation into the performance 
deficits associated with set-shifting ability.  
Compared to age-matched control subjects, AD patients have been found to commit more 
total errors in the WCST, largely due to an increase in perseverance29,31,32. Similarly, 
patients who experienced a clinically-documented stroke in their basal ganglia also 
showed an inability to flexibly shift attention from one set of rules to another during the 
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WCST34,35. Based on these clinical studies, we predicted that unilateral striatal ischemic 
injury would exacerbate the number of perseverative errors committed by the transgenic 
rats. Surprisingly, traditional error type profiling instead revealed that pathogenic hAPP 
expression decreased the number of perseverative errors made but increased never-
reinforced errors and regressive errors, whereas ET1 injection increased the number of 
regressive errors only. The combined effect of pathogenic hAPP expression and ET1 
injection significantly altered the types of errors committed such that the Tg-ET1 rats 
made the fewest perseverative errors and the greatest number of regressive errors. 
Interestingly, this increase in regressive errors is consistent with the error profile observed 
following bilateral disruption of the dorsal striatum in wildtype rats49,52, even though the 
Tg-ET1 group had only unilateral ischemic injury.  
It is important to note that although the comorbid rats in the present study showed the 
greatest change in error profile (Figure 5-4), it was not clear from these traditional 
analyses whether this shift from perseverative errors towards regressive errors truly 
reflected impaired behavioral flexibility, as the number of errors to criterion as well as the 
total number of errors committed were not significantly affected by genotype or ET1 
injection (Figure 5-3). Thus, we applied a logistic model of group-wise error rates to help 
characterize whether Tg-ET1 rats demonstrated a true functional impairment of 
behavioural flexibility. 
 
5.5.2 Logistic Modelling: Exposure-Response Curve 
The number of trials or errors to criterion provides some quantification of the timing of 
strategy change. On the other hand, scoring error types (perseverative, never-reinforced 
and regressive) helps to profile the components of set-shifting behaviour, but this 
approach does not offer a clear sense of the timing off these errors. Furthermore, using 
fixed 16-trial bins to distinguish perseverative and regressive blocks limits the temporal 
resolution that can capture behavioural change. By interpolating group-wise error rates 
using a logistic exposure-response regression model derived from all incongruent trials, 
we could capture trial-by-trial behavioural changes. To that end, the IC50 of the logistic 
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curve corresponded with when 50% strategy change had been achieved, whereas the 
Hill slope corresponded with the efficiency of strategy change. We found that Tg-ET1 rats 
indeed had the most impaired in the efficiency of strategy change (Figure 5-5C); although 
they appeared to disengage from the visual cue strategy earlier, the Tg-ET1 had a less 
efficient acquisition of RD. This also raises the possibility that the timing and the efficiency 
of strategy change may be differentially impaired. These findings demonstrate the added 
value of analyzing the set-shifting test using logistic modelling (Figure 5-5). 
 
5.5.3 Clinical Relevance of Comorbid Model 
In contrast to our predictions, the combined stress of pathogenic hAPP expression and 
striatal ischemic injury produced a decrease in perseverative errors and a synergistic 
increase in regressive errors during the set-shifting task. Consequently, it may appear 
that our model does not replicate the increase of perseverative errors observed in mild 
cognitive impairment, AD, and striatal stroke29-35. However, it is important to acknowledge 
the possibility that differences in the semantics and paradigms of rodent set-shift tasks 
and the WCST may prohibit the ability to draw clear parallels for specific components of 
behavioural flexibility. For example, the WCST literature often describes perseverative 
errors in a manner that encompasses both the perseverative and regressive errors as 
classified in the present study54,55. Furthermore, ‘non-perseverative’ WCST errors can 
also be subcategorized as ‘efficient errors’ and ‘random errors’, each associated with 
distinct cognitive impairments and neural correlates57 that do not have analogous 
parameters in a two-dimension set-shift paradigm like that of the present study.  
In support of the clinical relevance of our rat model, we elected to investigate the impact 
of unilateral, not bilateral, ET1 injections given that stroke victims are less likely to suffer 
infarcts of the same anatomy bilaterally. A bilateral injection would likely yield greater 
impairment of behavioural flexibility, and future studies using bilateral injections could be 
helpful in revealing the extent of contralateral compensation that may occur in our 
unilateral injection model. In the present study, rats were tested 3 months after ET1 
injection (at 16 months of age) in order to capture the permanent impairment incurred by 
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striatal ischemia, but also to capture the impact of pathogenic hAPP on longer-term 
recovery. AD-related pathology has been proposed to impair angiogenesis and repair of 
vascular injury due to the vasculotoxic accumulation of β-amyloid, which may be an 
important mechanism by which coincident AD-related pathology and vascular injury have 
synergistic effects58,59. However, it is noteworthy that infarct sizes did not differ between 
Wt-ET1 and Tg-ET1 rats 4 months after ET1 injury, thus differences in residual infarct 
size cannot account for the observed behavioural differences. In future studies, the age 
at injection and subsequent testing (and the delay period in between) will be additional 
important variables to consider, as well as the impact of therapeutic intervention and 
rehabilitation.  
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Chapter 6: Discussion 
6.1 Summary 
The studies presented in this thesis set out to advance a better understanding of the 
interactions between pathogenic APP, white matter inflammation, cerebrovascular 
disease, and executive dysfunction. In particular, these studies test the hypotheses that 
ageing and pathogenic APP induces white matter inflammation, resulting in 
executive dysfunction and that vascular injury exacerbates white matter 
inflammation and executive dysfunction induced by ageing and pathogenic APP. 
The TgAPP21 rat model of AD was studied to test these hypotheses and address the 
following research objectives 
1) To determine the effect of pathogenic APP on white matter inflammation and 
executive function (Chapter 2 and Chapter 3) 
2) To characterize the temporal relationship between age, pathogenic APP 
expression, white matter inflammation, and executive function (Chapter 3) 
3) To evaluate the impact of comorbid pathogenic APP and cerebrovascular stress 
(hypertension; Chapter 4) or injury (ischemia; Chapter 5) on executive function 
The TgAPP21 rat was found to spontaneously demonstrate a regressive form of 
behavioural inflexibility, reversal impairments, and increased white matter microglia 
activation (Chapter 2). When further characterized across 4 age points, TgAPP21 rats 
demonstrated precocious white matter microglia activation (Chapter 3). Regressive 
behavioural inflexibility and reversal impairments were also observed at an earlier age in 
TgAPP21 rats (8 months), but Wt rats also demonstrated increased white matter 
microglial activation with age and a regressive target quadrant preference at 13 months 
of age. These findings support the hypothesis that both age and pathogenic APP induces 
white matter inflammation, resulting in executive dysfunction. However, behavioural 
inflexibility did not continue to increase with age while white matter microglia activation 
did. Thus, the relationship between white matter inflammation and executive dysfunction 
may be dynamic and age-dependent. 
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In studying the impact of cerebrovascular disease, Wt rats demonstrated increased white 
matter astrocytosis in response to hypertension, while TgAPP21 rats had an elevated 
baseline of white matter astrocytosis that did not increase further in response to 
hypertension (Chapter 4). Hypertension impaired the working memory and behavioural 
flexibility of both Wt and TgAPP21 rats, while striatal ischemic injury exacerbated 
regressive behavioural inflexibility in the TgAPP21 rats (Chapter 5). Though astrocytosis 
was correlated with blood pressure in Wt rats, microgliosis did not increased in response 
to blood pressure elevation in either Wt or TgAPP21 rats, which makes it unclear that 
hypertension had an effect on white matter inflammation. However, the hypothesis that 
cerebrovascular disease can exacerbate executive dysfunction, namely behavioural 
flexibility and working memory, was supported by the MWM delayed match-sample test 
results. Overall, the results presented in this thesis both support and suggest specific 
revisions to the initial hypotheses, which are explored in the following sections.   
 
6.2 Regressive Behavioural Inflexibility  
Several deviations from common protocols used in behavioural testing proved to be highly 
insightful. In the MWM, TgAPP21 rats demonstrated a regressive-like preference for the 
target quadrant. To our knowledge, this behavioural phenomenon in the MWM has not 
been previously described. While most implementations of the probe tests are performed 
for only 30 – 60 s in order to avoid extinction1,2, performing the probe test for 90 s was 
crucial to capturing regressive behaviour in the MWM. This also presents important 
implications for the interpretation of the MWM test; behavioural inflexibility can confound 
evaluations of memory in the MWM probe. A conventional interpretation of increased 
target quadrant preference would suggest that TgAPP21 rats had more robust or precise 
memory of the learned platform location. The absence of genotype differences on 
memory dependent tasks, except in 22M Wt and TgAPP21 rats, makes it  less likely that 
the TgAPP21 rats’ increased target quadrant preference could be attributed to better 
memory. At the same time, the TgAPP21 rats’ concurrent regressive behaviour during 
RD supports the interpretation that the TgAPP21 rats’ increased preference for the target 
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quadrant, particularly in the last 30 s of the probe test, could be attributed to regressive 
inflexibility. Similarly, observing behaviour for a full 120 trials during RD, regardless of 
when shift criterion was observed, identified differences in the number of errors committed 
after criterion. In contrast, testing is commonly ceased once criterion is achieved3, 
although an increase of errors after criterion suggests a highly aberrant regressive 
inflexibility.  
Thus, behavioural testing paradigms may benefit from minor modifications that better 
capture regressive forms of behavioural inflexibility. This extends to clinical research as 
well, as current neuropsychological evaluations in human subjects do not distinguish 
between perseverative and regressive forms of inflexibility4-6. This may be attributed to 
the recency of the notion of a regressive subtype of behavioural inflexibility, which was 
first explicitly proposed by Ragozzino et al in 2002 in a rat model of dorsomedial striatal 
injury with unimpaired perseverative flexibility but increased regressive inflexibility7. 
However, dissociated impairments analogous to regressive inflexibility have been 
previously described in patients with Parkinson disease7. Similar to the WCST, the 
computerized Penn Conditional Exclusion Test (PCET) offers evaluation of cognitive 
flexibility but with added differentiation of  perseverative and regressive inflexibility8. The 
application of the PCET in studies of autism spectrum disorder5,9 and schizophrenia4,10 
identified dissociated increases of regressive cognitive flexibility, which were attributed to 
dysfunction in the striatum and frontostriatal systems. Accordingly, ET1 injury in the 
TgAPP21 rats’ striatum, a region commonly afflicted by SBI, resulted in an exacerbated 
increase of regressive inflexibility. Other conditions that disrupt the frontostriatal system, 
which includes extensive reciprocal connections carried in the white matter between the 
frontal cortex and the striatum, may also feature regressive forms of inflexibility that have 
been overlooked. This includes major depressive disorder11, schizophrenia12, bulimia 
nervosa13, attention-deficit/hyperactivity disorder14, obsessive-compulsive disorder14,15, 
frontotemporal dementia16, Parkinson disease7,17, and AD18,19. Thus, evaluation of 
regressive cognitive flexibility may have far-reaching clinical significance in psychiatry and 
neurology. In particular, our findings support the evaluation of regressive inflexibility in 
patients at risk of AD, patients with MCI, or patients with cerebrovascular disease of the 
frontostriatal system, using methods such as the PCET. 
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6.3 White Matter Inflammation 
While the importance of white matter integrity for executive function is widely supported 
in the current literature, very few studies have explored the impact of white matter 
inflammation on executive function in the context of neurodegenerative conditions. This 
is despite evidence of white matter inflammation as a common feature of both AD20,21 and 
VCI22. As new biomarker technology specific to white matter inflammation emerges, 
including both PET and MRI23, and neuropsychological evaluation of both AD and VCI 
continues to be refined, validating the link between white matter inflammation and 
cognitive function will be important for evaluating future anti-inflammatory therapeutics. 
White matter microglial activation has been linked to executive dysfunction in a rodent in 
a mouse model of carotid artery occlusion24 and in a mouse model of catatonic 
schizophrenia25. In human post-mortem studies, executive dysfunction was link to white 
matter microglia and astrocytic activation in both dementia pugilistica and alcohol-related 
neuropathology26,27. Our parallel findings of increased and precocious white matter 
microglia activation and regressive behavioural inflexibility in the TgAPP21 rat contributes 
to this limited literature and suggest that this neuropathological-cognitive correlate may 
also present in clinical cases of AD. Microglia activation was not observed in response to 
blood pressure increase, and reactive astrocytosis was not observed in AngII infused 
TgAPP21 rats which may have reached an upper limit of astrocyte reactivity independent 
of blood pressure. However, Wt rats demonstrated a linear increase in white matter 
reactive astrocytosis in response to MAP increase. At the same time, AngII infused Wt 
rats failed to demonstrate significant improvement in sample trial swim time in the MWM 
delayed match-sample test, indicating impaired working memory and behavioural 
flexibility. While it was less clear that hypertension caused white matter inflammation, as 
compared to the effect of pathogenic APP expression on microglia activation, chronic 
astrocytosis due to hypertension could lead to dystrophic astrocytes and dysfunctional 
inflammation20,28. This is also consistent with the central role of astrocytes in maintaining 
and recruiting microglia to the NVU29-31. These findings support further investigation of 
white matter inflammation as a substrate of cognitive inflexibility and other forms of 
executive dysfunction in patients diagnosed with or at risk of AD or VCI.  
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6.4 Mixed Pathology 
Large post-mortem studies strongly suggest that AD and VCI are not only frequently co-
incidental32,33, but also have synergistic effects on cognitive impairment33-35 and 
neuropathology33,36-39. The significance of a synergistic relationship, as opposed to a 
merely additive effect of two coincidental categories of neuropathology, is particularly 
relevant to the development of therapeutic strategies. If mechanisms that link 
cerebrovascular and AD pathology can be targeted, the burden of comorbidity could be 
greatly reduced. This is highlighted by the self-propagating pathological cycle of NVU 
dysfunction, for which targeted therapies are emerging40,41. Further studies are needed 
to evaluate whether the absence of a white matter astrocytic response to hypertension in 
AngII-infused TgAPP21 increased the risk of neuropathology. Thus, our current findings 
are inconclusive on whether hypertension and pathogenic APP expression have 
synergistic delirious effects. our finding of greatly altered pattern of behavioural flexibility 
in TgAPP21 rats with focal striatal injury, namely an impaired efficiency in set shifting 
manifesting with decreased perseverative errors and increased regressive errors. The 
comorbidity of striatal ischemic injury and pathogenic APP expression created a 
disruption of behavioural flexibility that was distinct from and greater than the effect of 
either pathology alone. This behavioural disruption in the comorbid group also would not 
have been predicted from an additive combination of either pathology, suggesting a 
synergistic effect on cognition.  
 
6.5 Limitations 
Although TgAPP21 rats demonstrated greater regressive inflexibility as well as increased 
and precocious white matter microglia activation, statistical power was not adequate for 
evaluating direct correlations between behaviour and histology. In 8-month-old rats, 
reversal errors did correlate with microglia activation in the supraventricular corpus 
callosum, but this was not observed across all ages. Similarly, group-wise analysis 
identified significant correlations between forceps minor astrocytosis and the number of 
regressive errors, but this was not observed within the different age cohorts, including the 
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8-month-old rats. Furthermore, while white matter microglia activation showed a 
precocious and greater age-dependent increase in TgAPP21 rats, regressive behaviour 
peaked at 8 months of age. While this indicates that white matter activated microglia and 
reactive astrocytes cannot entirely predict behavioural flexibility, it does not preclude a 
dynamic relationship.    
Though genotype differences in white matter astrocytosis was not observed in 8-month-
old rats, 9-month-old TgAPP21 rats infused with saline had greater reactive astrocytosis 
than Wt rats infused with saline. While this difference was not significant, it was still 
unexpected based on the findings presented in Chapters 2 and 3. This may indicate that 
the methods used in Chapter 4 (anesthesia, surgery, AngII, or the osmotic minipump) had 
different and non-benign effects on Wt and TgAPP21 rats, including white matter 
astrocyte reactivity. Anesthesia and surgery have been found to activate microglia, which 
can affect astrocyte activity42. However, isoflurane has also been shown to reduce 
expression of GFAP in astrocytes43. Additional control groups for the methods of Chapter 
4 could have identified whether or not the increased astrocytosis observed in TgAPP21 
was truly spontaneous or the result of the methods used. However, controlling for each 
major methodological variable (anesthesia, surgery, AngII, or the osmotic minipump) in 
addition genotype and infusate would not have been feasible. Moreover, while these 
potential confounds may challenge some of the interpretations regarding the direct effects 
of blood pressure elevations in Wt and TgAPP21 rats, it would still indicate that TgAPP21 
rats are more prone to increased astrocyte reactivity. Thus, physiological stressors are 
still more likely to induce a level of astrocytosis in TgAPP21 rats that results in a ceiling 
of reactivity, so that further astrocyte reactivity appears not to respond to increased blood 
pressure. 
Quantification of GFAP+ astrocytes and OX6+ microglia relied on cross-sectional area 
coverage by DAB staining. This approach was decided on the basis that DAB IHC does 
not follow a linear relationship between antigen quantity and chromogen level44-46, so 
instead of falsely quantifying the level of GFAP or MHC II (the target of the OX6 antibody), 
a binary detection of antigen-positive cells was used. This was particularly appropriate 
with GFAP and MHC II, which respectively differentiate reactive astrocytes and activated 
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microglia from quiescent astrocytes and microglia with incomplete but informative 
selectivity47,48. Thus, increased area coverage with these antibodies indicated increased 
activation of these glial cells, not increased protein expression. However, the dynamic 
morphology of both astrocytes and microglia presents a major limitation on this method, 
as ramification or amoeboid phases would alter a single cells’ cross-sectional area 
coverage. The cross-sectional area of a reactive astrocyte is greater than a quiescent 
astrocyte49, while ramified quiescent microglia have a greater mean cross-sectional area 
than amoeboid microglia50. Thus, increased GFAP+ area coverage should reflect either 
a greater number of reactive astrocytes or more extensive reactivity within the average 
astrocyte, while the relationship between OX6+ area coverage and microgliosis is less 
certain. Increased OX6+ area coverage could be due to an increase of quiescent ramified 
microglia or due to a greater number of activated microglia. Qualitative observation of 
OX6+ microglia found hyper-ramified or reactive states of activation as the most common 
phenotype, regardless of the number of cells that were OX6+ positive. Moreover, MHC II 
expression is linked upregulation of a key pro-inflammatory cytokine (IFN-γ) and 
downregulation of anti-inflammatory cytokine (IL-10)51. Thus, while area coverage is an 
imperfect DAB IHC measure of microglia activation, increased area coverage is still most 
likely to indicate a pro-inflammatory environment.   
Lastly, the TgAPP21 rat expresses a pathogenic variant of APP that is known to cause 
autosomal dominant-inherited EOAD, which may involve distinct disease mechanisms 
from LOAD. However, while leukoaraiosis was previously associated more with LOAD, 
which was attributed to the more multifactorial nature of LOAD52, the recent DIAN study 
found leukoaraiosis to also be a core feature of EOAD53. While the etiology of 
leukoaraiosis continues to be studied, the TgAPP21 rat model still offers evaluation of the 
role of white matter microglial activation in white matter integrity, which is pertinent to age-
associated cognitive decline, VCI, EOAD, and also LOAD.  
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6.6 Future Directions 
The studies presented in this thesis offer a foundation for several future directions of 
research. The TgAPP21 rat has demonstrated plaque-independent behavioural 
inflexibility, increased white matter inflammation, and increased vulnerability to 
cerebrovascular disease, two expressions of AD that corroborate clinical studies but are 
considered to be hallmarks of the disease. However, cognitive flexibility is important for 
maintaining functional independence and both inflammatory processes and vascular 
disease are responsive to current pharmacological interventions. Moreover, the TgAPP21 
rat models early stages of AD, prior to accumulation of senile plaque and NFT; earlier 
identification and treatment of AD has greater potential to delay cognitive decline54. Thus, 
TgAPP21 rat model offers an important opportunity to learn more of the early stages of 
AD, for which current diagnostic methods have limited specificity54, and to evaluate the 
potential of therapeutic interventions such as anti-inflammatory medications and anti-
hypertensive medications. While the benefit of NSAIDs for preventing AD has been 
controversial, the most recent meta-analysis of 236 000 participants in 16 cohort studies 
concluded that NSAID use significant reduced AD diagnosis rate by 19%, despite 
considerable heterogeneity in drug and dosing regimen55. A randomized-controlled trial 
did find reduced incidence when NSAID therapy was initiated in asymptomatic 
participants but increased incidence when treatment was initiated in participants with 
cognitive impairment or dementia56. Thus, early intervention may be essential, for which 
the TgAPP21 rat would be a good model.  Other emerging anti-inflammatory interventions 
for AD, targeting TNF-α and activation of microglia and astrocytes, would be informed by 
evaluation in the TgAPP21 rat model: rapamycin, minocycline, pioglitazone, thalidomide, 
etanercept, and celastrol57-59. Investigating the benefit of anti-hypertensive drugs on 
working memory impairment and astrocyte activity in the comorbid hypertensive 
TgAPP21 rat could also model whether and how anti-hypertensive medication may offer 
cognitive protection which currently, continues to be inconclusive60-65. Similarly, studying 
the effect of therapeutics that may the extent of stroke injury in the TgAPP21 rat may 
reveal important mechanisms that lead to post-stroke cognitive impairment and dementia. 
This includes 3K3A-APC, a modified activated protein C which has anticoagulant and 
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cytoprotective properties that has been shown to protect neurons and endothelial cells 
following ischemic injury66,67. The modelling and treatment of other comorbidities and risk 
factors in the TgAPP21 rat that were not evaluated in this thesis, such as hearing loss, 
obesity, and diabetes mellitus type II68, may also be highly informative. Several major 
categories of existing therapeutics are being evaluated in preclinical and clinical studies 
for their potential as disease modifying treatments of AD, including medications used to 
treat hypertension, diabetes, rheumatological conditions, viral infections, and cancer 
57,69,70; the TgAPP21 rat may be an important preclinical model for this effort, particularly 
for evaluating intervention in earlier stages of AD and the impact on executive dysfunction 
and neuroinflammation. Therapeutic studies that show an impact, either directly or 
indirectly, on white matter microglial activation in the TgAPP21 rat would also offer 
stronger mechanistic evaluation of the role of white matter inflammation in cognitive 
impairment.  
Establishing priorities for therapeutic intervention should be guided by further 
characterization of the TgAPP21 rat. While behavioural flexibility and working memory 
were studied in this thesis, testing paradigms have also been established for evaluation 
of inhibitory control, namely the stop signal task71. Astrocyte and microglia were identified 
using antibodies for GFAP and MHC-Class II but identifying the cell populations activated 
in the TgAPP21 rat or in response to vascular injury with greater specificity would require 
more selective molecular targets. In particular, co-labelling astrocytes and blood vessels 
may focus investigation on astrocytes directly involved in NVU homeostasis; co-labelling 
astrocytes and Aβ or other APP products would test whether increased astrocytosis in 
TgAPP21 rats infused with saline in Chapter 4 was in response to amyloid burden. 
Identifying subpopulations of activated microglia may also clarify the pro-inflammatory 
stimulus in TgAPP21 rats. Molecular targets may specify whether activated microglia are 
responding to amyloid protein (TREM-2, LRP receptors) or degenerated myelin 
(complement receptors, scavenger receptors, Galectin-3/Mac-2)72. Importantly, the 
impact of white matter microgliosis and astrocytosis on oligodendrocytes and myelin 
should also be evaluated in the TgAPP21 rat, as demyelination and dysfunctional 
oligodendrocytes has been observed in rodent models of AD and in post-mortem 
evaluation of AD cases, though mechanisms remain speculative73. Similarly, the 
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functional effects of potential axonal injury by microglia and astrocytes could be evaluated 
by studying synaptic integrity74,75 in cortical, subcortical, and hippocampal tissue using 
IHC76,77, morphological and ultrastructural analysis of synaptic spines78,79, or in vivo with 
PET80,81. Electrophysiological evaluation would also offer important functional evaluation 
of axonal and synaptic function82. Plaque-independent disruption of synaptic transmission 
has been observed in mouse models of AD82, and white matter microglial activation in the 
TgAPP21 warrants similar investigation.  
PET imaging continues to emerge as a potentially critical diagnostic tool in AD diagnosis. 
However, the use of PET in clinical AD research is dominated by radiotracers for amyloid 
and tau protein. To study the role of microglia activation in AD, especially in the context 
of comorbid cerebrovascular disease, PET offers an important opportunity for in vivo 
evaluation. Radioligands have been developed to bind the translocator protein (TSPO), 
an outer-mitochondrial-membrane bound protein that is upregulated in activated microglia 
and astrocyte83-87. Preliminary data of the application of this technology in a comorbid 
TgAPP21 rat with striatal ischemic injury is presented in Appendix F.  
 
6.7 Conclusion 
The findings presented in this thesis support the hypothesis that age and pathogenic APP 
induce behavioural inflexibility and white matter inflammation, as indicated by microglial 
activation and reactive astrocytes. Pathogenic APP in the TgAPP21 rat both increased 
the magnitude and accelerated the onset of behavioural inflexibility and white matter 
inflammation. The additional impact of hypertension as a representative form of 
cerebrovascular stress did not affect white matter microglia activation. However, 
hypertension did impair the working memory and behavioural flexibility of both Wt and 
TgAPP21 rats. While Wt rats demonstrated increased white matter astrocytosis in 
response to hypertension, TgAPP21 rats appeared to have an elevated baseline level of 
white matter astrocytosis and did not demonstrate a further astrocytic response to 
hypertension. Thus, it cannot be concluded that hypertension, a form of cerebrovascular 
stress, exacerbated white matter inflammation. However, the comorbidity of pathogenic 
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APP expression and ischemic injury did result in a synergistic impairment of behavioural 
flexibility; the TgAPP21 rats’ vulnerability to cerebrovascular injury was more apparent 
following focal ischemic injury of the dorsal striatum, which resulted in greatly impaired 
behavioural flexibility. Thus, the TgAPP21 rat is an important model for studying the 
complex relationship between age, pathogenic APP, and cerebrovascular disease. The 
TgAPP21 rat also presents important opportunities for future evaluation of novel 
therapeutic interventions that target inflammatory processes and the links between AD 
and cerebrovascular disease. These findings support the emerging significance of white 
matter inflammation and executive dysfunction in the pathophysiology of ageing, AD, and 
VCI.  
  
194 
 
 
6.7 References 
1. Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms 
of learning and memory. Nat Protoc. 2006;1(2):848-858. 
2. Blokland A, Geraerts E, Been M. A detailed analysis of rats' spatial memory in a probe trial of a 
Morris task. Behav Brain Res. 2004;154(1):71-75. 
3. Brady AM, Floresco SB. Operant procedures for assessing behavioral flexibility in rats. J Vis Exp. 
2015(96):e52387. 
4. Hill SK, Reilly JL, Ragozzino ME, et al. Regressing to Prior Response Preference After Set 
Switching Implicates Striatal Dysfunction Across Psychotic Disorders: Findings From the B-SNIP 
Study. Schizophr Bull. 2015;41(4):940-950. 
5. Miller HL, Ragozzino ME, Cook EH, Sweeney JA, Mosconi MW. Cognitive set shifting deficits and 
their relationship to repetitive behaviors in autism spectrum disorder. J Autism Dev Disord. 
2015;45(3):805-815. 
6. Barceló F, Knight RT. Both random and perseverative errors underlie WCST deficits in prefrontal 
patients. Neuropsychologia. 2002;40(3):349-356. 
7. Ragozzino ME, Ragozzino KE, Mizumori SJ, Kesner RP. Role of the dorsomedial striatum in 
behavioral flexibility for response and visual cue discrimination learning. Behav Neurosci. 
2002;116(1):105-115. 
8. Kurtz MM, Ragland JD, Moberg PJ, Gur RC. The Penn Conditional Exclusion Test: a new measure 
of executive-function with alternate forms of repeat administration. Arch Clin Neuropsychol. 
2004;19(2):191-201. 
9. D'Cruz AM, Ragozzino ME, Mosconi MW, Shrestha S, Cook EH, Sweeney JA. Reduced behavioral 
flexibility in autism spectrum disorders. Neuropsychology. 2013;27(2):152-160. 
10. Nelson CLM, Amsbaugh HM, Reilly JL, et al. Beneficial and adverse effects of antipsychotic 
medication on cognitive flexibility are related to COMT genotype in first episode psychosis. 
Schizophr Res. 2018. 
11. Furman DJ, Hamilton JP, Gotlib IH. Frontostriatal functional connectivity in major depressive 
disorder. Biol Mood Anxiety Disord. 2011;1(1):11. 
12. Lin P, Wang X, Zhang B, et al. Functional dysconnectivity of the limbic loop of frontostriatal circuits 
in first-episode, treatment-naive schizophrenia. Hum Brain Mapp. 2018;39(2):747-757. 
13. Berner LA, Marsh R. Frontostriatal circuits and the development of bulimia nervosa. Front Behav 
Neurosci. 2014;8:395. 
14. Norman LJ, Carlisi CO, Christakou A, et al. Frontostriatal Dysfunction During Decision Making in 
Attention-Deficit/Hyperactivity Disorder and Obsessive-Compulsive Disorder. Biol Psychiatry Cogn 
Neurosci Neuroimaging. 2018;3(8):694-703. 
15. Vaghi MM, Vertes PE, Kitzbichler MG, et al. Specific Frontostriatal Circuits for Impaired Cognitive 
Flexibility and Goal-Directed Planning in Obsessive-Compulsive Disorder: Evidence From Resting-
State Functional Connectivity. Biol Psychiatry. 2017;81(8):708-717. 
195 
 
 
16. Bertoux M, O'Callaghan C, Flanagan E, Hodges JR, Hornberger M. Fronto-Striatal Atrophy in 
Behavioral Variant Frontotemporal Dementia and Alzheimer's Disease. Front Neurol. 2015;6:147. 
17. Zgaljardic DJ, Borod JC, Foldi NS, et al. An examination of executive dysfunction associated with 
frontostriatal circuitry in Parkinson's disease. J Clin Exp Neuropsychol. 2006;28(7):1127-1144. 
18. Oh H, Madison C, Villeneuve S, Markley C, Jagust WJ. Association of gray matter atrophy with 
age, beta-amyloid, and cognition in aging. Cereb Cortex. 2014;24(6):1609-1618. 
19. Buckner RL. Memory and executive function in aging and AD: multiple factors that cause decline 
and reserve factors that compensate. Neuron. 2004;44(1):195-208. 
20. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer 
disease. Nat Rev Neurosci. 2015;16(6):358-372. 
21. Raj D, Yin Z, Breur M, et al. Increased White Matter Inflammation in Aging- and Alzheimer's 
Disease Brain. Front Mol Neurosci. 2017;10(June):206. 
22. Rosenberg GA. Inflammation and white matter damage in vascular cognitive impairment. Stroke. 
2009;40(3 Suppl):S20-23. 
23. Pulli B, Chen JW. Imaging Neuroinflammation - from Bench to Bedside. J Clin Cell Immunol. 
2014;5. 
24. Kim DH, Choi BR, Jeon WK, Han JS. Impairment of intradimensional shift in an attentional set-
shifting task in rats with chronic bilateral common carotid artery occlusion. Behav Brain Res. 
2016;296:169-176. 
25. Janova H, Arinrad S, Balmuth E, et al. Microglia ablation alleviates myelin-associated catatonic 
signs in mice. J Clin Invest. 2018;128(2):734-745. 
26. Saing T, Dick M, Nelson PT, Kim RC, Cribbs DH, Head E. Frontal cortex neuropathology in 
dementia pugilistica. J Neurotrauma. 2012;29(6):1054-1070. 
27. de la Monte SM, Kril JJ. Human alcohol-related neuropathology. Acta Neuropathol. 
2014;127(1):71-90. 
28. Thal DR. The role of astrocytes in amyloid beta-protein toxicity and clearance. Exp Neurol. 
2012;236(1):1-5. 
29. Thurgur H, Pinteaux E. Microglia in the Neurovascular Unit: Blood–Brain Barrier–microglia 
Interactions After Central Nervous System Disorders. Neuroscience. 2018. 
30. Barakat R, Redzic Z. The Role of Activated Microglia and Resident Macrophages in the 
Neurovascular Unit during Cerebral Ischemia: Is the Jury Still Out? Med Princ Pract. 2016;25 Suppl 
1:3-14. 
31. Zenaro E, Piacentino G, Constantin G. The blood-brain barrier in Alzheimer's disease. Neurobiol 
Dis. 2017;107:41-56. 
32. Toledo JB, Arnold SE, Raible K, et al. Contribution of cerebrovascular disease in autopsy confirmed 
neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. Brain. 
2013;136(Pt 9):2697-2706. 
196 
 
 
33. Arvanitakis Z, Capuano AW, Leurgans SE, Bennett DA, Schneider JA. Relation of cerebral vessel 
disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross-sectional 
study. Lancet Neurol. 2016;15(9):934-943. 
34. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction 
and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277(10):813-817. 
35. Azarpazhooh MR, Avan A, Cipriano LE, Munoz DG, Sposato LA, Hachinski V. Concomitant 
vascular and neurodegenerative pathologies double the risk of dementia. Alzheimer's & Dementia. 
2018;14:148-156. 
36. Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular 
dysfunction in Alzheimer disease. Nat Rev Neurosci. 2017;18(7):419-434. 
37. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 
2005;28(4):202-208. 
38. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other 
disorders. Nat Rev Neurosci. 2011;12(12):723-738. 
39. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev 
Neurosci. 2004;5(5):347-360. 
40. Carnevale D, Mascio G, D'Andrea I, et al. Hypertension induces brain beta-amyloid accumulation, 
cognitive impairment, and memory deterioration through activation of receptor for advanced 
glycation end products in brain vasculature. Hypertension. 2012;60(1):188-197. 
41. Deane R, Singh I, Sagare AP, et al. A multimodal RAGE-specific inhibitor reduces amyloid beta-
mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest. 2012;122(4):1377-
1392. 
42. Bell JD, Stary CM. Anesthetic neurotoxicity: an emerging role for glia in neuroprotection. J Mol Med 
(Berl). 2017;95(4):349-351. 
43. Culley DJ, Cotran EK, Karlsson E, et al. Isoflurane affects the cytoskeleton but not survival, 
proliferation, or synaptogenic properties of rat astrocytes in vitro. Br J Anaesth. 2013;110 Suppl 
1:i19-28. 
44. van der Loos CM. Multiple immunoenzyme staining: methods and visualizations for the observation 
with spectral imaging. J Histochem Cytochem. 2008;56(4):313-328. 
45. Shu J, Dolman GE, Duan J, Qiu G, Ilyas M. Statistical colour models: an automated digital image 
analysis method for quantification of histological biomarkers. Biomed Eng Online. 2016;15:46. 
46. Rimm DL. What brown cannot do for you. Nat Biotechnol. 2006;24(8):914-916. 
47. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol. 2010;119(1):7-
35. 
48. Wong WT. Microglial aging in the healthy CNS: phenotypes, drivers, and rejuvenation. Front Cell 
Neurosci. 2013;7:22. 
49. Rodriguez JJ, Olabarria M, Chvatal A, Verkhratsky A. Astroglia in dementia and Alzheimer's 
disease. Cell Death Differ. 2009;16(3):378-385. 
197 
 
 
50. Caldeira C, Oliveira AF, Cunha C, et al. Microglia change from a reactive to an age-like phenotype 
with the time in culture. Front Cell Neurosci. 2014;8:152. 
51. Frank MG, Barrientos RM, Biedenkapp JC, Rudy JW, Watkins LR, Maier SF. mRNA up-regulation 
of MHC II and pivotal pro-inflammatory genes in normal brain aging. Neurobiol Aging. 
2006;27(5):717-722. 
52. Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer 
disease: differences between early- and late-onset Alzheimer disease and stability during the 
course of disease. Arch Neurol. 1999;56(6):673-680. 
53. Lee S, Viqar F, Zimmerman ME, et al. White matter hyperintensities are a core feature of 
Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. Ann Neurol. 
2016;79(6):929-939. 
54. Solomon A, Mangialasche F, Richard E, et al. Advances in the prevention of Alzheimer's disease 
and dementia. J Intern Med. 2014;275(3):229-250. 
55. Zhang C, Wang Y, Wang D, Zhang J, Zhang F. NSAID Exposure and Risk of Alzheimer's Disease: 
An Updated Meta-Analysis From Cohort Studies. Front Aging Neurosci. 2018;10:83. 
56. Breitner JC, Baker LD, Montine TJ, et al. Extended results of the Alzheimer's disease anti-
inflammatory prevention trial. Alzheimers Dement. 2011;7(4):402-411. 
57. Corbett A, Williams G, Ballard C. Drug repositioning in Alzheimer's disease. Front Biosci (Schol 
Ed). 2015;7:184-188. 
58. Calsolaro V, Edison P. Neuroinflammation in Alzheimer's disease: Current evidence and future 
directions. Alzheimers Dement. 2016;12(6):719-732. 
59. Decourt B, Lahiri DK, Sabbagh MN. Targeting Tumor Necrosis Factor Alpha for Alzheimer's 
Disease. Curr Alzheimer Res. 2017;14(4):412-425. 
60. Lithell H, Hansson L, Skoog I, et al. The Study on COgnition and Prognosis in the Elderly (SCOPE); 
outcomes in patients not receiving add-on therapy after randomization. J Hypertens. 
2004;22(8):1605-1612. 
61. Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the 
Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-
blind, placebo controlled trial. Lancet Neurol. 2008;7(8):683-689. 
62. McGuinness B, Todd S, Passmore P, et al. Blood pressure lowering in patients without prior 
cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database 
Syst Rev. 2009(4):CD004034-CD004034. 
63. Sörös P, Whitehead S, Spence JD, et al. Antihypertensive treatment can prevent stroke and 
cognitive decline. Nat Rev Neurol. 2013;9(3):174-178. 
64. Perrotta M, Lembo G, Carnevale D. Hypertension and Dementia: Epidemiological and 
Experimental Evidence Revealing a Detrimental Relationship. Int J Mol Sci. 2016;17(3):347. 
65. Walker V, Davies N, Kehoe P, Martin R. Can treatments for hypertension be repurposed for the 
treatment of dementia? Revue d'Épidémiologie et de Santé Publique. 2018;66:S262-S262. 
198 
 
 
66. Guo H, Singh I, Wang Y, et al. Neuroprotective activities of activated protein C mutant with reduced 
anticoagulant activity. European Journal of Neuroscience. 2009;29(6):1119-1130. 
67. D. Williams P, V. Zlokovic B, H. Griffin J, E. Pryor K, P. Davis T. Preclinical Safety and 
Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke. 
Current Pharmaceutical Design. 2012;18(27):4215-4222. 
68. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 
2017;390(10113):2673-2734. 
69. Appleby BS, Nacopoulos D, Milano N, Zhong K, Cummings JL. A review: treatment of Alzheimer's 
disease discovered in repurposed agents. Dement Geriatr Cogn Disord. 2013;35(1-2):1-22. 
70. Corbett A, Pickett J, Burns A, et al. Drug repositioning for Alzheimer's disease. Nature Reviews 
Drug Discovery. 2012;11(11):833-846. 
71. Mayse JD, Nelson GM, Park P, Gallagher M, Lin SC. Proactive and reactive inhibitory control in 
rats. Front Neurosci. 2014;8:104. 
72. Fu R, Shen Q, Xu P, Luo JJ, Tang Y. Phagocytosis of microglia in the central nervous system 
diseases. Mol Neurobiol. 2014;49(3):1422-1434. 
73. Nasrabady SE, Rizvi B, Goldman JE, Brickman AM. White matter changes in Alzheimer's disease: 
a focus on myelin and oligodendrocytes. Acta Neuropathol Commun. 2018;6(1):22. 
74. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's 
disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30(4):572-
580. 
75. Neuman KM, Molina-Campos E, Musial TF, et al. Evidence for Alzheimer's disease-linked synapse 
loss and compensation in mouse and human hippocampal CA1 pyramidal neurons. Brain Struct 
Funct. 2015;220(6):3143-3165. 
76. Masliah E, Terry RD, DeTeresa RM, Hansen LA. Immunohistochemical quantification of the 
synapse-related protein synaptophysin in Alzheimer disease. Neurosci Lett. 1989;103(2):234-239. 
77. Ippolito DM, Eroglu C. Quantifying synapses: an immunocytochemistry-based assay to quantify 
synapse number. J Vis Exp. 2010(45). 
78. Scheff SW, Price DA. Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. 
Neurobiol Aging. 2003;24(8):1029-1046. 
79. Mancuso JJ, Chen Y, Li X, Xue Z, Wong ST. Methods of dendritic spine detection: from Golgi to 
high-resolution optical imaging. Neuroscience. 2013;251:129-140. 
80. Chen MK, Mecca AP, Naganawa M, et al. Assessing Synaptic Density in Alzheimer Disease With 
Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. JAMA Neurol. 2018. 
81. Finnema SJ, Nabulsi NB, Eid T, et al. Imaging synaptic density in the living human brain. Sci Transl 
Med. 2016;8(348):348ra396. 
82. Hsia AY, Masliah E, McConlogue L, et al. Plaque-independent disruption of neural circuits in 
Alzheimer's disease mouse models. Proc Natl Acad Sci U S A. 1999;96(6):3228-3233. 
199 
 
 
83. Venneti S, Lopresti BJ, Wiley CA. The peripheral benzodiazepine receptor (Translocator protein 
18kDa) in microglia: from pathology to imaging. Prog Neurobiol. 2006;80(6):308-322. 
84. Chen MK, Guilarte TR. Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and 
repair. Pharmacol Ther. 2008;118(1):1-17. 
85. Lavisse S, Guillermier M, Herard AS, et al. Reactive astrocytes overexpress TSPO and are 
detected by TSPO positron emission tomography imaging. J Neurosci. 2012;32(32):10809-10818. 
86. Vivash L, O'Brien TJ. Imaging Microglial Activation with TSPO PET: Lighting Up Neurologic 
Diseases? J Nucl Med. 2016;57(2):165-168. 
87. Wilson AA, Garcia A, Parkes J, et al. Radiosynthesis and initial evaluation of [18F]-FEPPA for PET 
imaging of peripheral benzodiazepine receptors. Nucl Med Biol. 2008;35(3):305-314. 
 
200 
 
 
Appendices 
Appendix A: Set Shift Data Extraction 203 
A1  MED-PC to Excel Conversion 204 
A2  Visual Cue Workbook 205 
A3  Response Discrimination Workbook 206 
 
Appendix B: MWM Regressive Preference for Target Quadrant 210 
 
Appendix C: Immunohistochemistry Protocols 211 
C1  Solutions 211 
C2  Immunohistochemistry Protocol 213 
 
Appendix D: Microscopy and Image Analysis Protocols 214 
D1  Threshold Analysis: Detailed Walkthrough 217 
D2  Threshold Analysis: Protocol Summary 225 
 
Appendix E: Rat Tail Cuff Blood Pressure Measurement Protocol 226 
E1  Background 226 
E2  Equipment Use & Maintenance 228 
E2.1 Software Set-up 228 
E2.2 Recommended Session Parameters 229 
E2.3 Warming Platform 229 
E2.4 Cuff Replacement 230 
E2.5 Cleaning & Storage 230 
E2.6 Animal Handling 231 
E3 Data Quality & Analysis 231 
E4 Operating Summary 234 
E5 References 236 
 
201 
 
 
Appendix F: PET/MRI Study 237 
F1 Introduction 237 
F1.1 Objectives 238 
F2 Methods 238 
F3 Results 240 
F4 Conclusions 243 
F5 References 244 
 
Appendix G: Animal Use Protocol 246 
 
 
List of Appendix Tables 
Appendix Table A-1: Set Shifting Indices 209 
 
 
List of Appendix Figures 
Appendix Figure A-1: MED-PC to Excel Setup 204 
Appendix Figure A-2: Sample Visual Cue Discrimination Output 205 
Appendix Figure A-3: Sample Response Discrimination Output for Error 
Profile 207 
Appendix Figure A-4: Sample Response Discrimination Output for Logistic 
Regression of Mean Group Error Rates 208 
Appendix Figure D-1: Microscope Imaging Parameters 214 
Appendix Figure D-2: Focus Surface Setup 215 
Appendix Figure D-3: Micrograph Stitching 216 
Appendix Figure D-4: Forceps Minor 219 
202 
 
 
Appendix Figure D-5: Anterior Corpus Callosum 220 
Appendix Figure D-6: Anterior Supraventricular Corpus Callosum 220 
Appendix Figure D-7: Anterior Cingulum 221 
Appendix Figure D-8: Middle corpus callosum, supraventricular corpus 
callosum, cingulum 221 
Appendix Figure D-9: Posterior Corpus Callosum, Cingulum 222 
Appendix Figure D-10: Internal capsule 222 
Appendix Figure D-11: Anterior Dorsal Hippocampus 223 
Appendix Figure D-12: Posterior Dorsal and Ventral Hippocampus 223 
Appendix Figure E-1: Cuff Positioning on Restrained Rat's Tail 226 
Appendix Figure E-2: Sample channel output for one cycle 227 
Appendix Figure E-3: Suggested organization of data 233 
Appendix Figure F-1: Endothelin-1 injection into the dorsal striatum 239 
Appendix Figure F-2: Brain Segmentation Model 239 
Appendix Figure F-3: Immunohistochemistry Corroborates 18F-FEPPA-
PET/MR Findings 240 
Appendix Figure F-4: 18F-FEPPA Uptake Following Injury Persists in Anterior 
White Matter Tracts 241 
Appendix Figure F-5: Mean Transit Time Prolonged by Ischemic Injury 241 
Appendix Figure F-6: 18F-FEPPA Kinetic Profile 242 
 
  
203 
 
 
Appendix A: Set Shift Data Extraction 
This appendix details the Excel (Microsoft) workbooks that were developed to extract 
meaningful set shifting data from the raw data generated by MED-PC software (Med 
Associates; St. Albans, VT). The supplemental file, Visual Cue Workbook.xlsm, extracts 
visual cue discrimination data and relies on the import of raw data using the MED-PC to 
Excel tool provided by Med Associates. The supplemental file, Response Discrimination 
Workbook.xlsm, extracts response discrimination data and also relies on the import of 
raw data using the MED-PC to Excel tool provided by Med Associates and includes VBA 
macros. To ensure the stability of the workbooks, the files are designated as ‘read-only’; 
do not save or overwrite the files and copy any extracted data into separate data files. 
The workbooks were developed using Excel 2016; the instructions outlined below are 
specific to Excel 2016.  
204 
 
 
A1  MED-PC to Excel Conversion 
1. Open MPC2XL.EXE (MED-PC to Excel) 
2. Under “Row Transfer” in the “Transfer Data” tab, press “Select” 
3. Open “$Visual cue deminationnew.MRP” for visual cue discrimination files, open 
“$Shift Response Discrimination.MRP” for response discrimination files.  
4. Make sure both “Column Labels” and “Data” are select under the “Transfer” box 
5. Select “Vertical (Column)” under the “Orientation” box 
6. Open Excel workbook and ensure that the A1 cell on the first tab (Input) is selected; 
this applies to both workbooks. Transferring data into any other cell can cause 
irreversible malfunction of the workbooks. 
7. Return to MED-PC to Excel, press “Transfer”, select raw data file 
 
Appendix Figure A-1: MED-PC to Excel Setup 
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A2  Visual Cue Workbook 
Once data is transferred into Visual Cue Workbook.xlsm, key measures will appear in 
cells E3-5: Trials to Criterion, Errors to Criterion, Errors after Criterion. Criterion is set to 
8 consecutive correct response. Omissions do not reset a series of correct responses. 
Rows 27-426 show raw data with annotations: Trial number, whether criteria have been 
met, running total counts of errors, and running counts of consecutive correct responses 
(performance).  
 
Appendix Figure A-2: Sample Visual Cue Discrimination Output 
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A3  Response Discrimination Workbook 
The Excel workbook Response Discrimination Workbook.xlsm requires the use of VBA 
macros. To enable the use of VBA macros in excel, users must first enable the developer 
tab (see “Show the Developer tab” in Microsoft Office Support documentation) and enable 
macros (see “Enable or disable macros in Office files” in Microsoft Office Support 
documentation).  
Once Data is transferred into Response Discrimination Workbook.xlsm, go to the 
‘Developer’ tab and select ‘Macros’. Run Compiled_Left2 (shortcut key: Ctrl + Shift + E) 
or Compiled_Right2 (shortcut key: Ctrl + Shift + R) depending on whether the left or right 
lever was selected to be rewarding, respectively. If uncertain which lever was selected to 
be rewarding in a given experiment, the raw data file can be inspected using a text editor 
such as Notepad or Word (Microsoft) and the experiment protocol can be found next to 
‘MSN:’ as either $Shift Response Discrimination LEFT or $Shift Response Discrimination 
RIGHT corresponding to left or right rewarding levers, respectively. Once the 
Compiled_Left/Right2 macro is run, Excel should end on the Summary tab with error 
profile data.    
To reset the workbook, run the Clear All macro (shortcut key: Ctrl + Shift + C).  
To produce a list of errors for each incongruent trial, as required for logistic regression 
modelling, run Compiled_Left (shortcut key: Ctrl + E) or Compiled_Right (shortcut key: 
Ctrl + R) on transferred data. Return to the Input tab and copy the data under Column D 
which will indicate ‘1’ for incorrect lever presses or ‘0’ for correct lever presses or 
omissions for all incongruent trials in order from the top of the column to the bottom. 
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Appendix Figure A-3: Sample Response Discrimination Output for Error Profile 
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Appendix Figure A-4: Sample Response Discrimination Output for Logistic 
Regression of Mean Group Error Rates 
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Appendix Table A-1: Set Shifting Indices 
Trials & Errors to 
Criterion 
8 correct consecutive responses (irrespective of trial 
congruency). 
Perseverative Errors Reflect a failure to disengage from the old VCD strategy 
and occur on incongruent trials, early in set shifting. RD 
trials were analyzed in blocks of 16; 8 of these trials were 
incongruent trials. When rats showed adherence to the old 
strategy by selecting the incorrect lever on 6 or more of a 
block’s 8 incongruent trials (≥ 75%), all incongruent trial 
errors in that block were characterized as perseverative.  
Never-Reinforced 
Errors 
Incorrect lever responses on congruent trials. These errors 
tend to occur as rats explore new strategies and reflects 
the ability to filter out non-rewarding options.  
Regressive Errors Reflect a failure to learn or maintain the new RD strategy 
due to regression towards the old VCD strategy. These 
occur later in set-shifting on incongruent trials, after the rat 
had already begun to disengage from VCD. RD trials were 
analyzed in blocks of 16; 8 of these trials were incongruent 
trials. If rats demonstrated disengagement from the old 
VCD strategy (chose the incorrect lever) on 5 or fewer of a 
block’s 8 incongruent trials (<75%), all incongruent trial 
errors in that block were characterized as regressive. Once 
a regressive block occurred, all subsequent blocks were 
considered regressive as well.  
Logistic model: 
Trials to 50% Strategy 
Change 
The interpolated number of incongruent trials needed for 
half of a group's responses to demonstrate a strategy 
change during RD; when only 50% of a group’s responses 
follow the old strategy (commit errors). Equivalent to the 
IC50 of a logistic exposure-response curve. 
Logistic model:  
Hill Slope 
The Hill slope of a logistic exposure-response curve 
quantifies the steepness of the curve, reflecting the 
efficiency of strategy change. 
Since omissions did not clearly indicate which strategy was followed, omissions were not 
scored as errors in these indices. VCD = Visual Cue Discrimination, RD = Response 
Discrimination  
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Appendix B: MWM Regressive Preference for Target Quadrant 
Representative recordings of probe test swimming behaviour. Both videos are run at 4x 
speed and trace respective swim paths in the top left corner.  The platform was previously 
learned to be located in the top-right quadrant.  
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Appendix C: Immunohistochemistry Protocols  
C1  Solutions 
Cryoprotectant (1 L) 
10 g   PVP-40 
500 mL 0.1M Phosphate Buffer (PB) solution (same as 0.1M PBS, but without NaCl) 
300 g   Sucrose  
300 ml Ethylene glycol 
Solution can take 0.5 – 2 h to dissolve. Recommended order: add PVP to PB, slowly 
added sucrose and wait for both PVP & Sucrose to dissolve, add ethylene glycol, bring 
volume up to 1L with PB. 
Before use, put a test sample in freezer (falcon tube) ensure that the cryoprotectant does 
not freeze 
 
DAB Solution 
0.05% diaminobenzidine tetrahydrochloride (Sigma-Aldrich #D5637) in 0.01M PBS 
stir for 15 min and run through filter paper (Whatman Grade 2/8µm) 
add 3% H2O2 15 s prior to use, stir.  
 
Gelatin  
1.5 g   Powdered Gelatin  
500ml  Distilled water 
Heat in microwave for ~30s (do not allow water to boil) and stir. Discard if there is any 
indication that an old solution has spoiled.  
 
Paraformaldehyde Solution (1 L) 
40 g  paraformaldehyde  
500 mL distilled water  
1 ml   NaOH (or ~15 drops) 
100 mL 0.1M PBS 
390 mL distilled water; or enough to form 1 L solution 
Adjust pH to 7.35 with HCl 
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Phosphate Buffered Saline (PBS) 
1L 10X PBS Stock Solution (0.1M; 1 L) 
90 g   NaCl 
10.9 g  Na2HPO4 anhydrous or 20.6 g for Na2HPO4 heptahydrate 
3.2 g   NaH2PO4  anhydrous or 3.7 g for NaH2PO4 monohydrate 
Add distilled water to 1L once dissolved 
Adjust pH to 7.35 using HCl and NaOH dropper  
1x PBS Working Solution (0.01M) 
Dilute 1 part 10X Stock solution with 9 parts distilled water; adjust pH 
 
Phosphate Buffer Saline with 0.2% TritonX detergent (PBST) 
add 1 mL TritonX to 500 mL 0.01M PBS 
 
Sucrose 30% (500 ml) 
150 g   sucrose 
Add enough distilled water to make 500 ml solution once sucrose is fully dissolved  
For long term storage (> 1 month), add pinch of isoniazid to solution (preservative; 
caution! Highly toxic) 
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C2  Immunohistochemistry Protocol 
Primary:  
OX6 mouse monoclonal (BD Pharmingen #554926); use 1:1000 in primary solution 
GFAP mouse monoclonal (Sigma-Aldrich #G3893); use 1:2000 in primary solution 
 
Secondary: Biotinylated Horse anti-mouse IgG (Thermo Fisher Scientific #31806) 
 
Other reagents:  
Normal Horse Serum (Abcam #7484) 
ABC reagent kit (Thermo Fisher Scientific # 32020) 
Day 1 
Wash 
 
0.01M PBS 10 min x 6 times 
If weak DAB staining due to prolonged storage, 
may need to wash 10 min x 10 times   
Block endogenous peroxidase 1% H2O2 10 min 
Wash  0.01M PBS 5 min x 3 times 
Block nonspecific antigens 2% horse serum in PBST 
Incubate with Primary Antibody Primary in 2% horse serum in PBST 
Overnight in 4°C 
Day 2 
Wash  0.01M PBS 5 min x 3 times 
Incubate with Secondary Antibody 1:500 biotinylated secondary in PBST 
Wash  0.01M PBS 5 min x 3 times 
Incubate with  
Horseradish Peroxidase  
2 drops of Avidin, 2 drops of Biotin  
in 10 mL PBST 
Wash  0.01M PBS 5 min x 3 times 
Incubate with DAB Solution OX6: 30 s                  
GFAP: 120 s  
Wash  0.01M PBS 5 min x 3 times 
Mount sections, airdry overnight  
Day 3 
Dehydrate in sequential 
concentrations 
5 min in 50% 70% 95% and 100% Ethanol, then 
5 min in 50/50% Ethanol/xylene solution, then  
10 min in 100% Xylene; use new xylene if cloudy 
Coverslip DePex Mounting Medium; air dry for >48 h  
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Appendix D: Microscopy and Image Analysis Protocols 
This appendix outlines specific parameters used in acquiring micrographs (Nikon Eclipse 
Ni-E, Nikon DS Fi2 colour camera, NIS Elements Imaging; Mississauga, ON) and in 
analysis using ImageJ v1.50b.  
 
Appendix Figure D-1: Microscope Imaging Parameters 
Using the 10x Objective, ensure that the following are set to: 
- Quality: 2560x1920 Fine 
- Exposure: 10 ms  
- Analogue gain: 1.0 
- Zoom: 1.0x  
- Light: 46 
- No filters on Turret1 
- Analyzer: Out 
- Aperture: 11.5 
- Field Stop: 10.5 
- Condenser: 7N1 
- Neutral Density Filter 8 & 32 only; 
NCB32 filter should be out. 
 
With every new section, perform white balance correction using a probe on off-tissue 
direct light as reference  
215 
 
 
 
Appendix Figure D-2: Focus Surface Setup 
A focus surface allows the software to interpolate optimal focus depths, based on a 
sampling of points by the user. This corrects for any slant in the stage or slide; this is 
particularly useful when scanning a large stitched image, e.g. greater than 1 mm in any 
dimension, with any greater magnification than the 2x objective.  Ensure that the 
interpolation method is selected.  
Placing 4-6 focus points around the perimeter of the section and several focus points on 
ROIs is recommended. A flat focus plane (i.e. colour gradient follows a straight line across 
the plane) identifies a slide or stage slant; non-flat focus planes (i.e. colour gradient 
follows a curved line, or a peak/valley is in the middle of the focus plane) may indicate 
errors in the setting of focus points or in the program’s interpolation. If the focus plane 
does not appear flat, continue to add focus points until the plane is flat – if this does not 
resolve, use of the focus surface is not advised and automatic step-by-step focus is 
recommended instead.  
Note the range of the focus surface; the difference between the maximum and minimum 
depth (measured in the z dimension) should not exceed ~50 µm across a coronal section 
of ~15 mm width. This indicates a major stage or slide slope that will result in blurry 
artifacts.  
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Appendix Figure D-3: Micrograph Stitching 
For consistent image sizes, pre-determined X & Y field dimensions are advised. Note that 
the microscope software (and also ImageJ) does not reliably handle images greater than 
28 000 pixels in any dimension.  
Select “Focus manually at start”, “Focus Surface” or “Use step-by-step focus” as 
appropriate.  
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D1  Threshold Analysis: Detailed Walkthrough 
Before starting, set & check the following settings:  
Analyze > Set measurements.  
 
 
 
 
 
 
 
 
 
Measure (Ctrl+M);  
in the results window, Results>Options: 
Make sure JPEG quality is set to 100. 
 
 
 
 
 
 
 
 
 
218 
 
 
Step 1. Set/check scale for each new image  
 
 
 
 
 
Step 2. Using the polygon tool, trace out the ROI of interest 
(start with corpus callosum) 
- Do not include edges (tend to be darker than rest of 
white matter tract) 
- Note that anchors can be dragged after selection is 
complete – careful not to click outside of selection 
before it is saved (will lose selection) 
- When selection is complete, press [T]. ROI manager 
window will appear 
- Select new ROI, and Rename: ID_Section_Anatomy eg, 876_CCA_CC 
- Recommended abbreviations: 
- FM: Forceps minor 
- CC: Corpus callosum 
- CCEnds: Supraventricular 
Corpus callosum 
- Cing: Cingulum 
- HPC: Hippocampus  
- IC: Internal capsule  
Measure [M]; paste area to “ROI area” column in appropriate data spreadsheet  
- Ensure µm2, not pixels! Area value should have decimals.  
Save! When all ROIs in the image are outlined and named, select all ROIs in the 
Manager (click on the list of ROIs, Ctrl + A, or hold Ctrl/Shift as you select the ROIs > 
More >> Save > Name as ID_Section in the image folder 
- Avoid large tears, artifacts 
- To remove artifacts or tears from selection: 
- If large or extends beyond ROI, make multiple selections to construct ROI of 
interest 
- If smaller, use freehand too to outline artifact, save outline of artifact [T], select 
ROI of interest and artifact outline, more>>XOR, save corrected ROI [T] 
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Consult Paxinos’ & Watsons’ 6th edition The Rat Brain in Stereotaxic Coordinates to help 
guide anatomical selection, especially for OX6 staining & IC. 
 
 
 
Appendix Figure D-4: Forceps Minor 
- Bregma +3.00 mm 
- Yellow trace indicates ROI 
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Appendix Figure D-5: Anterior Corpus Callosum 
- Bregma +2.00 mm 
- Extend selection to lateral ends of cingulum 
- Lateral ends of selection should be roughly parallel to the dorsal/ventral axis  
- On anterior corpus callosum, middle of selection should dip down to most ventral 
reach of the CC 
 
 
 
 
Appendix Figure D-6: Anterior Supraventricular Corpus Callosum 
On anterior and middle corpus callosum, remove selection between medial borders of 
ventricles  
1. Outline white matter tract to be deleted; lateral ends of this selection should be 
roughly parallel with dorsal-ventral axis. 
2. Edit > Selection > Make Inverse. Add to manager [T] 
3. In ROI manager, select CC and Inverse middle sections,  
More >> And, add to manager [T], rename as supraventricular corpus callosum 
(CC Ends) 
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Appendix Figure D-7: Anterior Cingulum 
- Bregma +2.00 mm 
- To combine bilateral Cingulum/HPC/IC selections, select both in the manager 
(hold Ctrl while selecting), More >> OR (Combine), add selection to manager [T] 
 
 
 
Appendix Figure D-8: Middle corpus callosum, supraventricular corpus callosum, 
cingulum 
- Bregma +0.00 mm 
222 
 
 
 
 
 
 
 
 
 
 
 
 
 
- Bregma -3.00 mm 
 
 
 
 
 
 
 
 
 
 
 
- Bregma -3.00 mm 
- Exclude optic tract, ventral and often adjacent to IC. 
 
Appendix Figure D-9: Posterior Corpus Callosum, Cingulum 
Appendix Figure D-10: Internal capsule 
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- Bregma -3.00 mm 
- Exclude fimbriae 
 
Appendix Figure D-12: Posterior 
Dorsal and Ventral Hippocampus 
- Bregma -5.50 mm 
- Horizontal line extending to the 
most latera reach of the hippocampus 
delineated the dorsal and ventral 
hippocampus.  
 
 
 
 
 
 
 
 
Appendix Figure D-11: Anterior Dorsal Hippocampus 
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Step 3. Change to 8-bit grayscale (Image > Type > 8-bit) 
 
Step 4. Subtract Background (Process > Subtract Background) 
Make sure no ROIs are selected before this step! 
 
 
 
 
Step 5. Threshold (Ctrl + Shift + T); set Max to 237. Do not apply! 
 
 
 
 
 
Step 6. Measure Thresholded Area  
- Select ROI, press [M] 
- Ensure measurement is limited to threshold (Area should not be 100%). 
- Paste all measurements to data spreadsheet (do not paste over ROI area 
column).  
 
  
Step 7. Repeat for each ROI of interest 
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D2  Threshold Analysis: Protocol Summary  
Make sure correct measurements & options are set before following summary! 
1. Set/Check scale for each new image  
a. 2.942 “distance in pixels” pixels per 1.00 “Known distance” (µm); 2.942 
pixels/unit 
b. Select “Global” 
 
2. Using the polygon tool, select ROIs.  
a. Add selections to ROI manager (Shortcut: [T]), name accordingly. 
b. Measure [M]; paste area to “ROI area” column in appropriate data 
spreadsheet (ensure µm2, not pixels!) 
c. Select all ROIs, save to image’s folder (ROI Manager>More>>Save) 
 
3. Change to 8-bit grayscale (Image>Type>8-bit) 
 
4. Subtract Background (Process>Subtract Background) 
a. Make sure no ROIs are selected before this step! 
 
5. Threshold (Ctrl+Shift+T); set Max to 237. Do not apply! 
 
6. Measure Thresholded Area (Ensure measurement is limited to threshold).  
a. Select ROI, press [M] 
b. Paste measurements to data spreadsheet 
 
7. Repeat step 6 for each ROI on the image 
 Clear ROI manager before starting on next section 
 
Tips & Useful Keys 
(File>Revert) to re-open current image  
You can drag and drop Images and ROIs onto the ImageJ toolbar to open them  
Custom shortcut keys and Macros can speed up the process 
(Plugins>Shortcuts/Macros),  
[Space] allows you to drag the picture with your cursor 
[+]/[-] for zooming in/out 
[Ctrl] + [ ] ] to view all ImageJ windows  
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Appendix E: Rat Tail Cuff Blood Pressure Measurement 
Protocol  
This appendix supplements the methods for blood pressure measurement outlined in 
Chapter 4. This supplementary guide will include a summary of specific operating details 
and suggestions for the CODA High Throughput Non-Invasive Blood Pressure system 
(Kent Scientific; CODA-HT6) that are not found in the equipment user guide. The 
parameters and suggestions outlined here were followed in generating data for Chapter 
4.  
 
Appendix Figure E-1: Cuff Positioning on Restrained Rat's Tail 
Model rat in a restraining tube with an Occlusion cuff (O-Cuff) placed at the base of the 
tail and a Volume Pressure Recording cuff (VPR-Cuff) distal to the base. 
 
E1  Background 
CODA allows non-invasive measurements of rodent blood pressure. This is accomplished 
by occluding blood flow into and out of the tail using a cuff positioned near the base of 
the tail, followed by controlled deflation of the occlusion cuff. As this cuff deflates, changes 
in the volume of the tail are detected by a second cuff positioned distally on the tail. This 
allows estimation of systolic and diastolic blood pressures. Rodents are held in a tightly 
fitted tube that isolates the tail and confines the rodent to minimize movement. The 
confined animals are held on warming platforms that help to increase tail surface 
temperature, so that changes in tail volume can be more readily measured. The 
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Whitehead lab’s high-throughput CODA equipment can measure 6 channels (i.e. rodents) 
simultaneously. 
 
 
Appendix Figure E-2: Sample channel output for one cycle 
The horizontal axis denotes the time of the cycle. The red line represents the pressure of 
the gradually deflating occlusion cuff. The blue line represents the volume recorded by 
the VPR cuff.  
 
When the O-Cuff (occlusion cuff) inflates to occlude blood flow to and from the tail, tail 
volume remains constant or decreases, as measured by the VPR (Volume Pressure 
Recording) cuff (Appendix Figure E-2). The VPR cuff acts as a differential pressure 
transducer to estimate changes in tail volume. As the pressure of the O-cuff falls below 
systolic blood pressure, blood begins to flow into the tail. The left (first) blue vertical line 
indicates this point, which coincides with the minimum of the VPR curve: as flow returns, 
tail volume increases (Appendix Figure E-2). This is exaggerated by reactive hyperemia. 
When the O-cuff reaches diastolic pressure, blood flow into and out of the tail reaches a 
maximum. This is indicated by the right (second) blue vertical line and coincides with the 
inflection point of the VPR curve (maximum slope of the curve, indicating greatest rate of 
volume change). Spikes at the right end of the VPR curve are artefacts. Only movement 
artefacts between or near the systolic and diastolic pressures will interfere with successful 
measurement. “Precipitous” decreases in O-Cuff pressure or VPR volume indicate a 
broken/leaking cuff (see page 17-18 of User’s Guide and “Cuff Replacement”). 
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The product manufacturers claim to measure heart rate, but these are inaccurate. Mean 
pressure might also be inaccurate since the equipment does not record the length of 
systolic or diastolic phases. This is necessary for the most correct estimate of mean 
pressure. It appears that the program calculates mean pressure using the formula (mean 
pressure) = 1/3*(systolic pressure) + 2/3*(diastolic pressure) which is not accurate at 
increased heart rates.  
Several published studies1-4 have validated the accuracy of VPR as a method for non-
invasive estimation of blood pressure, using arterial catheterization & telemetry as the 
gold standard for comparison. The systolic pressure estimate is more accurate than the 
diastolic pressure estimate, and you can expect a slightly greater variance in inter-cycle 
diastolic blood pressure recordings within individual channels & sessions 
 
E2  Equipment Use & Maintenance 
E2.1 Software Set-up 
The user’s guide has thorough instructions on operating the software, starting on page 8. 
Each Session consists of a user-set number (e.g. 25) of inflation/deflation cycles and 
includes all the channels that were indicated for measurement. Sessions can be further 
divided into sets of cycles. An experiment is the collection of all sessions that belong to 
it; multiple sessions will be run as part of a project. Since sessions will likely be run on 
multiple dates for multiple animal groups, it is recommended to name the sessions by 
Date and Animal Group.  
CODA Users guide instruction on pages 9-1 &, 19 are useful for first time use. Once an 
experiment is set up using the Experiment Wizard, multiple sessions can be run as part 
of the same experiment using the New Session Wizard. In the new session wizard, use 
selected session as template allows you start a session quickly while keeping the same 
session parameters as the selected session. Be sure to name new sessions appropriately 
(e.g. Date and Animal Group) and to allocate the correct animals to their respective CODA 
channels. It is useful to assign animals to animal groups for ease off initiating sessions. 
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On the last window of either experiment or new session wizards, do not press “Start” until 
the cuffs are in place on the animals.  
 
E2.2 Recommended Session Parameters 
Acclimation cycles: 0 
Number of sets: 1 
Time between sets: Default (does not matter if there is only one set) 
Cycles per set: 25 
Time between cycles: 5 seconds 
Deflation time: 20 seconds for smaller rats, 15 second for larger rats (>400g) 
Minimum volume: 15µL  
Display style: Chart for each animal  
10 successful cycles are recommended for an accurate mean measurement of blood 
pressures. Running 25 cycles (without any designated “acclimation” cycles) should 
produce a sufficient number of successful reads, though this may be reduced if the rats 
consistently show low inter-cycle variance. Furthermore, the data is organized more 
simply (fewer spreadsheets) when there are no designated “acclimation” cycles. The 
program will automatically remove any cycles which are unsuccessful (see error codes in 
user’s guide), though additional filtering will further reduce the number of successful 
cycles; see E3 Data Quality & Analysis. With manual filtering of the data, it is not 
recommended to discard any initial acclimation meet desired data quality.  
 
E2.3 Warming Platform 
The user’s guide has thorough instructions on operating the warming platforms, adapted 
from page 5: begin warming platform by pressing the START/STOP button. Press it again 
to stop warming. The controls of each warming platform apply to all four channels 
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(channels cannot be controlled independently). By default, the platform will turn off 
automatically after 1 hour– adjust the running time using the up and down buttons beside 
the time display. Be sure that the warming platform will run for sufficient time, so that it 
does not turn off mid-session. L1 warms up to 32°C, L2 to 35°C, and L3 to 38°C. There 
are additional levels (L4-6) that can be activated by holding down the up button for 10 
seconds (found below the heating level display). L4 is effective for keeping holding tubes 
warm (i.e. while the rats are habituating to the room) but is often uncomfortable for the 
animals. When warming is active, the green LED lights will flash when the set temperature 
level is achieved. When the temperature of a channel falls below the set level, the light 
will glow steadily. There is a tendency for animals to have lower surface temperature on 
the leftmost channel (of the left platform) and rightmost channel (of the right platform). 
For this reason, it is recommended to hold 3 rats on either warming platform on the 
channels closest to the centre of the cart.  
 
E2.4 Cuff Replacement 
Cuffs will need to be replaced. At the time of writing this guide, only a total of four cuffs 
were replaced over ~3000 cycles. Page 17-18 of the user’s guide has good information 
on when and how to replace the cuff. Testing the cuffs using the device manager before 
running a session will help prevent mid-session complications.  
 
E2.5 Cleaning & Storage 
Do not use alcohol or abrasive detergents on any equipment. Water should suffice for 
regular cleaning of waste found on warming platforms. Following use, animal holders 
should be soaked in Sparkleen solution, followed by warm water rinse and dry. Cuffs 
should be disconnected and stored in a dry storage baggie/container to prevent damage 
to bladder and tubing. If measurements are taken daily, it may be convenient to keep 
cuffs connected to the CODA controller. When cuffs are not connected, the CODA 
controller ports should be protected by the dust covers.  
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E2.6 Animal Handling  
For initial acclimation, the JOVE article recommends2: “To train and improve animal 
acclimation, add additional cycles to your experiment and run the experiment for five 
consecutive days. You also can assist with acclimation by placing the animal in the holder 
for 15 minutes for 3 consecutive days prior to the actual study.” 
Appendix Figure E-1 does not offer an accurate representation of the space that a rat 
should be permitted during testing. Appropriate holding tubes should be selected 
according to the width of the animals, and the nose cone should be positioned so as to 
minimize animal movement. This means that the rat nares should be visible at the narrow 
opening of the nose cone, and the posterior end of the animal should be pressed up 
against the back cover of the holding tube. This will often require some pressure against 
the animal when securing the back cover, with care not to pinch any tissue. Advance the 
nose cone position as necessary if the rat still manages to move excessively or to draw 
in its tail through the back cover; try not to reinforce this kind of behaviour (e.g. by 
returning the animal to its cage). Blood pressure may be affected if the chest cavity does 
not have enough room to expand, and as always, strive to minimize any animal 
discomfort. Note that animals may also experience discomfort due to excess heating from 
the warming platform; do not keep animals on L4 for a prolonged amount of time. 
Movement and apparent stress should subside with repeated sessions. Placing a rat in 
the same holding tube and warming platform channel for all sessions may reduce stress 
and makes organization simpler for the experimenter. If randomization of holding tube 
and placement is desired, take note of the holding tube numbers and platform channels.  
 
E3 Data Quality & Analysis 
The CODA software will automatically remove any cycles that do not meet its standards 
for reliability; see error codes on page 16 of the user guide. Note that the program may 
sometimes accept clearly inaccurate cycles and may occasionally reject seemingly 
accurate measurements. It is worthwhile taking note of any cycles that were wrongfully 
rejected/accepted for later filtering. Once the full report is exported to an excel file, data 
should be transferred to spreadsheets that will organize sessions from multiple dates 
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across multiple tabs. Data sheets should be organized such that excel functions can be 
formulated to calculate: means, standard deviations, standard errors for systolic, diastolic, 
and mean blood pressures, as well as tail volume (Appendix Figure E-3).  
From consultation with the representative for the company that developed and distributes 
the CODA equipment, it was recommended that any cycles with a volume reading of 15 
or less should be discarded. The program is supposed to do this automatically (as per 
session parameters), but it does not do so. Tail blood volume fluxes can readily reach 
into the 100’s of µL, if enough time is granted during and before sessions (see operating 
“operating summary”). The following are additional standards that can be met to help 
ensure reliability of blood pressure measurements, though the values may need to be 
adjusted with different groups of animals:  
- SD of pressure measurements for each channel should be less than 20 
- Total number of successful counts after automatic and manual filtering of cycles 
should be greater than 15. 
- Mean volume across cycles should be greater than 50.  
These values were based on subjective evaluation of data reliability. Another source 
recommended deleting measurements if the standard deviation is greater than 302. When 
data does not meet these standards despite filtering for cycles with volume 
measurements <15, it may not be necessary to exclude the final pressure means of 
individual channels/animals; it only suggests that more time and care should be given 
during future sessions. Ultimately, the mean systolic, diastolic and mean pressure 
measurement given for each channel should be used a single data point (not as a sample 
with variance, since cycles are not independent of each other).  
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Appendix Figure E-3: Suggested organization of data 
Each spreadsheet tab includes CODA data from a different date, for all channels/animals. 
Rows 27-30 show the outputs of automated formulas (X corresponds to respective 
columns): 
Row 27: =AVERAGE(X2:X26) 
Row 28: =STDEV.S(X2:X26) 
Row 29: =COUNT(X2:X26) 
Row 30: =X28/SQRT(X29) 
Additionally, automated cells can be added to notify when a column does not meet the 
quality standards mentioned above. In this figure, B31-B33 indicate when the SD of 
respective columns are too high (greater than 20) using the following code =IF(B28>20, 
"!!!",""). B32 indicates when the total number of successful cycles (post manual filtering) 
is too low (less than 15) using the following code =IF(B29<15, "!!!", "").  G31 indicates 
when the mean volume reading is too low (less than 50) using the following code 
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=IF(G27<50,"!!!",""). This template, including notification cells, can then be replicated 
(copied and pasted) for each channel across multiple sessions.  
 
E4 Operating Summary 
1. Place rats in testing room to habituate to the room. Dim/red lighting is 
recommended. Make sure that drinking water is accessible to the rats. Allow one 
hour before placing rats into holding tubes.  
 
2. Turn on warming platform to L4 with holding tubes and cuffs on the platform. 
Warmer tubes will help the rats reach sufficient surface temperatures. (see E2.3 
Warming Platform) 
 
3. Test connected cuffs using the device manager. Replace cuffs as necessary (see 
E2.4 Cuff Replacement). 
 
4. After allowing the rats to habituate to the room for one hour, allow them to enter 
the holding tubes. If removed from their cage, the rats will readily enter the 
holding tubes. This should be accomplished with ease on a flat surface (such as 
the top of a cart). Be sure not to pinch any fat, paws, or testicles when securing 
back of tube. See E2.6 Animal Handling for more details.  
 
5. Place cuffs onto rat tails. O-cuffs may reach the base of the tail and will work 
well if they can be advanced to anywhere on the proximal third of the tail. Ensure 
that O-cuffs stop at minimal resistance and are not too tight on the tail. The same 
applies to VPR cuffs (placed distal to the O-cuff). The higher up the VPR cuff is 
placed, the more blood volume will be measured; however, the two cuffs should 
not be in contact with each other as this can affect inflation/deflation of the bladders 
and produce measurement artefacts.  
  
6. Turn warming platforms down to L3 or even lower if animals show distress from 
heat (persistently vocalizing stress, moving tails off of the heated platform, 
unusually active). Cover tails with the black blanket for efficiency of heating and to 
provide some weight against tail movement. It is recommended to keep the blanket 
over the tails during the course of all sessions, though it may be removed at the 
user’s discretion.  
 
7. Wait 10-15 minutes to allow tail surface temperatures to reach levels that facilitate 
sufficient tail blood volume for BP measurements. Note that tail surface 
temperatures (measured at base of tail) do not always correlate well with volumes 
seen in BP measurement. The CODA user’s guide recommends 32-35°C. See 
trade-off note in step 8. Waiting may not be necessary with larger tails (greater 
blood volumes may be more readily measured), remove or reduce the wait time in 
step 7 if it does not help with initial measurements.  
 
235 
 
 
8. Run cycles. 
o  Pause as necessary to reposition cuffs or rats, though excessive handling 
can increase fluctuations in blood pressure; handling of cuffs and animals 
should be avoided unless necessary (cuffs fall off or shift to positions where 
insufficient volume is measured, or a tail is withdrawn into the holding 
tubes). 
o You may also need to pause in between cycles to allow tail volumes to 
increase gradually. Tail volume seems to increase with repeat 
inflation/deflation cycles, so you can use the first several cycles to help 
increase tail volume to satisfactory levels. 
o If tail volumes are resistant to increase as cycles are being run, consider 
increasing the heating level of the warming platform.  
o Recognize the trade-off: as the rats are held on the warming platform for 
longer, tail volume may increase, but the rats may also become agitated 
and movement artifacts or cuff displacement can result.  
o  See E2.1 Software Setup for recommendations on number of cycles to run.  
9. Remove cuffs, return rats to cage. Be mindful of any feces and urine and avoid 
contact of rat waste with cuff material.  
 
10. Save & Back Up data. Experiment Manager> navigate to session of interest> 
produce a full report and export to excel. When the excel file opens, be sure to 
save it. The CODA software keeps a copy of all data for later retrieval, including 
measurement charts. 
 
11. Consider rewarding rats with sunflower seeds.  
 
12. Wash holding tubes with Sparkleen detergent and rinse with warm water, dry 
with paper towel. A mouse shoebox cage is useful for soaking holding tubes in 
detergent.  
 
13. Wash warming platform. Water & paper towel usually suffices.  
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Appendix F: PET/MRI Study 
The following appendix outlines a pilot study of in vivo measurement of microglia 
activation in the TgAPP21 rat following ET1 ischemic injury of the dorsal striatum. PET 
imaging with a radioligand that localizes to activated microglia and reactive astrocytes 
was complemented with MR and CT imaging to improve anatomical localization.    
 
F1 Introduction 
Subcortical infarcts indicate a greater risk for future strokes and cognitive impairment, 
even when patients do not initially present with symptoms1,2. This sequela is thought to 
be mediated in part by secondary chronic inflammation, particularly in the white matter, 
which may also interact with other neurodegenerative conditions such AD3-5. White matter 
pathology initiated by small vessel disease or infarcts is predictive for cognitive decline6-
10 and involves inflammatory processes10-13. In vivo imaging of an animal model of 
ischemic subcortical injury would be instrumental for characterizing secondary 
inflammation and for testing therapeutic interventions. 
18F-FEPPA is a PET-ligand that binds to the translocator protein (TSPO), an outer-
mitochondrial-membrane bound protein that is upregulated in activated microglia and 
astrocytes14-18. This radiotracer was injected into 8 – 12-month-old male Fischer 344 rats 
following ischemic injury of the dorsal striatum. Following dynamic 90 min PET, the rats 
also underwent 3T MRI and contrast-enhanced CT-perfusion imaging to help localize 
radiotracer uptake and to explore additional in vivo imaging correlates of 
neuroinflammation. To corroborate multimodal imaging findings, brain tissue was 
analyzed using immunohistochemistry for microglia activation and reactive astrocytosis. 
As integrity of prefrontal-subcortical circuits are particularly critical to cognitive status 
following stroke,2,19 differences in 18F-FEPPA uptake were compared across white matter 
segments anterior, proximal, or posterior to the site of injury. Blood sampling offers 
important corrections to radiotracer input functions, but it is challenging in rodents; an 
accurate population-derived input function would forego the need for future manual blood 
sampling. 
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F1.1 Objectives 
- Establish protocol for multimodal imaging (18F-FEPPA-PET/MR/CT) of a rodent 
ischemic stroke model. 
- Determine spatial and temporal progression of white matter injury and 
inflammation. 
- Evaluate the kinetics of 18F-FEPPA and develop a population-derived input 
function 
 
F2 Methods 
8 – 12-month-old TgAPP21 rats were imaged 7 – 10 days prior to focal ischemic injury of 
the dorsal striatum (baseline imaging), 7 days following injury, and 30 days following 
injury. To model focal ischemic injury, unilateral ET1 (60 pmol dissolved in 3 µl sterile 
0.9% saline) was injected into the dorsal striatum of (n = 6), as described in 5.3.2 
Endothelin-1 Focal Ischemic Injury. On each of the 3 imaging days, 18F-FEPPA was 
produced at an onsite cyclotron. Injected doses averaged 29.6 MBq, ranging from 22.4 – 
37.6 MBq. Immediately following 18F-FEPPA injection, a dynamic 90 min PET scan 
(Siemens Inveon) was initiated, followed by a 40 min MR imaging sequence (Siemens 
Biograph mMR), and then iopamidol (Isovue®)-enhanced CT (GE VCT). Dynamic PET 
data was manually registered to subsequently acquired T2-weighted MR images. CT 
analysis of cerebral circulation was focused on mean transit time (MTT), which estimates 
the average time needed for blood to pass through tissue and corresponds to the ratio of 
cerebral blood volume : flow. During baseline and 30-day post-injury imaging, arterial 
blood samples were acquired from 5 subjects at 2, 8, 16, 64, and 90 min after 18F-FEPPA 
injection. The ratio of unmetabolized 18F-FEPPA in plasma and blood was determined by 
solid-phase extraction chromatography20,21. Following imaging 30 days after ET1 
ischemic injury, rats were euthanized, and brain tissue was collected for IHC, as 
described in 2.3.5 Immunohistochemistry & Image Processing. 
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Appendix Figure F-1: Endothelin-1 injection into the dorsal striatum 
Dashed outline identifies glial scar formed after ET1 injection, observed on DAB-IHC with 
a primary antibody for GFAP (30µm coronal section). 
 
 
 
 
Appendix Figure F-2: Brain Segmentation Model 
Neuroanatomy and injury site identified by T2-weighted MRI; these segments were then 
applied to co-registered PET data.   
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F3 Results 
 
 
 
Appendix Figure F-3: Immunohistochemistry Corroborates 18F-FEPPA-PET/MR 
Findings 
High penumbral 18F-FEPPA uptake was observed 7 days after ET1-ischemic injury of the 
dorsal striatum. Localization of increased uptake corresponded with OX6+ activated 
microglia more consistently than GFAP+ reactive astrocytes. 30 days following injury, 
continued uptake and microglial activation was observed distal to the injury site, 
particularly in white matter tracts. 
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Appendix Figure F-4: 18F-FEPPA Uptake Following Injury Persists in Anterior 
White Matter Tracts 
18F-FEPPA uptake was significantly increased around the injury site and proximal white 
matter (WM) following injury. 30 days after injury, uptake in these regions reduced from 
levels seen at day 7 but was still relatively increased throughout the brain, especially in 
anterior white matter. *p<0.05, **p<0.01, ****p<0.0001 compared to baseline. n = 6, error 
bars = SEM 
 
 
 
 
 
Appendix Figure F-5: Mean Transit Time Prolonged by Ischemic Injury 
These experiments were conducted following PET & MR imaging, thus anesthesia time 
and quality was likely an important variable that affected cerebral circulation. Despite this 
confound, MTT was found to be prolonged in the penumbral region 7 days after injury 
and normalized by day 30. Axial resolution = 500 µm, scale = time (s)  
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Appendix Figure F-6: 18F-FEPPA Kinetic Profile 
The blood:plasma-bound ratio of the 18F-FEPPA radiotracer was well modelled by a bi-
exponential function (R2 = 0.87), while the unmetabolized fraction of the radiotracer was 
well modelled by a Hill function (R2 = 0.92). These population-derived kinetic models will 
be applied to future arterial input functions in dynamic PET.  
n = 5, error bars = SD. 
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F4 Conclusions 
This study demonstrates the feasibility of 18F-FEPPA-PET as an effective method for in 
vivo imaging of microglia activity in a rat model of ischemic stroke. The localization of 
microglia activity was further improved with MRI co-registration. Qualitative evaluation of 
immunohistochemistry revealed that 18F-FEPPA uptake corresponded better with 
increased microglia activation than reactive astrocytosis (Appendix Figure F-3). PET 
findings indicated sustained wide spread inflammation, especially in anterior white matter, 
following ischemic injury of the dorsal striatum (Appendix Figure F-4).  
Reduced MTT warrants further investigation of the impact of disrupted perfusion and 
circulation on radiotracer uptake (Appendix Figure F-5). This also raises the question of 
whether BBB disruption following ischemic injury may confound the distribution of 18F-
FEPPA in the brain22,23. Despite these limitations, the methods described here will enable 
comparative investigation, such as the comparison of Wt and TgAPP21 rats’ response to 
ischemic injury and the effect of anti-inflammatory interventions. Future studies can apply 
the population-derived 18F-FEPPA kinetics to arterial input functions (Appendix Figure 
F-6), foregoing the need for further blood sampling.  
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Appendix G: Animal Use Protocol 
 
 
 
 
AUP Number: 2014-016 
PI Name: Whitehead, Shawn N 
AUP Title: Role of vascular risk factors in cognitive decline 
 
Official Notification of AUS Approval: A MODIFICATION to Animal Use Protocol 2014-
016 has been approved. 
 
The holder of this Animal Use Protocol is responsible to ensure that all associated safety 
components (biosafety, radiation safety, general laboratory safety) comply with 
institutional safety standards and have received all necessary approvals. Please consult 
directly with your institutional safety officers. 
 
Submitted by: Kinchlea, Will D 
on behalf of the Animal Use Subcommittee 
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including live question polling. 
 
Editorial Experience & Peer Review  
Editorial Review Board, Clinical & Investigative Medicine 2018 – ongoing 
Contributed peer review of manuscripts submitted to CIM, the official journal of the Canadian Society for 
Clinical Investigation 
Co-Editor-In-Chief, University of Western Ontario Medical Journal 2017 – 2018 
Oversaw the publication of 3 issues, including themed issues: Pain Management and Robotics, AI & Big 
Data, and coordinated the responsibilities of the entire UWOMJ team of 33 colleagues, including editors, 
IT directors, finance officers, and staff writers. Introduced blinded peer-review and DOI indexing   
Senior Associate Editor, University of Western Ontario Medical Journal 2016 – 2017 
Oversaw the publication of 3 issues, including themed issues: Trauma & Disaster Medicine and 
Healthcare Systems. Directly involved in peer review, copy-editing, and establishing stylistic standards 
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Junior Associate Editor, University of Western Ontario Medical Journal 2015 – 2016 
Oversaw the publication of 3 issues, including themed issues: Preventive Medicine and Drugs. Directly 
involved in peer review and copy-editing. Expanded journal authorship to graduate research students.  
Editorial Review Board, Journal of Undergraduate Life Science 2011 – 2012 
Contributed to peer review 
 
Training Seminars & Other Conferences 
Applied Suicide Intervention Skills Training (ASIST); London, ON May 26 – 27, 2018 
Heart & Stroke Clinical Update; Toronto, ON Dec 8 – 9, 2017 
Principles & Practice of Clinical Research; Burlington, ON  Sep 21 – 22, 2017 
American Psychiatric Association Annual Meeting; Toronto, ON  May 16 – 20, 2015 
Point of Care Ultrasound Medical Student Summer Symposium; London ON  Aug 23 – 24, 2014 
  
Public Advocacy & Community Engagement 
Social Media Manager, Schulich Political Advocacy Committee (PAC) 2018 
Set up and coordinated Schulich PAC’s social media campaigns, including the successful 2018 
municipal lobby initiative to promote naloxone kit availability in public buildings.  
CIM-Liaison, CITAC 2018 – ongoing 
Acting as liaison between the Clinical & Investigative Medicine journal and the Clinician-Investigator 
Trainee Association of Canada, I promoted CIM to Canadian medical students and residents across 
Canada and founded publication awards to recognize outstanding healthcare research conducted by 
medical students and residents.   
Municipal Lobbyist, Schulich Political Advocacy Committee (PAC) 2017 
Participated in lobby and communications training programs led by the Ontario Medical Association 
and Schulich School of Medicine & Dentistry’s medical student-led Political Advocacy Committee. Met 
with municipal city councilor to advocate for our ask: expand municipal funding for My Sister’s Place, a 
women’s shelter that provides essential support services for housing and mental health.  
Co-Chair, Retiring With Strong Minds 2015 – 2017 
Retiring With Strong Minds is a graduate student led program that aims to promote knowledge exchange 
between university students and older adults.  
• Partnered with local communities to provide accessible venues and promote monthly seminars. 
• Recruited graduate student from all academic faculties to present their expertise. 
• Consulted presenters on communication of expert knowledge to a layman audience Facilitated 
discussions about sensitive health issues and research 
 
